CN116829586A - 用于治疗眼部疾病的抗-VEGF及抗-TrkB双特异性结合分子 - Google Patents

用于治疗眼部疾病的抗-VEGF及抗-TrkB双特异性结合分子 Download PDF

Info

Publication number
CN116829586A
CN116829586A CN202180070390.8A CN202180070390A CN116829586A CN 116829586 A CN116829586 A CN 116829586A CN 202180070390 A CN202180070390 A CN 202180070390A CN 116829586 A CN116829586 A CN 116829586A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
heavy chain
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180070390.8A
Other languages
English (en)
Inventor
P·M·本茨
R·A·巴克尔
H·福克斯
韩飞
S·库马尔
S·洛
J·M·舍尔
L·托马斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN116829586A publication Critical patent/CN116829586A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35Valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/53Hinge
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

本发明涉及特异性结合血管内皮生长因子(Vascular Endothelial Growth Factor;VEGF)及原肌球蛋白受体激酶B(Tropomyosin receptor kinase B;TrkB)的结合分子及其在药物中的用途;包含其的药物组合物;及使用其作为药剂用于治疗和/或预防眼部疾病的方法。

Description

用于治疗眼部疾病的抗-VEGF及抗-TrkB双特异性结合分子
技术领域
本发明涉及与血管内皮生长因子(Vascular Endothelial Growth Factor;VEGF)及原肌球蛋白受体激酶B(Tropomyosin receptor B;TrkB)结合的结合分子及其在药物中的用途;包含其的药物组合物;及使用其作为药剂用于治疗和/或预防眼部疾病的方法。
背景技术
黄斑变性且特别是老年性黄斑变性(AMD)为发达国家中失明的主要原因。其晚期阶段分成湿性新生血管性AMD及干性地图状萎缩(geographic atrophy;GA)。wAMD的特征在于眼部新血管形成及血管渗漏增加以及进行性神经退化及感光体损失。抗VEGF治疗为此疾病的当前标准照护。疗法通常由靶向VEGF的药剂(阿瓦斯汀(Avastin)、雷珠单抗(Lucentis)、艾力雅(Eylea)及最近的Beovu)组成,所述药剂通过注射至眼睛后部给药。
尽管VEGF清除减少血管渗漏且因此最初改善视力,但视网膜仍处于受损条件下,导致进一步的细胞损失。尽管过去十年间已见到针对wAMD伴随玻璃体内抗VEGF的突破性治疗,但无针对地图状萎缩(一种减缓进行性疾病,最终导致失明)的治疗选择。
在wAMD诊断后两年内且实时成功进行抗VEGF治疗,但几乎三分之一的患者罹患进行性地图状萎缩。其为与进行性视觉障碍相关的较晚阶段。患者失去其视力及独立性。其日常生活因为不能驾驶、阅读、看电视或识别面部而严重受影响。wAMD患者通常在现实世界环境中治疗不足且需要返回门诊以进行频繁的玻璃体内注射。
目前无治疗可用于任何类型的地图状萎缩,包括在wAMD期间发展的地图状萎缩。此外,一些证据表明,较频繁的抗VEGF治疗可能与较高比率的地图状萎缩发展相关。
因此,迫切需要提供可在抗VEGF治疗中频繁使用而同时减轻并行地图状萎缩发展的风险的新治疗性生物分子。
发明内容
本发明基于将与血管内皮生长因子(VEGF)特异性结合的抗原结合位点与同原肌球蛋白受体激酶B(TrkB)特异性结合的抗原结合位点组合在单一结合分子内的概念。
在第一方面中,本发明涉及一种结合分子,其包含至少一个与血管内皮生长因子(VEGF)特异性结合的抗原结合位点及至少一个与原肌球蛋白受体激酶B(TrkB)特异性结合的抗原结合位点。在关于第一方面的一个实施方案中,结合分子是双特异性的且是四价的。在关于根据第一方面或其实施方案中的任一者的结合分子的另一实施方案中,该至少一个与VEGF特异性结合的抗原结合位点为免疫球蛋白(Ig)分子。在关于根据第一方面或其实施方案中的任一者的结合分子的另一实施方案中,该至少一个与TrkB特异性结合的抗原结合位点与Ig分子的重链的C端融合。在关于根据第一方面或其实施方案中的任一者的结合分子的另一实施方案中,该至少一个与TrkB特异性结合的抗原结合位点包含一个或多个scFv。在关于根据第一方面或其实施方案中的任一者的结合分子的另一实施方案中,该至少一个与VEGF特异性结合的抗原结合位点为免疫球蛋白(Ig)分子,且该至少一个与TrkB特异性结合的抗原结合位点包含一个或多个scFv。在一相关实施方案中,该一个或多个scFv自N端至C端具有VL-VH定向。在又一相关实施方案中,该一个或多个scFv与Ig分子的重链的C端融合。在关于根据第一方面或其实施方案中的任一者的结合分子的另一实施方案中,Ig分子为单克隆抗体、人类单克隆抗体、人源化单克隆抗体、嵌合抗体、(scFv)2或抗体的片段,诸如F(ab')2片段。在关于根据第一方面或其实施方案中的任一者的结合分子的另一实施方案中,Ig分子为IgG或F(ab')2。在关于根据第一方面或其实施方案中的任一者的结合分子的另一实施方案中,该一个或多个scFv通过肽接头,优选地长度为约4至20个氨基酸的肽接头与Ig分子融合。
在关于根据第一方面或其实施方案中的任一者的结合分子的另一实施方案中,与TrkB特异性结合的抗原结合位点选自:
a)包含轻链CDR的抗原结合位点,该轻链CDR包含SEQ ID NO:201(CDR1)、SEQ IDNO:202(CDR2)及SEQ ID NO:203(CDR3)的氨基酸序列,及
包含重链CDR的抗原结合位点,该重链CDR包含SEQ ID NO:204(CDR1)、SEQ ID NO:205(CDR2)及SEQ ID NO:206(CDR3)的氨基酸序列;或
包含重链CDR的抗原结合位点,该重链CDR包含SEQ ID NO:207(CDR1)、SEQ ID NO:208(CDR2)及SEQ ID NO:209(CDR3)的氨基酸序列;或
包含重链CDR的抗原结合位点,该重链CDR包含SEQ ID NO:210(CDR1)、SEQ ID NO:211(CDR2)及SEQ ID NO:212(CDR3)的氨基酸序列。
在关于根据第一方面或其实施方案中的任一者的结合分子的另一实施方案中,与TrkB特异性结合的抗原结合位点选自:
a)包含轻链可变域及重链可变域的抗原结合位点,该轻链可变域包含与SEQ IDNO:213或215的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列,该重链可变域包含与SEQ ID NO:214或216的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列。
在关于根据第一方面或其实施方案中的任一者的结合分子的另一实施方案中,结合分子包含SEQ ID NO:222的氨基酸序列、或SEQ ID NO:223的氨基酸序列、或SEQ ID NO:224的氨基酸序列或SEQ ID NO:225的氨基酸序列。
在关于根据第一方面或其实施方案中的任一者的结合分子的另一实施方案中,与VEGF特异性结合的抗原结合位点选自由抗原结合位点a)至c)组成的组:
a)包含轻链CDR的抗原结合位点,该轻链CDR包含SEQ ID NO:145(CDR1)、SEQ IDNO:146(CDR2)及SEQ ID NO:147(CDR3)的氨基酸序列,及
包含重链CDR的抗原结合位点,该重链CDR包含SEQ ID NO:148(CDR1)、SEQ ID NO:149(CDR2)及SEQ ID NO:150(CDR3)的氨基酸序列;或
包含重链CDR的抗原结合位点,该重链CDR包含SEQ ID NO:151(CDR1)、SEQ ID NO:152(CDR2)及SEQ ID NO:153(CDR3)的氨基酸序列;或
包含重链CDR的抗原结合位点,该重链CDR包含SEQ ID NO:154(CDR1)、SEQ ID NO:155(CDR2)及SEQ ID NO:156(CDR3)的氨基酸序列;
b)包含轻链CDR的抗原结合位点,该轻链CDR包含SEQ ID NO:157(CDR1)、SEQ IDNO:158(CDR2)及SEQ ID NO:159(CDR3)的氨基酸序列,及
包含重链CDR的抗原结合位点,该重链CDR包含SEQ ID NO:160(CDR1)、SEQ ID NO:161(CDR2)及SEQ ID NO:162(CDR3)的氨基酸序列;或
包含重链CDR的抗原结合位点,该重链CDR包含SEQ ID NO:163(CDR1)、SEQ ID NO:164(CDR2)及SEQ ID NO:165(CDR3)的氨基酸序列;或
包含重链CDR的抗原结合位点,该重链CDR包含SEQ ID NO:166(CDR1)、SEQ ID NO:167(CDR2)及SEQ ID NO:168(CDR3)的氨基酸序列;
c)包含轻链CDR的抗原结合位点,该轻链CDR包含SEQ ID NO:169(CDR1)、SEQ IDNO:170(CDR2)及SEQ ID NO:171(CDR3)的氨基酸序列,及
包含重链CDR的抗原结合位点,该重链CDR包含SEQ ID NO:172(CDR1)、SEQ ID NO:173(CDR2)及SEQ ID NO:174(CDR3)的氨基酸序列;或
包含重链CDR的抗原结合位点,该重链CDR包含SEQ ID NO:175(CDR1)、SEQ ID NO:176(CDR2)及SEQ ID NO:177(CDR3)的氨基酸序列;或包含重链CDR的抗原结合位点,该重链CDR包含SEQ ID NO:178(CDR1)、SEQ ID NO:179(CDR2)及SEQ ID NO:180(CDR3)的氨基酸序列。
在关于根据第一方面或其实施方案中的任一者的结合分子的另一实施方案中,与VEGF特异性结合的抗原结合位点选自由抗原结合位点a)至d)组成的组:
a)包含轻链可变域及重链可变域的抗原结合位点,该轻链可变域包含与SEQ IDNO:181的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列,该重链可变域包含与SEQ ID NO:182的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列;
b)包含轻链可变域及重链可变域的抗原结合位点,该轻链可变域包含与SEQ IDNO:183的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列,该重链可变域包含与SEQ ID NO:184的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列;
c)包含轻链可变域及重链可变域的抗原结合位点,该轻链可变域包含与SEQ IDNO:189的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列,该重链可变域包含与SEQ ID NO:190、191、192或194的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列;
d)包含轻链可变域及重链可变域的抗原结合位点,该轻链可变域包含与SEQ IDNO:193的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列,该重链可变域包含与SEQ ID NO:190、191、192或194的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列。
在关于根据第一方面或其实施方案中的任一者的结合分子的另一实施方案中,与VEGF特异性结合的抗原结合位点选自由抗原结合位点a)至d)组成的组:
a)包含轻链及重链的抗原结合位点,该轻链包含与SEQ ID NO:185的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列,该重链包含与SEQ ID NO:186的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列;
b)包含轻链及重链的抗原结合位点,该轻链包含与SEQ ID NO:187的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列,该重链包含与SEQ ID NO:188的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列;
c)包含轻链及重链的抗原结合位点,该轻链包含与SEQ ID NO:195的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列,该重链包含与SEQ ID NO:196、197、198或200的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列;
d)包含轻链及重链的抗原结合位点,该轻链包含与SEQ ID NO:199的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列,该重链包含与SEQ ID NO:196、197、198或200的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列。
在第二方面中,本发明涉及一种结合分子,其包含轻链及重链,该轻链包含与SEQID NO:1、3、5、7、9、11、13、15、17、19、21、23、25、27、29、31、33、35、37、39、41、43、45、47、49、51、53、55、57、59、61、63、65、67、69、71、73、75、77、79、81、83、85、87、89、91、93、95、97、99、101、103、105、107、109、111、113、115、117、119、121、123、125、127、129、131、133、135、137、139、141或143的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列,该重链包含与SEQ ID NO:2、4、6、8、10、12、14、16、18、20、22、24、26、28、30、32、34、36、38、40、42、44、46、48、50、52、54、56、58、60、62、64、66、68、70、72、74、76、78、80、82、84、86、88、90、92、94、96、98、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、136、138、140、142或144的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列。
在第三方面中,本发明涉及一种结合分子,其包含:(i)包含SEQ ID NO:41的氨基酸序列的轻链及包含SEQ ID NO:42的氨基酸序列的重链;或(ii)包含SEQ ID NO:43的氨基酸序列的轻链及包含SEQ ID NO:44的氨基酸序列的重链;或(iii)包含SEQ ID NO:45的氨基酸序列的轻链及包含SEQ ID NO:46的氨基酸序列的重链;或(iv)包含SEQ ID NO:47的氨基酸序列的轻链及包含SEQ ID NO:48的氨基酸序列的重链;或(v)包含SEQ ID NO:49的氨基酸序列的轻链及包含SEQ ID NO:50的氨基酸序列的重链;或(vi)包含SEQ ID NO:51的氨基酸序列的轻链及包含SEQ ID NO:52的氨基酸序列的重链;或(vii)包含SEQ ID NO:53的氨基酸序列的轻链及包含SEQ ID NO:54的氨基酸序列的重链;或(viii)包含SEQ ID NO:55的氨基酸序列的轻链及包含SEQ ID NO:56的氨基酸序列的重链;或(ix)包含SEQ ID NO:57的氨基酸序列的轻链及包含SEQ ID NO:58的氨基酸序列的重链;或(x)包含SEQ ID NO:59的氨基酸序列的轻链及包含SEQ ID NO:60的氨基酸序列的重链;或(xi)包含SEQ ID NO:61的氨基酸序列的轻链及包含SEQ ID NO:62的氨基酸序列的重链;或(xii)包含SEQ ID NO:63的氨基酸序列的轻链及包含SEQ ID NO:64的氨基酸序列的重链;或(xiii)包含SEQ IDNO:65的氨基酸序列的轻链及包含SEQ ID NO:66的氨基酸序列的重链;或(xiv)包含SEQ IDNO:67的氨基酸序列的轻链及包含SEQ ID NO:68的氨基酸序列的重链;或(xv)包含SEQ IDNO:69的氨基酸序列的轻链及包含SEQ ID NO:70的氨基酸序列的重链;或(xvi)包含SEQ IDNO:71的氨基酸序列的轻链及包含SEQ ID NO:72的氨基酸序列的重链;或(xvii)包含SEQID NO:73的氨基酸序列的轻链及包含SEQ ID NO:74的氨基酸序列的重链;或(xviii)包含SEQ ID NO:75的氨基酸序列的轻链及包含SEQ ID NO:76的氨基酸序列的重链;或(xix)包含SEQ ID NO:77的氨基酸序列的轻链及包含SEQ ID NO:78的氨基酸序列的重链;或(xx)包含SEQ ID NO:79的氨基酸序列的轻链及包含SEQ ID NO:80的氨基酸序列的重链;或(xxi)包含SEQ ID NO:81的氨基酸序列的轻链及包含SEQ ID NO:82的氨基酸序列的重链;或(xxii)包含SEQ ID NO:83的氨基酸序列的轻链及包含SEQ ID NO:84的氨基酸序列的重链;或(xxiii)包含SEQ ID NO:85的氨基酸序列的轻链及包含SEQ ID NO:86的氨基酸序列的重链;或(xxiv)包含SEQ ID NO:87的氨基酸序列的轻链及包含SEQ ID NO:88的氨基酸序列的重链;或(xxv)包含SEQ ID NO:89的氨基酸序列的轻链及包含SEQ ID NO:90的氨基酸序列的重链;或(xxvi)包含SEQ ID NO:91的氨基酸序列的轻链及包含SEQ ID NO:92的氨基酸序列的重链;或(xxvii)包含SEQ ID NO:93的氨基酸序列的轻链及包含SEQ ID NO:94的氨基酸序列的重链;或(xxviii)包含SEQ ID NO:95的氨基酸序列的轻链及包含SEQ ID NO:96的氨基酸序列的重链;或(xxix)包含SEQ ID NO:97的氨基酸序列的轻链及包含SEQ ID NO:98的氨基酸序列的重链;或(xxx)包含SEQ ID NO:99的氨基酸序列的轻链及包含SEQ ID NO:100的氨基酸序列的重链;或(xxxi)包含SEQ ID NO:101的氨基酸序列的轻链及包含SEQ IDNO:102的氨基酸序列的重链;或(xxxii)包含SEQ ID NO:103的氨基酸序列的轻链及包含SEQ ID NO:104的氨基酸序列的重链;或(xxxiii)包含SEQ ID NO:105的氨基酸序列的轻链及包含SEQ ID NO:106的氨基酸序列的重链;或(xxxiv)包含SEQ ID NO:107的氨基酸序列的轻链及包含SEQ ID NO:108的氨基酸序列的重链;或(xxxv)包含SEQ ID NO:109的氨基酸序列的轻链及包含SEQ ID NO:110的氨基酸序列的重链;或(xxxvi)包含SEQ ID NO:111的氨基酸序列的轻链及包含SEQ ID NO:112的氨基酸序列的重链;或(xxxvii)包含SEQ IDNO:113的氨基酸序列的轻链及包含SEQ ID NO:114的氨基酸序列的重链;或(xxxviii)包含SEQ ID NO:115的氨基酸序列的轻链及包含SEQ ID NO:116的氨基酸序列的重链;或(xxxix)包含SEQ ID NO:117的氨基酸序列的轻链及包含SEQ ID NO:118的氨基酸序列的重链;或(xl)包含SEQ ID NO:119的氨基酸序列的轻链及包含SEQ ID NO:120的氨基酸序列的重链;或(xli)包含SEQ ID NO:121的氨基酸序列的轻链及包含SEQ ID NO:122的氨基酸序列的重链;或(xlii)包含SEQ ID NO:123的氨基酸序列的轻链及包含SEQ ID NO:124的氨基酸序列的重链;或(xliii)包含SEQ ID NO:125的氨基酸序列的轻链及包含SEQ ID NO:126的氨基酸序列的重链;或(xliv)包含SEQ ID NO:127的氨基酸序列的轻链及包含SEQ IDNO:128的氨基酸序列的重链;或(xlv)包含SEQ ID NO:129的氨基酸序列的轻链及包含SEQID NO:130的氨基酸序列的重链;或(xlvi)包含SEQ ID NO:131的氨基酸序列的轻链及包含SEQ ID NO:132的氨基酸序列的重链;或(xlvii)包含SEQ ID NO:133的氨基酸序列的轻链及包含SEQ ID NO:134的氨基酸序列的重链;或(xlviii)包含SEQ ID NO:135的氨基酸序列的轻链及包含SEQ ID NO:136的氨基酸序列的重链;或(xlix)包含SEQ ID NO:137的氨基酸序列的轻链及包含SEQ ID NO:138的氨基酸序列的重链;或(l)包含SEQ ID NO:139的氨基酸序列的轻链及包含SEQ ID NO:140的氨基酸序列的重链;或(li)包含SEQ ID NO:141的氨基酸序列的轻链及包含SEQ ID NO:142的氨基酸序列的重链;或(lii)包含SEQ ID NO:143的氨基酸序列的轻链及包含SEQ ID NO:144的重链。
在第四方面中,本发明涉及一种TrkB结合分子,其包含两个scFv或由其组成,其中各scFv与TrkB特异性结合。
在关于第四方面的另一实施方案中,TrkB结合分子进一步包含Ig分子。
在关于第四方面或其实施方案中的任一者的另一实施方案中,Ig分子为单克隆抗体;人类单克隆抗体;人源化单克隆抗体;嵌合抗体;抗体的片段,诸如Fv、Fab、Fab'或F(ab')2片段;单链抗体,诸如单链可变片段(single chain variable fragment;scFv);小模块免疫药物(Small Modular Immunopharmaceutical;SMIP);域抗体;纳米抗体;或双抗体。
在关于第四方面或其实施方案中的任一者的另一实施方案中,各scFv与Ig分子的重链的C端融合。在关于第四方面或其实施方案中的任一者的另一实施方案中,Ig分子为IgG、F(ab)、F(ab')2。在关于第四方面或其实施方案中的任一者的另一实施方案中,Ig分子包含Fc区或由其组成。在关于第四方面或其实施方案中的任一者的另一实施方案中,TrkB结合分子是双特异性的且是四价的。
在第五方面中,本发明涉及一种与TrkB特异性结合的scFv结合,其包含(i)包含SEQ ID NO:213的氨基酸序列的轻链可变域及包含SEQ ID NO:214的氨基酸序列的重链可变域;或(ii)包含SEQ ID NO:215的氨基酸序列的轻链可变域及包含SEQ ID NO:216的氨基酸序列的重链可变域。
在关于第五方面的另一实施方案中,scFv包含SEQ ID NO:222的氨基酸序列、或SEQ ID NO:223的氨基酸序列、或SEQ ID NO:224的氨基酸序列或SEQ ID NO:225的氨基酸序列。
在第六方面中,本发明涉及一种与VEGF特异性结合的抗体分子,其包含:
(i)轻链可变域,其包含SEQ ID NO:189的氨基酸序列,及
重链可变域,其包含SEQ ID NO:191的氨基酸序列;或
重链可变域,其包含SEQ ID NO:192的氨基酸序列;或
重链可变域,其包含SEQ ID NO:194的氨基酸序列;
(ii)重链可变域,其包含SEQ ID NO:190的氨基酸序列,及
轻链可变域,其包含SEQ ID NO:192的氨基酸序列;或
轻链可变域,其包含SEQ ID NO:193的氨基酸序列。
在关于第六方面的另一实施方案中,抗体分子包含:
轻链,其包含SEQ ID NO:195或199的氨基酸序列,及
重链,其包含SEQ ID NO:196、197、198或200的氨基酸序列。
在第七方面中,本发明涉及一种经分离的核酸分子,其编码前述方面及实施方案中的任一者的结合分子的(i)重链或重链可变域和/或(ii)轻链或轻链可变域。
在第八方面中,本发明涉及一种经分离的核酸分子,其编码根据前述方面及实施方案中的任一者的TrkB结合分子的(i)重链或重链可变域和/或(ii)轻链或轻链可变域。
在第九方面中,本发明涉及一种经分离的核酸分子,其编码根据前述方面及实施方案中的任一者的scFv的(i)重链可变域和/或(ii)轻链可变域。
在第十方面中,本发明涉及一种经分离的核酸分子,其编码根据前述方面及实施方案中的任一者的抗体分子的(i)重链或重链可变域和/或(ii)轻链或轻链可变域。
在第十一方面中,本发明涉及一种病毒载体,其包含根据第七、第八、第九或第十方面的经分离的核酸分子。
在第十二方面中,本发明涉及一种表达载体,其包含根据第十一方面的核酸分子。
在第十三方面中,本发明涉及一种宿主细胞,其用根据第十二方面的表达载体转染。
在第十四方面中,本发明涉及一种制造根据前述方面及实施方案中的任一者的结合分子、TrkB结合分子、scFv或抗体分子的方法,其包含
(a)在允许该分子表达的条件下培养第十三方面的宿主细胞;及
(b)回收该分子;及任选
(c)进一步纯化和/或修饰和/或调配该分子。
在第十五方面中,本发明涉及根据前述方面及实施方案中的任一者的结合分子、TrkB结合分子、scFv或抗体分子,其用于药物中。
在关于第十五方面的一个实施方案中,本发明涉及根据第十五方面使用的结合分子、TrkB结合分子、scFv或抗体分子,其中用途为治疗眼部或视网膜或神经退化性疾病。
在关于第十五方面的另一实施方案中,本发明涉及根据第十五方面使用的结合分子、TrkB结合分子、scFv或抗体分子,其中该用途为用于治疗神经/神经元眼部或视网膜疾病。
在关于第十五方面的另一实施方案中,本发明涉及根据第十五方面使用的结合分子、TrkB结合分子、scFv或抗体分子,其中该用途为用于治疗黄斑变性、老年性黄斑变性、糖尿病性视网膜病变、糖尿病性黄斑水肿、色素性视网膜炎、遗传性视网膜营养性萎缩、遗传性黄斑营养不良、近视变性、地图状萎缩、视网膜动脉阻塞、眼内炎、葡萄膜炎、囊样黄斑水肿、继发于任何视网膜疾病的脉络膜新生血管性膜、视神经病、青光眼、视网膜脱落、毒性视网膜病、辐射性视网膜病、及创伤性视网膜病、前驱性及轻度至中度阿尔茨海默氏症(Alzheimer′s disease),延迟患有阿尔茨海默氏病、亨廷顿氏症(Huntington′sdisease)、帕金森氏症(Parkinson′s disease)、严重抑郁症、精神分裂症、与精神分裂症相关的认知障碍的患者的疾病进展,预防患有减弱精神病综合征的个体的第一次精神病发作,预防患有精神分裂症、难治性抑郁、暴食、肥胖症或代谢综合征的患者复发。
在关于第十五方面的一个实施方案中,本发明涉及根据第十五方面使用的结合分子、TrkB结合分子、scFv或抗体分子,其中该用途为用于治疗黄斑变性,且特别是湿性年龄相关的黄斑变性(wet age-related macular degeneration;wAMD)。
在关于第十五方面的一个实施方案中,本发明涉及根据第十五方面使用的结合分子、TrkB结合分子、scFv或抗体分子,其中该用途为用于治疗视网膜静脉阻塞(retinalvein occlusion;RVO)。
在关于第十五方面的一个实施方案中,本发明涉及根据第十五方面使用的结合分子、TrkB结合分子、scFv或抗体分子,其中该用途为用于治疗和/或预防地图状萎缩。
在第十六方面中,本发明涉及一种药物组合物,其包含药学上可接受的载剂及根据前述方面及实施方案中的任一者的结合分子、TrkB结合分子、scFv或抗体分子。
在第十七方面中,本发明涉及一种治疗或预防眼部疾病或视网膜疾病或神经退化性疾病的方法,其包含向需要其的患者施用治疗有效量的根据前述方面及实施方案中的任一者的结合分子、TrkB结合分子、scFv或抗体分子。
在第十八方面中,本发明涉及一种根据前述方面及实施方案中的任一者的结合分子、TrkB结合分子、scFv或抗体分子的用途,其用于制备治疗或预防眼部疾病或视网膜疾病或神经退化性疾病的药物组合物。
附图说明
图1:系列1至系列4的VEGF-TrkB单一结合分子的设计说明。
图2A至图2B:在与增加浓度的指示分子一起培育之后,在稳定表达人类TrkB的CHO细胞中测量(A)TrkB磷酸化(Y706/707)或(B)ERK1/2磷酸化(T202/Y204-ERK1)(T185/Y187-ERK2)。数据表示平均值+/-SEM。
图3A至图3D:在与增加浓度的指示分子一起培育之后,在稳定表达(A)食蟹猕猴TrkB、(B)兔TrkB、(C)大鼠TrkB或(D)小鼠TrkB的CHO细胞中测量TrkB磷酸化(Y706/707)。数据表示平均值+/-SEM。
图4A至图4C:在与增加浓度的指示分子一起培育之后,在稳定表达(A)人类TrkA、(B)人类TrkB或(C)人类TrkC的CHO细胞中测量Trk磷酸化(Y706/707)。TrkA的天然配体NGF、TrkB的天然配体BDNF及TrkC的天然配体NT-3用作对照。数据表示平均值+/-SEM。
图5A至图5B:(A)将稳定表达人类TrkB的CHO细胞与指示浓度的天然TrkB配体BDNF(重复两次)、1nM BDNF+指示浓度的促效TrkB抗体C2(重复三次)或1nM BDNF+指示浓度的多普单抗(Doppelmab)TPP-11736(重复三次)一起培育。(B)通过表面TrkB受体的免疫荧光染色,随后共焦显微分析来评价TrkB内化。热图的深色及浅色场分别表示高于荧光临限值的高及低百分比的细胞。
图6:在200ng/mL人类VEGF-A预培育或未预培育的情况下,在与增加浓度的指示分子一起培育之后,在稳定表达人类TrkB的CHO细胞中测量ERK1/2磷酸化(T202/Y204-ERK1)(T185/Y187-ERK2)。仅与VEGF-A的培育充当对照。数据表示平均值。为了清晰起见,省略误差杆。
图7:糖尿病诱发的视网膜神经退化的大鼠模型中的TrkB活化的神经保护性功能。动物用STZ处理以诱导高血糖症。接着,通过在即将玻璃体内施用促效TrkB抗体C2或多普单抗TPP-11736之前及其两周后进行视网膜电描记术(ERG)及视杆驱动的B波隐含时间延迟来评价视网膜功能;平均值+/-SEM;n.s.p>0.05,不显著;**p<0.01;***p<0.001;单向Anova与Tukey多比较测试。抗TNP充当同型对照抗体。
图8A至图8B:通过测量VEGF受体2磷酸化(Y1175-VEGFR2)评价VEGF-A清除。出于此目的,使人类视网膜微血管内皮细胞(human retinal microvascular endothelial cell;HRMEC)饥饿,且接着在与增加浓度的指示分子一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。(A)多普单抗TPP-11735、TPP-736、TPP-737及TPP-738的比较。(B)TPP-11736及TPP-11738与艾力雅的比较。未刺激细胞(基础)及无抗体处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。
图9A至图9B:通过ERK1/2磷酸化(T202/Y204-ERK1)(T185/Y187-ERK2)评价VEGF-A清除。出于此目的,使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的指示分子一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。(A)多普单抗TPP-11735、TPP-736、TPP-737及TPP-738的比较。(B)TPP-11736、TPP-738与艾力雅的比较。未刺激细胞(基础)及无抗体处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。
图10:通过测量p38 MAPK磷酸化(T180/Y182)评价VEGF-A清除。出于此目的,使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的指示分子一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。未刺激细胞(基础)及无抗体处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。
图11A至图11E:使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的指示分子:(A)TPP-11735、(B)TPP-11736、(C)艾力雅、(D)TPP-11737、(E)TPP-11738一起预培育或未预培育的情况下,与10ng/mL人类VEGF一起培育。分子浓度以mol/L为单位给出。通过基于影像的HRMEC细胞数目的定量来评价VEGF-A清除。显示相对细胞数目。将在t=0时的细胞数目设定为一。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。
图12:在与增加浓度的指示分子一起培育之后,在稳定表达人类TrkB的CHO细胞中测量TrkB磷酸化(Y706/707)。数据表示平均值+/-SEM。
图13:在与增加浓度的指示分子一起培育之后,在稳定表达人类TrkB的CHO细胞中测量ERK1/2磷酸化(T202/Y204-ERK1)(T185/Y187-ERK2)。数据表示平均值+/-SEM。
图14A至图14B:通过测量(A)VEGF受体2磷酸化(Y1175)或(B)ERK1/2磷酸化(T202/Y204-ERK1)(T185/Y187-ERK2)评价VEGF-A清除。出于此目的,使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的指示分子一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。未刺激细胞(基础)及无分子处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。
图15:通过基于影像的HRMEC细胞数目的定量来评价VEGF-A清除。出于此目的,使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与0.5nM多普单抗或1nM艾力雅一起预培育或未预培育的情况下,与10ng/mL人类VEGF一起培育。每四个小时记录影像,持续总共96小时的时段。显示相对细胞数目。将在t=0时的细胞数目设定为一。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。
图16:内皮出芽通过共焦显微术评价且显示获自Z-堆栈的最大投影的球体周界。出于此目的,人类视网膜微血管内皮细胞(HRMEC)的球体包埋于胶原蛋白基质中。通过在与2.5nM的指示多普单抗或5nM艾力雅一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育24小时,来诱导内皮出芽24小时。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。
图17A至图17C:通过测量(A)VEGF受体2磷酸化(Y1175)、(B)ERK1/2磷酸化(T202/Y204-ERK1)(T185/Y187-ERK2)或(C)p38 MAPK磷酸化(T180/Y182)评价VEGF-A清除。出于此目的,使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的多普单抗TPP-11736或TPP-13788(B20 IgG)一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。无抗体处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。
图18:内皮出芽通过共焦显微术评价且显示获自Z-堆栈的最大投影的球体周界。出于此目的,人类视网膜微血管内皮细胞(HRMEC)的球体包埋于胶原蛋白基质中。通过在与2.5nM的多普单抗TPP-11736或2.5nM TPP-13788(B20 IgG)一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育,来诱导内皮出芽24小时。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。
图19A至图19C:在与增加浓度的指示分子一起培育之后,在稳定表达人类TrkB的CHO细胞中测量(A)TrkB磷酸化(Y706/707)或(B及C)ERK1/2磷酸化(T202/Y204-ERK1)(T185/Y187-ERK2)。数据表示平均值+/-SEM。
图20A至图20B:在与增加浓度的指示分子一起培育之后,在稳定表达(A)食蟹猕猴TrkB或(B)大鼠TrkB的CHO细胞中测量TrkB磷酸化(Y706/707)。数据表示平均值+/-SEM。
图21A至图21C:通过测量(A)VEGF受体2磷酸化(Y1175)、(B)ERK1/2磷酸化(T202/Y204-ERK1)(T185/Y187-ERK2)或(C)Src磷酸化(Y419)评价VEGF-A清除。出于此目的,使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的指示分子一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。无抗体处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。
图22:内皮出芽通过共焦显微术评价且显示获自Z-堆栈的最大投影的球体周界。出于此目的,人类视网膜微血管内皮细胞(HRMEC)的球体包埋于胶原蛋白基质中。通过在与2.5nM的指示分子一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育,来诱导内皮出芽24小时。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。n.s.p>0.05,不显著,****p<0.0001。
图23A至图23D:通过基于影像的HRMEC细胞数目的定量来评价VEGF-A清除。于此目的,使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的指示分子:(A)TPP-11736、(B)TPP-14936、(C)TPP-14937或(D)艾力雅一起预培育或未预培育的情况下,与10ng/mL人类VEGF一起培育。结合分子/艾力雅浓度以mol/L为单位给出。每四个小时记录影像,持续总共84小时的时段。显示相对细胞数目。将在t=0时的细胞数目设定为一。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。
图24A至图24B:在增加浓度的所指示的第二系列分子与一起培育之后,在稳定表达人类TrkB的CHO细胞中测量(A)TrkB磷酸化(Y706/707)或(B)ERK1/2磷酸化(T202/Y204-ERK1)(T185/Y187-ERK2)。数据表示平均值+/-SEM。
图25:描绘所提出的VEGF诱导的与单一结合分子的聚类的潜在作用,导致TrkB活化的功效及效能增加的草图。
图26A至图26B:在与增加浓度的所指示的第二系列分子一起培育之后,在稳定表达(A)食蟹猕猴TrkB或(B)大鼠TrkB的CHO细胞中测量TrkB磷酸化(Y706/707)。数据表示平均值+/-SEM。
图27A至图27C:在与200ng/mL人类VEGF-A一起预培育或未预培育的情况下,在与增加浓度的多普单抗(A)TPP-14940、(B)TPP-14941或(C)C2抗体一起培育之后,在稳定表达人类TrkB的CHO细胞中测量TrkB磷酸化(Y706/707)。数据表示平均值+/-SEM。
图28A至图28C:在与200ng/mL人类VEGF-A一起预培育或未预培育的情况下,在与增加浓度的多普单抗((A)TPP-14940、(B)TPP-14941或(C)C2抗体一起培育之后,在稳定表达人类TrkB的CHO细胞中测量ERK1/2磷酸化(T202/Y204-ERK1)(T185/Y187-ERK2)。数据表示平均值+/-SEM。
图29A至图29B:在与增加浓度的人类VEGF-A、或与增加浓度的单独BDNF或增加浓度的BDNF与200ng/mL固定浓度的hVEGF一起培育之后,在稳定表达人类TrkB的CHO细胞中测量(A)TrkB磷酸化(Y706/707)或(B)ERK1/2磷酸化(T202/Y204-ERK1)(T185/Y187-ERK2)。数据表示平均值+/-SEM。
图30A至图30C:在与200ng/mL人类VEGF-A一起预培育或未预培育的情况下,在与增加浓度的多普单抗(A)TPP-14940、(B)TPP-14941或(C)C2抗体一起培育之后,在稳定表达食蟹猕猴TrkB的CHO细胞中测量TrkB磷酸化(Y706/707)。数据表示平均值+/-SEM。
图31A至图31C:在与200ng/mL人类VEGF-A一起预培育或未预培育的情况下,在与增加浓度的多普单抗(A)TPP-14940、(B)TPP-14941或(C)C2抗体一起培育之后,在稳定表达食蟹猕猴TrkB的CHO细胞中测量ERK1/2磷酸化(T202/Y204-ERK1)(T185/Y187-ERK2)。数据表示平均值+/-SEM。
图32A至图32C:通过测量(A)VEGF受体2磷酸化(Y1175)、(B)ERK1/2磷酸化(T202/Y204-ERK1)(T185/Y187-ERK2)或(C)Src磷酸化(Y419)评价VEGF-A清除。出于此目的,使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的指示分子一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。无抗体处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。
图33A至图33C:使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的指示分子:(A)TPP-11736、(B)TPP-14938、(C)TPP-14939一起预培育或未预培育的情况下,与10ng/mL人类VEGF一起培育。分子浓度以mol/L为单位给出。通过基于影像的HRMEC细胞数目的定量来评价VEGF-A清除。显示相对细胞数目。将在t=0时的细胞数目设定为一。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。
图34A至图34C:通过测量(A)VEGF受体2磷酸化(Y1175)、(B)ERK1/2磷酸化(T202/Y204-ERK1)(T185/Y187-ERK2)或(C)Src磷酸化(Y419)评价VEGF-A清除。出于此目的,使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的指示分子一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。无抗体处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。
图35A至图35D:通过基于影像的HRMEC细胞数目的定量来评价VEGF-A清除。于此目的,使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的指示分子:(A)TPP-14936、(B)TPP-14937、(C)TPP-14940或(D)TPP-14941一起预培育或未预培育的情况下,与10ng/mL人类VEGF一起培育。分子浓度以mol/L为单位给出。每四个小时记录影像,持续总共84小时的时段。显示相对细胞数目。将在t=0时的细胞数目设定为一。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。
图36A至图36C:通过测量(A)VEGF受体2磷酸化(Y1175)、(B)ERK1/2磷酸化(T202/Y204-ERK1)(T185/Y187-ERK2)或(C)Src磷酸化(Y419)评价VEGF-A清除。出于此目的,使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的指示分子一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。无抗体处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。
图37A至图37D:通过基于影像的HRMEC细胞数目的定量来评价VEGF-A清除。于此目的,使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的指示分子:(A)TPP-14938、(B)TPP-14939、(C)TPP-14940或(D)TPP-14941一起预培育或未预培育的情况下,与10ng/mL人类VEGF一起培育。分子浓度以mol/L为单位给出。每四个小时记录影像,持续总共84小时的时段。显示相对细胞数目。将在t=0时的细胞数目设定为一。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。
图38:内皮出芽通过共焦显微术评价且显示获自Z-堆栈的最大投影的球体周界。出于此目的,人类视网膜微血管内皮细胞(HRMEC)的球体包埋于胶原蛋白基质中。通过在与2.5nM的指示分子一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育,来诱导内皮出芽24小时。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。n.s.p>0.05无显著差异;相较于50ng/mL hVEGF,§p<0.0001;相较于50ng/mL hVEGF,#p>0.05无显著差异。***p<0.001;单向Anova与Tukey多比较测试。
图39A至图39B:(A)显示实验程序的时间方案。在玻璃体内(ivt)施用抗VEGF化合物(每只眼睛13或26pmol的艾力雅或TPP-14940)或对照(26pmol TPP-11737)之后十五分钟,通过ivt注射每只眼睛施用13pmol人类VEGF-A。PBS注射充当对照。二十四小时后,在分离及固定眼睛之前通过静脉内(iv)注射施用1mL/kg伊凡氏蓝(Evans Blue;EB)溶液(45mg/mL于0.9%盐水中)30分钟。在相同时间点收集血浆样品以确认相等全身性EB暴露。(B)通过利用共焦显微术测量视网膜铺片中的EB外渗来定量Brown Norway大鼠的视网膜中的VEGF-A诱导的高渗透性。沿着锯齿缘切割眼睛,移除晶状体及玻璃体,且将眼杯固定在4℃下的多聚甲醛(4%)中1h且接着转移至在4℃的PBS隔夜。将视网膜与外部区段(巩膜及脉络膜)分开,且转移至载玻片并切割四次以达成平坦三叶草样结构。组织用封固剂(含有DNA染料DAPI的Vectashield H-1200)覆盖且将盖玻片置于顶部上以获得视网膜铺片。样品在639nm波长下激发,且用LSM 700共焦激光扫描显微镜(Carl Zeiss,Jena;放大率800,激光强度2%,60μm的5个堆栈)记录伊凡氏蓝在669nm下的发射,且获得具有最大强度投影的视网膜铺片的影像。在临限值为30的程序ImageJ中打开影像之后,进行荧光强度总和的分析。***p<0.001;*p<0.05;n.s.p>0.05;相对于TPP-11737+PBS,#p>0.05不显著。单向Anova与Tukey多比较测试,n=9-17。
图40A至图40D:在与增加浓度的BDNF或增加浓度的指示分子一起培育之后,在稳定表达人类TrkB的CHO细胞中测量(A及B)TrkB磷酸化(Y706/707)或(C及D)ERK1/2磷酸化(T202/Y204-ERK1)(T185/Y187-ERK2)。
图41A至图41B:(A)将稳定表达人类TrkB的CHO细胞与指示浓度的天然TrkB配体BDNF(重复两次)或1nM BDNF与指示浓度的多普单抗(各重复三次)一起培育。(B)通过表面TrkB受体的免疫荧光染色,随后共焦显微分析来评价TrkB内化。热图的深色及浅色场分别表示高于荧光临限值的高及低百分比的细胞。
图42:通过测量VEGF受体2磷酸化(Y1175)评价VEGF-A清除。出于此目的,使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的指示分子一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。无分子处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。
图43:内皮出芽通过共焦显微术评价且显示获自Z-堆栈的最大投影的球体周界。出于此目的,人类视网膜微血管内皮细胞(HRMEC)的球体包埋于胶原蛋白基质中。通过在与2.5nM的指示分子一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育,来诱导内皮出芽24小时。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。n.s.p>0.05无显著差异;相较于50ng/mL hVEGF,§p<0.0001;相较于50ng/mL hVEGF,#p>0.05无显著差异。***p<0.001;单向Anova与Tukey多比较测试。
图44A至图44D:在与增加浓度的多普单抗(A)TPP-22180与TPP-22204、(B)TPP-22192与TPP-22216、(C)TPP-22190与TPP-22214、(D)TPP-22191与TPP-22215一起培育之后,在稳定表达人类TrkB的CHO细胞中测量TrkB磷酸化(Y706/707)。数据表示平均值+/-SEM。
图45A至图45B:在与增加浓度的多普单抗(A)TPP-22180与TPP-22204、(B)TPP-22192与TPP-22216一起培育之后,在稳定表达大鼠TrkB的CHO细胞中测量TrkB磷酸化(Y706/707)。数据表示平均值+/-SEM。
图46A至图46C:在与增加浓度的C2抗体或多普单抗TPP-22204或TPP-22214一起培育之后,在稳定表达(A)人类TrkA、(B)人类TrkB或(C)人类TrkC的CHO细胞中测量Trk磷酸化(Y706/707)。TrkA的天然配体NGF、TrkB的天然配体BDNF及TrkC的天然配体NT-3用作对照。数据表示平均值+/-SEM。
图47A至图47B:在(A)在具有或不具有0.3nM、1nM或3nM恒定浓度的BDNF的情况下,与增加浓度的C2抗体一起培育;或(B)在具有或不具有0.3nM、1nM或3nM恒定浓度的BDNF的情况下,与增加浓度的多普单抗TPP-22214一起培育之后,在稳定表达人类TrkB受体的CHO细胞中测量TrkB磷酸化(Y706/707)。数据表示平均值+/-SEM。
图48A至图48D:在与(A)200ng/mL人类VEGF-A(hVEGF)、(B)50ng/mL hVEGF、(C)10ng/mL hVEGF或(D)2ng/mL hVEGF一起预培育或未预培育的情况下,在与增加浓度的多普单抗TPP-22214一起培育之后,在稳定表达人类TrkB受体的CHO细胞中测量TrkB磷酸化(Y706/707)。数据表示平均值+/-SEM。
图49A至图49D:在与(A)200ng/mL人类VEGF-A(hVEGF)、(B)50ng/mL hVEGF、(C)10ng/mL hVEGF或(D)2ng/mL hVEGF一起预培育或未预培育的情况下,在与增加浓度的多普单抗TPP-22214一起培育之后,在稳定表达人类TrkB的CHO细胞中测量ERK1/2磷酸化(T202/Y204-ERK1)(T185/Y187-ERK2)。数据表示平均值+/-SEM。
图50:使用尺寸排阻色谱与多角度光散射检测器组合来评价多普单抗复合物的大小。在自尺寸排阻柱洗脱出蛋白质所花费的时间上,监测差示折射率(黑色、深灰色、浅灰色及虚线)及光散射。使用光散射数据来判定各点处的摩尔质量。各峰中点处的摩尔质量由星形指示且使用右轴来测量。研究单独TPP-22214(虚线)或呈各种比率的与VEGF的复合物(黑色20:1、深灰色4:1、浅灰色1:1)。A至D表示基于所测量摩尔质量的可能的复合物示意图。
图51A至图51C:通过在不渗透细胞的情况下对表面TrkB受体进行免疫荧光染色,随后共焦显微分析来评价TrkB内化。将稳定表达人类TrkB的CHO细胞与(A)增加浓度的天然TrkB配体BDNF、(B)增加浓度的TPP-22214或(C)1nM BDNF与增加浓度的TPP-22214一起培育。数据表示表面TrkB染色强度高于临限值的细胞百分比;平均值+/-SEM。
图52:糖尿病诱发的视网膜神经退化的大鼠模型中的TrkB活化的神经保护性功能。动物用STZ处理以诱导高血糖症。接着,通过在即将玻璃体内施用促效TrkB抗体C2或多普单抗TPP-22214之前及其两周后进行视网膜电描记术(ERG)及视杆驱动的B波隐含时间延迟来评价视网膜功能;平均值+/-SEM;n.s.p>0.05;不显著(n.s.),****p<0.0001;单向Anova与Tukey多比较测试。抗TNP充当同型对照抗体。
图53A至53B:通过测量VEGF受体2磷酸化(Y1175)评价VEGF-A清除。出于此目的,使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的指示分子一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。(A)多普单抗TPP-14941、TPP-22216、TPP-22192、TPP-22204及TPP-22180的比较。(B)多普单抗TPP-14940、TPP-14941、TPP-22190、TPP-22214、TPP-22191及TPP-22215的比较。未刺激细胞(基础)及无分子处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。
图54A至图54B:通过测量(A)VEGF受体2(VEGFR2)磷酸化(Y1175)或(B)ERK1/2磷酸化(T202/Y204-ERK1)(T185/Y187-ERK2)评价VEGF-A清除。出于此目的,使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的TPP-22214或艾力雅一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。无分子处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。
图55A至图55E:使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的指示分子:(A)TPPP-22204、(B)TPP-22214c、(C)TPP-22216或(D)艾力雅一起预培育或未预培育的情况下,与10ng/mL人类VEGF一起培育。分子浓度以mol/L为单位给出。通过基于影像的HRMEC细胞数目的定量来评价VEGF-A清除。每四个小时记录影像,持续总共84小时的时段。显示相对细胞数目。将在t=0时的细胞数目设定为一。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。(E)显示相对于艾力雅或TPP-22214的浓度的生长曲线及基础曲线下面积的差异的曲线。
图56A至图56B:通过测量(A)VEGF受体2磷酸化(Y1214)或(B)p38-MAPK磷酸化(T180/Y182)评价VEGF-A清除。出于此目的,使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的TPP-22214或艾力雅一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。无分子处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。
图57A至图57B:人类视网膜微血管内皮细胞(HRMEC)的球体包埋于胶原蛋白基质中。通过在与2.5nM的TPP-22204、TPP-22214、TPP-22215、TPP-22216或5nM艾力雅一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育,来诱导内皮出芽24小时。(A)内皮出芽通过共焦显微术评价且显示获自Z-堆栈的最大投影的球体周界。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。n.s.p>0.05,不显著,****p<0.0001。(B)显示在基础条件下出芽24小时之后或在未预培育或与2.5nM TPP-22214或5nM艾力雅一起预培育的情况下用50ng/mL人类VEGF刺激之后,来自球体的代表性最大投影影像。条(Bar)=100μm。
图58A至图58B:通过测量(A)VEGF受体2磷酸化(Y951)或(B)Src磷酸化(Y419)评价VEGF-A清除。出于此目的,使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的TPP-22214或艾力雅一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。无抗体处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。
图59A至图59B:TPP-22214防止大鼠视网膜中的人类VEGF-A诱导的高渗透性。(A)显示实验程序的时间方案。在玻璃体内(ivt)施用抗VEGF化合物(每只眼睛13或26pmol的艾力雅或TPP-14940)或对照(26pmol TPP-11737)之后十五分钟,通过ivt注射每只眼睛施用13pmol人类VEGF-A。PBS注射充当对照。二十四小时后,在分离及固定眼睛之前通过静脉内(iv)注射施用1mL/kg伊凡氏蓝(Evans Blue;EB)溶液(45mg/mL于0.9%盐水中)30分钟。在相同时间点收集血浆样品以确认相等全身性EB暴露。(B)通过利用共焦显微术测量视网膜铺片中的EB外渗来定量Brown Norway大鼠的视网膜中的VEGF-A诱导的高渗透性。沿着锯齿缘切割眼睛,移除晶状体及玻璃体,且将眼杯固定在4℃下的多聚甲醛(4%)中1h且接着转移至在4℃的PBS隔夜。将视网膜与外部区段(巩膜及脉络膜)分开,且转移至载玻片并切割四次以达成平坦三叶草样结构。组织用封固剂(含有DNA染料DAPI的Vectashield H-1200)覆盖且将盖玻片置于顶部上以获得视网膜铺片。样品在639nm波长下激发,且用LSM 700共焦激光扫描显微镜(Carl Zeiss,Jena;放大率800,激光强度2%,60μm的5个堆栈)记录伊凡氏蓝在669nm下的发射,且获得具有最大强度投影的视网膜铺片的影像。在临限值为30的程序ImageJ中打开影像之后,进行荧光强度总和的分析。***p<0.001;*p<0.05;n.s.p>0.05。单向Anova与Tukey多比较测试,n=9-17。显示与67:1摩尔比的艾力雅:VEGF一起的培育以用于比较。
图60A至图60B:(A)TkrB胞外域(TrkB-ECD)的功能特征。将稳定表达人类TrkB的CHO细胞与增加浓度的天然配体BDNF或10nM BDNF与增加浓度的TrkB-ECD一起培育。通过测量TrkB磷酸化(Y706/707)评价TrkB活化。(B)TPP-22214的TrkB-ECD结合对于抑制VEGF诱导的VEGFR2磷酸化的影响。使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着与50ng/mL人类VEGF、50ng/mL人类VEGF及增加浓度的TPP-22214、或50ng/mL人类VEGF及增加浓度的TPP-22214及100nm TrkB-ECD一起培育。在具有或不具有50ng/mL VEGF的情况下,HRMEC与增加浓度的TrkB-ECD一起培育以及未刺激的细胞(基础)充当对照。通过测量VEGF受体2磷酸化(Y1175)评价VEGF-A清除。数据表示平均值+/-SEM。
图61A至图61B:在与增加浓度的指示分子一起培育之后,在稳定表达人类TrkB的CHO细胞中测量(A)TrkB磷酸化(Y706/707)或(B)ERK1/2磷酸化(T202/Y204-ERK1)(T185/Y187-ERK2)。数据表示平均值+/-SEM。
图62A至图62C:在与200ng/mL人类VEGF-A一起预培育或未预培育的情况下,在与增加浓度的多普单抗(A)TPP-23457、(B)TPP-23459或(C)TPP-6830抗体一起培育之后,在稳定表达人类TrkB的CHO细胞中测量TrkB磷酸化(Y706/707)。数据表示平均值+/-SEM。
图63A至图63C:在与200ng/mL人类VEGF-A一起预培育或未预培育的情况下,在与增加浓度的多普单抗(A)TPP-23457、(B)TPP-23459或(C)TPP-6830抗体一起培育之后,在稳定表达人类TrkB的CHO细胞中测量ERK1/2磷酸化(T202/Y204-ERK1)(T185/Y187-ERK2)。数据表示平均值+/-SEM。
图64A至图64B:在(A)在具有或不具有0.3nM、1nM或3nM恒定浓度的BDNF的情况下,与增加浓度的C2抗体一起培育;或(B)在具有或不具有0.3nM、1nM或3nM恒定浓度的BDNF的情况下,与增加浓度的多普单抗TPP-23457一起培育之后,在稳定表达人类TrkB受体的CHO细胞中测量TrkB磷酸化(Y706/707)。数据表示平均值+/-SEM。
图65A至图65B:在(A)在具有或不具有0.3nM、1nM或3nM恒定浓度的BDNF的情况下,与增加浓度的C2抗体一起培育;或(B)在具有或不具有0.3nM、1nM或3nM恒定浓度的BDNF的情况下,与增加浓度的多普单抗TPP-23457一起培育之后,在稳定表达人类TrkB受体的CHO细胞中测量ERK1/2磷酸化(T202/Y204-ERK1)(T185/Y187-ERK2)。数据表示平均值+/-SEM。
图66A至图66B:通过测量(A)VEGF受体2(VEGFR2)磷酸化(Y1175)或(B)ERK1/2磷酸化(T202/Y204-ERK1)(T185/Y187-ERK2)评价VEGF-A清除。出于此目的,使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的多普单抗TPP-22215、TPP-23457、TPP-23459或艾力雅一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。无分子处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。
具体实施方式
本发明基于将与血管内皮生长因子(VEGF)特异性结合的抗原结合位点与同原肌球蛋白受体激酶B(TrkB)特异性结合的抗原结合位点组合在单一结合分子内的概念。
必须指出的是,在本发明之前,还没有公开或甚至根本没有考虑过制备靶向这两种抗原的结合分子。因此,本发明人制备的结合分子包括至少一个与VEGF特异性结合的抗原结合位点及至少一个与TrkB特异性结合的抗原结合位点。
本发明人的初始目标是设计一种当相较于其各自的单独结合剂,亦即仅与其各自的靶标结合的单独的VEGF或TrkB结合剂,具有相当的功效和/或效能的单一结合分子。这本身已被视为是具有挑战性的,原因在于未完全了解但预期将单独结合剂格式化成单一结合分子将不利地影响单一结合分子内的单独结合剂的初始功效和/或效能。
出人意料地发现,将TrkB活化与VEGF清除组合于单一结合分子中导致TrkB活化的功效以及效能两者出人意料的增加。根据本发明的单一结合分子显示完全TrkB促效活性--与单独TrkB结合剂的部分激动剂活性相对。此外,TrkB活化的效能在VEGF与单一结合分子结合之后进一步增强。
不希望受理论所束缚,似乎VEGF诱导的与本发明的单一结合分子聚类可为造成所观测到的TrkB活化的效能增加的原因。另外,与所提出的VEGF诱导的聚类机制无关,明显地,本发明的结合分子中的TrkB结合位点的设计支持TrkB结合的最佳空间形成,此导致观测到的完全TrkB促效活性。有利的是,通过将VEGF清除(导致抑制血管功能异常及渗漏)与神经保护性TrkB受体的活化(导致神经元死亡减少)组合,患者现获益于单一注射。这是重要的,因为视网膜专家不赞成在同一天向同一眼睛注射超过一次治疗。因此,解决wAMD及GA的两个分开治疗将需要每眼进行两次单独的治疗。综上所述,根据本发明的结合分子对治疗和/或预防视觉功能的丧失,从而改善生活质量是有用的。
在一个方面中,本发明提供一种结合分子,特别是一种具有至少一个与血管内皮生长因子VEGF,优选为VEGF-A特异性结合的抗原结合位点及至少一个与原肌球蛋白受体激酶B(TrkB)特异性结合的抗原结合位点的分子,其具有本文下文所描述的特性中的一或多个。
在另一方面中,本发明的结合分子以高亲和力与人类TrkB结合。在关于此方面的一个实施方案中,本发明的结合分子以KD<500nM与人类TrkB结合。在另一实施方案中,本发明的结合分子以KD<450nM与人类TrkB结合。在另一实施方案中,本发明的结合分子以KD<400nM与人类TrkB结合。在另一实施方案中,本发明的结合分子以KD<300nM与人类TrkB结合。在另一实施方案中,本发明的结合分子以KD<250nM与人类TrkB结合。在关于此方面的一个实施方案中,本发明的结合分子以KD<200nM与人类TrkB结合。在另一实施方案中,本发明的结合分子以KD<150nM与人类TrkB结合。在另一实施方案中,本发明的结合分子以KD<100nM与人类TrkB结合。在另一实施方案中,本发明的结合分子以KD<50nM与人类TrkB结合。
在另一方面中,本发明的结合分子—在包含与200ng/mL人类VEGF-A一起预培育的条件下—以高效能活化TrkB。在关于此方面的一个实施方案中,本发明的结合分子以EC50<100nM活化人类TrkB。在又一实施方案中,本发明的结合分子以EC50<90nm活化人类TrkB。在又一实施方案中,本发明的结合分子以EC50<80nm活化人类TrkB。在又一实施方案中,本发明的结合分子以EC50<70nm活化人类TrkB。在又一实施方案中,本发明的结合分子以EC50<60nm活化人类TrkB。在又一实施方案中,本发明的结合分子以EC50<50nm活化人类TrkB。在又一实施方案中,本发明的结合分子以EC50<40nm活化人类TrkB。在又一实施方案中,本发明的结合分子以EC50<30nm活化人类TrkB。在又一实施方案中,本发明的结合分子以EC50<20nm活化人类TrkB。在又一实施方案中,本发明的结合分子以EC50<10nm活化人类TrkB。
在另一方面中,本发明的结合分子以高亲和力与人类VEGF(优选为VEGF-A)结合。在关于此方面的一个实施方案中,本发明的结合分子以KD<1nM与人类VEGF-A结合。在另一实施方案中,本发明的结合分子以KD<900pM与人类VEGF-A结合。在另一实施方案中,本发明的结合分子以KD<800pM与人类VEGF-A结合。在另一实施方案中,本发明的结合分子以KD<700pM与人类VEGF-A结合。在另一实施方案中,本发明的结合分子以KD<600pM与人类VEGF-A结合。在另一实施方案中,本发明的结合分子以KD<500pM与人类VEGF-A结合。在另一实施方案中,本发明的结合分子以KD<400pM与人类VEGF-A结合。
在另一方面中,本发明的结合分子以高效能抑制VEGF-A磷酸化(Tyr1175)。在关于此方面的一个实施方案中,本发明的结合分子以IC50<1nM抑制人类VEGF-A磷酸化(Tyr1175)。在关于此方面的一个实施方案中,本发明的结合分子以IC50<900pM抑制人类VEGF-A磷酸化(Tyr1175)。在关于此方面的一个实施方案中,本发明的结合分子以IC50<800pM抑制人类VEGF-A磷酸化(Tyr1175)。在关于此方面的一个实施方案中,本发明的结合分子以IC50<700pM抑制人类VEGF-A磷酸化(Tyr1175)。在关于此方面的一个实施方案中,本发明的结合分子以IC50<600pM抑制人类VEGF-A磷酸化(Tyr1175)。在关于此方面的一个实施方案中,本发明的结合分子以IC50<500pM抑制人类VEGF-A磷酸化(Tyr1175)。在关于此方面的一个实施方案中,本发明的结合分子以IC50<400pM抑制人类VEGF-A磷酸化(Tyr1175)。在关于此方面的一个实施方案中,本发明的结合分子以IC50<300pM抑制人类VEGF-A磷酸化(Tyr1175)。
在另一方面中,与天然TrkB配体BDNF相比,本发明的结合分子更强效地诱导TrkB下游信号传递路径的活化。在另一方面中,本发明的结合分子经由TrkB介导的信号传递路径以与BDNF相当的模式调控基因表达。
在又另一方面中,本发明的结合分子不降低BDNF诱导的ERK磷酸化。在另一方面中,本发明的结合分子对TrkB磷酸化和/或活化具有特异性且不会非特异性地磷酸化/活化TrkA或TrkC。
在一个方面中,根据本发明的结合分子适用于预防疾病相关动物模型中的神经退化及视网膜功能损失。在又一方面中,本发明的结合分子通过刺激TrkB依赖性存活信号传递路径且因此提供神经保护而保护患有例如黄斑变性、老年性黄斑变性、地图状萎缩或糖尿病性视网膜病变的患者的视网膜中的神经元、神经胶细胞和/或神经血管单元。
在另一方面中,在例如黄斑变性、老年性黄斑变性、地图状萎缩或糖尿病性视网膜病变中,本发明的结合分子使视网膜中的轴突/树突和/或突触在疾病发作之后再生,且由此使得神经再生。在一个方面中,本发明的结合分子可调配至高浓度以用于玻璃体内注射至眼睛中。
在另一方面中,就抑制VEGF诱导的信号传递、内皮细胞增殖/出芽和/或抑制VEGF诱导的大鼠视网膜中的高渗透性而言,相较于当前抗VEGF标准照护化合物阿柏西普(aflibercept)(艾力雅),根据本发明的结合分子显示优良的VEGF-A清除。
在另一方面中,相较于例如艾力雅或其他IgG抗体,根据本发明的结合分子在兔PK研究中显示实质上更长的玻璃体半衰期。因此,根据本发明的结合分子适合于季度注射或甚至更低频率的注射。
在另一方面中,根据本发明的结合分子适用于靶向患有wAMD及处于发展地图状萎缩风险下的患者的高度未满足的需求。在一相关实施方案中,根据本发明的结合分子尤其适用于治疗患有wAMD的患者及预防发展地图状萎缩。在另一相关实施方案中,延迟发展地图状萎缩,或降低疾病的严重程度,亦即降低地图状萎缩发作和/或其进展速率。就此而言,用根据本发明的结合分子治疗患者可在确切诊断出地图状萎缩之前起始,亦即对于处于发展地图状萎缩风险下的患者。
在另一方面中,根据本发明的结合分子适用于靶向患有视网膜静脉阻塞(CRVO)的患者的高度未满足的需求。
在另一方面中,当相较于当前标准照护(艾力雅)时,根据本发明的结合分子改善ERG缺陷隐含时间。
在一个方面中,根据本发明的结合分子与TrkB的结合不会诱导受体内化。在一相关方面中,当相较于天然配体BDNF时,根据本发明的结合分子与TrkB的结合将导致更少的受体内化。
在一个方面中,与根据本发明的结合分子结合的VEGF-A增加TrkB活化的效能。
该效能增加可例如通过在用单一结合分子处理后,测定适当细胞模型,诸如过度表达(人类)TrkB的CHO细胞中的TrkB或Erk1/2磷酸化的EC50来体外测量(参见实施例)。将在使细胞与适当浓度的人类VEGF-A(hVEGF)(诸如200ng/mL、50ng/mL、10ng/mL或2ng/mL)一起预培育的情况下,测试单一结合分子。在使细胞与人类VEGF-A一起预培育之后,本发明的单一结合分子将显示效能增加,如通过TrkB或Erk1/2磷酸化的EC50所测量,当相较于未与VEGF-A一起预培育的细胞时,效能增加至少大致2倍、3倍、4倍、5倍、6倍、7倍、8倍、9倍或至少大致10倍。
在另一方面中,根据本发明的结合分子显示完全TrkB促效活性。因此,根据本发明的结合分子在活化TrkB上与天然配体BDNF一样有效。
在另一方面中,根据本发明的结合分子可同时活化TrkB受体及清除VEGF,优选为VEGF-A。
定义
未在本文中特别定义的术语应被赋予本领域技术人员依据本发明及上下文将对其赋予的含义。然而,如本说明书中所使用,除非相反说明,否则以下术语具有指定的含义且将遵守以下惯例。
如本文所用,术语“抗原结合位点”包含来源于抗体的重链可变域(VH)及轻链可变域(VL)。在此情况下,各可变域包含3个CDR。在一个方面中,根据本发明的抗原结合位点或该蛋白质的某些部分一般来源于抗体。抗体或免疫球蛋白分子的通用型结构是本领域技术人员熟知的。
“抗体”或“免疫球蛋白分子”(也称为免疫球蛋白,缩写为Ig)是可在脊椎动物的血液或其他体液中发现的γ球蛋白蛋白质,且供免疫系统用于鉴别及中和外来物体,诸如细菌及病毒。其通常由基础结构单元构成,各结构单元具有两条大重链及两条小轻链,形成例如具有一个单元的单体、具有两个单元的二聚体或具有五个单元的五聚体。抗体可通过非共价相互作用与称为抗原的其他分子或结构结合。在抗体将仅以高亲和力与特异性结构结合的意义上,此结合具有特异性。由抗体识别的抗原的独特部分称为抗原决定基或抗原决定子。结合于抗原决定基的抗体部分有时称为互补位且存在于抗体的所谓可变域或可变区(Fv)中。可变域包含三个由构架区(FR)隔开的所谓互补决定区(CDR)。
在本发明的上下文内,对CDR的参考基于不同定义,诸如CCG,也称为IMGT(LefrancMP,PommiéC,Ruiz M,Giudicelli V,Foulquier E,Truong L,Thouvenin-Contet V,Lefranc G.“IMGT unique numbering for immunoglobulin and T cell receptorvariable domains and Ig superfamily V-like domains.”Dev Comp Immunol.2003年1月;27(1):55-77;Giudicelli V,Brochet X,Lefranc MP.“IMGT/V-QUEST:IMGTstandardized analysis of the immunoglobulin(IG)and T cell receptor(TR)nucleotide sequences”.Cold Spring Harb Protoc.2011;2011(6):695-715。CDR的替代定义基于Chothia(Chothia及Lesk,J.Mol.Biol.1987,196:901-917)以及Kabat(E.A.Kabat,T.T.Wu,H.Bilofsky,M.Reid-Miller及H.Perry,Sequence of Proteins ofImmunological Interest,National Institutes of Health,Bethesda(1983))。
如本文所用,表述“可变域”或“可变区”或Fv表示轻链及重链对中的每一者,其直接参与抗体与抗原的结合。轻链的可变域缩写为“VL”,且重链的可变域缩写为“VH”。可变轻链及重链域具有相同的通式结构,且各域包含四个由三个HVR(或CDR)连接的构架(FR)区,其序列是广泛保守的。构架区采用β-折叠构象,且CDR可形成连接β-折叠结构的环。各链中的CDR通过构架区保持其三维结构且与来自另一链的CDR一起形成抗原结合位点。抗体的重链及轻链CDR3区在根据本发明的抗体的结合特异性/亲和力方面发挥尤其重要作用且因此提供本发明的另一目标。如本申请中使用的术语“恒定域”或“恒定区”表示抗体除可变区以外的域的总和。此类恒定域及恒定区是目前本领域所熟知的且例如由Kabat等人(“Sequence of proteins of immunological interest”,US Public Health Services,NIH Bethesda,MD,公开案第91号)描述。
抗体的“Fc部分”不直接参与抗体与抗原的结合,但展现各种效应功能。“抗体的Fc部分”为本领域技术人员熟知的术语且基于抗体的番木瓜蛋白酶裂解而定义。视其重链的恒定区的氨基酸序列而定,抗体或免疫球蛋白分成以下类别:IgA、IgD、IgE、IgG及IgM。根据重链恒定区,不同类别的免疫球蛋白分别称为α、δ、ε、γ及μ。这些中的若干者可进一步分成子类(同型),例如IgGl、IgG2、IgG3及IgG4、IgAl及IgA2。基于补体活化、C1q结合及Fc受体结合,抗体的Fc部分直接参与ADCC(抗体依赖性细胞介导的细胞毒性)及CDC(补体依赖性细胞毒性)。补体活化(Complement activation;CDC)通过补体因子C1q与大部分IgG抗体子类的Fc部分的结合来起始。虽然抗体对于补体系统的影响视某些条件而定,但与C1q的结合由Fc部分内的界定结合位点造成。此类结合位点在目前最佳技术中已知且例如由以下描述:Boakle等人,Nature 282(1975)742-743,Lukas等人,J.Immunol.127(1981)2555-2560,Brunhouse及Cebra,Mol.Immunol.16(1979)907-917,Burton等人,Nature 288(1980)338-344,Thommesen等人,Mol.Immunol.37(2000)995-1004,Idusogie等人,J.Immunol.164(2000)4178-4184,Hezareh等人,J.Virology 75(2001)12161-12168,Morgan等人,Immunology 86(1995)319-324,EP 0307434。此类结合位点为例如L234、L235、D270、N297、E318、K320、K322、P331及P329(根据Kabat EU索引编号,参见下文)。这些残基中介导IgG1中C1q及Fcγ受体结合最关键的残基为L234及L235(Hezareh等人,J.Virology 75(2001)12161-12168)。子类别IgGl及IgG3的抗体通常显示补充活化及Clq及C3结合,而IgG2及IgG4不活化补体系统且不结合Clq及C3。
本领域已进一步研发出抗体且使其成为药物及技术中的通用工具。因此,在本发明的上下文中,术语“抗体分子”或“抗体”或“Ig分子”(本文中同义使用)不仅包括如可在自然界中发现的包含例如两条轻链及两条重链或如骆驼科物种中仅包含两条重链的抗体,亦进一步涵盖所有包含至少一个对抗原具有结合特异性且与免疫球蛋白的可变域具有结构类似性的互补位的分子。
因此,抗体或免疫球蛋白或Ig分子可包含单克隆抗体、人类抗体、人源化抗体、嵌合抗体、抗体片段,特别是Fv、Fab、Fab'或F(ab')2片段、单链抗体,特别是单链可变片段(scFv)、小模块免疫药物(SMIP)、域抗体、纳米抗体、双抗体。抗体可具有效应功能,诸如ADCC或CDC,其通常通过抗体的Fc部分(抗体恒定区)介导,或其可不具有效应功能,例如通过缺乏Fc部分或具有阻断、遮蔽的Fc部分,本质上免疫细胞或免疫系统组分(如补体系统)不识别或未充分识别的Fc部分。单克隆抗体(mAb)为氨基酸序列相同的单特异性抗体。其可通过杂交瘤技术自杂交细胞株(称为杂交瘤)制备,该杂交细胞株代表产生特异性抗体的B细胞与骨髓瘤(B细胞癌症)细胞融合的克隆(Kohler G,Milstein C.Continuous culturesof fused cells secreting antibody of predefined specificity.Nature 1975;256:495-7)。替代地,单克隆抗体可通过在宿主细胞中的重组表达制备(Norderhaug L,OlafsenT,Michaelsen TE,Sandlie I.(1997年5月).“Versatile vectors for transient andstable expression of recombinant antibody molecules in mammalian cells.”JImmunol Methods 204(1):77-87;亦参见下文)。“重组抗体”或“重组结合分子”为已通过以重组方式工程改造的宿主细胞产生的抗体或结合分子。其任选经分离或纯化。
对于人类中的应用,常需要降低最初来源于如小鼠的其他物种的抗体的免疫原性。此可通过构筑嵌合抗体,或通过称为“人源化”的方法进行。在此背景下,“嵌合抗体”应理解为包含来源于一种物种(例如小鼠)的序列部分(例如可变域)与来源于不同物种(例如人类)的序列部分(例如恒定域)融合的抗体。“人源化抗体”为包含最初来源于非人类物种的可变域的抗体,其中已使某些氨基酸突变,使得可变域的总序列更近似于人类可变域的序列。抗体嵌合化及人源化的方法是本领域熟知的(Billetta R,Lobuglio AF.“Chimericantibodies”.Int Rev Immunol.1993;10(2-3):165-76;Riechmann L,Clark M,WaldmannH,Winter G(1988).“Reshaping human antibodies for therapy”.Nature:332:323)。
“人源化”抗体是指包含来自非人类高变区(HVR)的氨基酸残基及来自人类FR的氨基酸残基的抗体。在某些实施方案中,人源化抗体将包含至少一个及通常两个可变域的基本上所有,其中所有或基本上所有的HVR(例如互补决定区(CDR))对应于非人类抗体的HVR,且所有或实质上全部构架区(FR)对应于人类抗体的构架区。人源化抗体任选可包含来源于人类抗体的抗体恒定区的至少一部分。抗体(例如非人类抗体)的“人源化形式”是指已经受人源化的抗体。
此外,已研发出用于基于来源于人类基因组的序列产生抗体的技术,例如通过噬菌体显示或使用转基因动物(WO 90/05144;D.Marks,H.R.Hoogenboom,T.P.Bonnert,J.McCafferty,A.D.Griffiths及G.Winter(1991)“By-passing immunisation.Humanantibodies from V-gene libraries displayed on phage.”J.Mol.Biol.,222,581-597;Knappik等人,J.Mol.Biol.296:57-86,2000;S.Carmen及L.Jermutus,“Concepts inantibody phage display”.Briefings in Functional Genomics and Proteomics 20021(2):189-203;Lonberg N,Huszar D.“Human antibodies from transgenic mice”.IntRev Immunol.1995;13(1):65-93.;Brüggemann M,Taussig MJ.“Production of humanantibody repertoires in transgenic mice”.Curr Opin Biotechnol.1997年8月;8(4):455-8.)。在本发明的上下文中,此类抗体为“人类抗体”。
抗体亦可包括保留抗原结合特性的免疫球蛋白片段,如Fab、Fab'或F(ab')2片段。此类片段可通过免疫球蛋白的片段化,例如通过蛋白分解消化,或通过此类片段的重组表达来获得。举例而言,免疫球蛋白消化可借助于常规技术,例如使用番木瓜蛋白酶或胃蛋白酶(WO 94/29348)实现。抗体的番木瓜蛋白酶消化通常产生两个一致抗原结合片段,所谓Fab片段,各自具有单一抗原结合位点,及残余Fc片段。胃蛋白酶处理产生F(ab')2。在Fab分子中,可变域各自与优选地人类来源的免疫球蛋白恒定域融合。因此,重链可变域可与CH1域(所谓Fd片段)融合,且轻链可变域可与CL域融合。Fab分子可通过宿主细胞中各自的核酸的重组表达来产生,参见下文。
已研发多种用于在不同分子环境下置放免疫球蛋白的可变域或来源于此类可变域的分子的技术。那些亦应视为根据本发明的“抗体”。一般而言,这些抗体分子在大小上相较于免疫球蛋白更小,且可包含单一氨基酸链或若干氨基酸链。举例而言,单链可变片段(scFv)为免疫球蛋白的重链及轻链的可变区的融合物,所述可变区用通常为丝氨酸(S)或甘氨酸(G)的短接头连接在一起(WO 88/01649;WO 91/17271;Huston等人;InternationalReviews of Immunology,第10卷,1993,195-217)。“单域抗体”或“纳米抗体”在单一Ig样域中具有抗原结合位点(WO 94/04678;WO 03/050531,Ward等人,Nature.1989年10月12日;341(6242):544-6;Revets等人,Expert Opin Biol Ther.5(1):111-24,2005)。对相同或不同抗原具有结合特异性的一种或多种单域抗体可连接在一起。双抗体是由两个包含两个可变域的氨基酸链组成的二价抗体分子(WO 94/13804,Holliger等人,Proc Natl Acad SciU S A.1993年7月15日;90(14):6444-8)。抗体样分子的其他实施例为免疫球蛋白超家族抗体(IgSF;Srinivasan及Roeske,Current Protein Pept.Sci.2005,6(2):185-96)。不同概念产生所谓小模块免疫药物(SMIP),其包含Fv域与单链铰链及效应子域连接,缺乏恒定域CH1(WO 02/056910)。
如本文所用,术语“结合”或“特异性结合”是指在体外分析中,抗体或抗原结合位点(例如在本文所描述的结合分子中)与抗原的抗原决定基的结合。亲和力为抗体分子上的单一抗原结合位点与单一抗原决定基之间的相互作用。其由平衡缔合常数Ka=kon/koff或平衡解离常数Kd=koff/kon表示。
抗体分子的结合亲和力可通过称为亲和力成熟的方法增强(Marks等人,1992,Biotechnology 10:779-783;Barbas等人,1994,Proc.Nat.Acad.Sci,USA 91:3809-3813;Shier等人,1995,Gene 169:147-155)。因此,亲和力成熟抗体亦涵盖于本发明中。
抗原决定基为由抗体或抗原结合部分结合的抗原区域。术语“抗原决定基”包括能够与抗体或抗原结合部分特异性结合的任何多肽决定子。在某些实施方案中,抗原决定基决定子包括分子的化学活性表面基团(诸如氨基酸、聚糖侧链、磷酰基或磺酰基),且在某些实施方案中,可具有特定三维结构特征,和/或特定电荷特征。构象抗原决定基与非构象抗原决定基的区别在于,在变性溶剂存在下,与前者的结合消失,但后者则不然。如本文所用,术语“结合”及“特异性结合”是指在体外分析中,优选在用经纯化的野生型抗原的等离子共振分析(GE-Healthcare Uppsala,Sweden)中,抗体或抗原结合部分与抗原的抗原决定基的结合。
“单链Fv片段”(scFv)为一种包含抗体重链可变域(VH)、接头及抗体轻链可变域(VL)的多肽,其中该抗体域及该接头在N端至C端方向上具有以下次序之一:a)VH-接头-VL,b)VL-接头-VH;且其中该接头为长度在15至25个氨基酸,优选20个氨基酸的多肽。
如本文所用,术语“一致”或“百分比一致性”在两个或更多个核酸或多肽序列的情况下是指在针对最大对应性比较及比对时,两个或更多个序列或子序列相同或有指定百分比的核苷酸或氨基酸残基相同。为了测定百分比一致性,出于最佳比较目的而比对序列(举例而言,可在第一氨基酸或核酸序列的序列中引入间隙以与第二氨基酸或核酸序列最佳比对)。接着比较对应氨基酸位置或核苷酸位置处的氨基酸残基或核苷酸。当第一序列中的位置被与第二序列中的对应位置相同的氨基酸残基或核苷酸占据时,则分子在该位置处一致。两个序列之间的百分比一致性为所述序列共有的相同位置数的函数(亦即,一致性%=相同位置数/位置(亦即重叠位置)总数×100)。在一些实施方案中,适当时,在序列内引入间隙之后,进行比较的两个序列长度相同(例如不包括延伸超过比较序列的额外序列)。举例而言,当比较可变区序列时,不考虑前导序列和/或恒定域序列。对于两个序列之间的序列比较,“对应”CDR是指两个序列中相同位置的CDR(例如各序列的CDR-H1)。
可使用数学算法实现测定两个序列之间的百分比一致性或百分比类似性。用于比较两个序列的数学算法的优选非限制性实施例为Karlin及Altschul,1990,Proc.Natl.Acad.Sci.USA 87:2264-2268的算法,如Karlin及Altschul,1993,Proc.Natl.Acad.Sci.USA 90:5873-5877中所修改。将此类算法并入Altschul等人,1990,J.Mol.Biol.215:403-410的NBLAST及XBLAST程序中。可用分数=100、字长=12的NBLAST程序进行BLAST核苷酸检索,以获得与编码所关注蛋白质的核酸同源的核苷酸序列。BLAST蛋白质检索可用XBLAST程序(分数=50,字长=3)执行,以获得与所关注蛋白质同源的氨基酸序列。为了使间隙式比对达成比较目的,可如Altschul等人,1997,Nucleic Acids Res.25:3389-3402中所描述使用间隙式BLAST。替代地,PSI-Blast可用于进行叠代检索,其检测分子间的远缘关系(同上)。在使用BLAST、间隙式BLAST及PSI-Blast程序时,可使用各自的程序(例如XBLAST及NBLAST)的预设参数。用于比较序列的数学算法的另一优选非限制性实施例为Myers及Miller,CABIOS(1989)的算法。将此类算法并入ALIGN程序(版本2.0)中,该程序为GCG序列比对软件包的一部分。当利用ALIGN程序来比较氨基酸序列时,可使用PAM120权重残基表、间隙长度罚分12及间隙罚分4。用于序列分析的额外算法在本领域已知且包括如Torellis及Robotti,1994,Comput.Appl.Biosci.10:3-5中所描述的ADVANCE及ADAM;及Pearson及Lipman,1988,Proc.Natl.Acad.Sci.USA 85:2444-8中描述的FASTA。在FASTA内,ktup为设定检索的敏感性及速度的对照选项。若ktup=2,则通过观察比对残基对得到比较的两个序列中的相似区域;若ktup=1,则检查单一比对氨基酸。对于蛋白质序列,ktup可设定为2或1,或对于DNA序列设定为1至6。若ktup未规定,则对于蛋白质默认值为2,且对于DNA为6。替代地,可使用CLUSTAL W算法进行蛋白质序列比对,如Higgins等人,1996,MethodsEnzymol.266:383-402所描述。
待施用分子的“治疗有效量”是预防、改善或治疗例如眼部或视网膜或神经退化性疾病的临床症状所必需的最少量,特别是对于这些病症有效的最少量。
如本文所用,术语“单价”、“二价”、“四价”是指结合分子中的抗原结合组件的数目(分别为一个、两个或四个)。
如本文所用,术语“单特异性”、“双特异性”是指结合分子特异性结合不同抗原或抗原决定基的数目(一个、两个)。
借助于实施例,典型单克隆抗体(MAb)为二价且单特异性的,具有两个均识别相同抗原决定基的抗原结合臂。双特异性抗体具有两个能够识别且结合两种不同抗原或抗原决定基的抗原结合位点。
TrkB结合
原肌球蛋白受体激酶B(TrkB)也称为酪氨酸受体激酶B或BDNF/NT-3生长因子受体或2型神经营养酪氨酸激酶受体,为一种人体内由NTRK2基因编码的蛋白质(Genbank ID:4915)。TrkB为用于大脑衍生神经滋养因子(brain-derived neurotrophic factor;BDNF)的受体。
神经营养酪氨酸激酶受体B(TrkB;基因符号:NTRK2)由视网膜神经元及神经胶细胞表达。在正常视网膜中,TrkB信号传递抵消细胞应激且促进细胞存活。在病变眼睛中,诸如在糖尿病性视网膜病变或地图状萎缩中,出现产生视觉减损及视觉损失的视网膜神经元及神经胶细胞的损失及功能减损。活化TrkB信号传递高于基础水平(其在糖尿病性视网膜病变中降低)可抵消神经元及神经胶细胞的损失及功能减损,因此改善视觉功能。此外,TrkB活化可使病变眼睛中的损失的突触连接再生,从而促进视觉功能恢复。在配体结合后,TrkB经历均二聚化,随后经历自体磷酸化。视磷酸化位点(Y516、Y702、Y706、Y707或Y817)而定,活化不同讯息传导路径,包括调节不同的重叠信号级联从而诱导轴索/神经突生长、增加突触可塑性或增加细胞存活的PLCγ1或AKT及ERK的不同亚型的活性。
本发明的结合分子(例如scFv或scFv2)的TrkB结合组分与天然或重组人类TrkB特异性结合。通过与TrkB结合,本发明的结合分子从而活化TrkB信号传递,因此本发明的结合分子充当TrkB激动剂。
本发明的结合分子识别特定“TrkB抗原决定基(TrkB antigen epitope/TrkBepitope)”。特别是,本发明的结合分子与人类TrkB的胞外域中的抗原决定基结合。优选地,结合分子的TrkB结合组分为TrkB激动剂且更优选地完全激动剂。
人类TrkB的胞外域基本上包含以下序列(SEQ ID NO.226):
如本文所用,术语“TrkB抗原决定基(TrkB antigen epitope/TrkB epitope)”是指能够与特异性结合原肌球蛋白受体激酶B的根据本发明的结合分子或结合分子片段的抗原结合位点结合的分子(例如肽)或分子片段。这些术语进一步包括例如由本发明的结合分子或结合分子片段中的任一者识别的TrkB抗原决定子,其具有选自以下的轻链及重链CDR组合:
轻链CDR,其包含SEQ ID NO:201(CDR1)、SEQ ID NO:202(CDR2)及SEQ ID NO:203(CDR3)的氨基酸序列,及
重链CDR,其包含SEQ ID NO:204(CDR1)、SEQ ID NO:205(CDR2)及SEQ ID NO:206(CDR3)的氨基酸序列;或
重链CDR,其包含SEQ ID NO:207(CDR1)、SEQ ID NO:208(CDR2)及SEQ ID NO:209(CDR3)的氨基酸序列;或
重链CDR,其包含SEQ ID NO:210(CDR1)、SEQ ID NO:211(CDR2)及SEQ ID NO:212(CDR3)的氨基酸序列。
TrkB抗原决定基可包括于蛋白质、蛋白质片段、肽或其类似物中。抗原决定基最常为蛋白质、短寡肽、寡肽模拟物(亦即模拟TrkB抗原的抗体结合特性的有机化合物)或其组合。
VEGF结合
血管内皮生长因子(VEGF)为最重要的促血管生成因子之一,也称为VEGF-A或血管渗透性因子(vascular permeability factor;VPF)。VEGF属于包括胎盘生长因子(PlGF)、VEGF-B、VEGF-C、VEGF-D、VEGF-E及VEGF-F的基因家族。人类VEGF的单一基因的mRNA的选择式剪接产生至少六种同功型(VEGF121、VEGF145、VEGF165、VEGF183、VEGF189及VEGF206),VEGF165为最丰富的同功型。
已鉴别出与VEGF相互作用的两种VEGF酪氨酸激酶受体(VEGFR),亦即VEGFR-1(也称为FIt-1)及VEGFR-2(也称为KDR或FIK-1)。VEGFR-1针对VEGF具有最高亲和力,而VEGFR-2针对VEGF具有略微降低的亲和力。Ferrara(Endocrine Rev.2004,25:581-611)提供VEGF的详细描述,与其受体的相互作用及其在正常及病理过程中的功能可见于Hoeben等人Pharmacol.Rev.2004,56:549-580中。
已报导VEGF是正常及异常血管生成的关键调节剂(Ferrara及Davis-Smyth,Endocrine Rev.1997,18:4-25;Ferrara J.MoL Med.1999,77:527-543)。相较于有助于血管形成过程的其他生长因子,VEGF的独特的处在于其针对血管系统内的内皮细胞的高特异性。
VEGF尤其涉及眼部疾病。眼流体中VEGF的浓度与患有糖尿病及其他局部缺血相关视网膜病的患者的血管存在活跃增殖高度相关。此外,研究已表明VEGF在受老年性黄斑变性(AMD)影响的患者的脉络膜新生血管膜中的定位。
本发明的结合分子(例如免疫球蛋白(Ig)分子)的VEGF结合组分对于VEGF具有特异性,原因在于其与VEGF分子内的一个或多个抗原决定基特异性结合。通过与VEGF结合,本发明的结合分子充当VEGF拮抗剂。优选地,本发明的结合分子与VEGF-A特异性结合。
可以本身已知的任何适合方式,包括(例如)本文所描述的分析、斯卡查德分析(Scatchard analysis)和/或竞争性结合分析,诸如放射免疫分析(RIA)、酶免疫分析(EIA及ELISA)及夹心竞争分析,及本领域本身已知的其不同变体来测定抗原结合组分与其抗原VEGF的特异性结合。当与其抗原结合时,对于TrkB结合组分而言,此亦成立。
关于抗原VEGF,本发明的VEGF结合组分(例如免疫球蛋白(Ig)分子)关于物种不受限制。因此,若预期用于人类中的治疗目的,则免疫球蛋白(Ig)分子优选地与人类VEGF结合。然而,与来自另一哺乳动物物种的VEGF结合的免疫球蛋白(Ig)分子亦在本发明的范畴内。与一种VEGF物种形式结合的免疫球蛋白(Ig)分子可与VEGF交叉反应,该VEGF具有来自一种或多种其他物种,与人类VEGF不同的序列。举例而言,与人类VEGF结合的免疫球蛋白(Ig)分子可与以下展现交叉反应性:来自一种或多种其他灵长类物种的VEGF;和/或与来自疾病动物模型中使用的一种或多种动物物种的VEGF,所述动物例如猴、小鼠、大鼠、兔、猪、狗,且特别是与VEGF介导的血管生成效果相关的疾病及病症动物模型中(诸如本文中提及的物种及动物模型)。显示此类交叉反应性的免疫球蛋白(Ig)分子有利于研究和/或药物研发,这是由于其允许本发明的免疫球蛋白单一可变域在已确认的疾病模型(诸如猴,特别是食蟹猕猴或恒河猴;或小鼠及大鼠)中进行测试。
优选地,鉴于与预期用于在研发治疗性VEGF拮抗剂期间用作动物模型的一种或多种来自除人类外的物种的VEGF分子的交叉反应性,VEGF结合组分识别与人类VEGF具有高度一致性的所关注VEGF区域中的抗原决定基。
因此,根据本发明的结合分子(例如免疫球蛋白(Ig)分子)的VEGF结合组分识别完全或部分位于与其受体结合相关的VEGF区域中的抗原决定基。根据优选方面,根据本发明的结合分子的VEGF结合组分阻断VEGF受体活化,优选地实质上且最佳完全阻断。
如上文所描述,VEGF结合组分阻断VEGF与其受体之间的相互作用的能力可通过放大发光接近性均相分析竞争ELISA或基于等离子共振(SPR)的分析测定,如实施例中所描述。
TrkB及VEGF结合分子
本发明涉及结合分子,其对至少两种不同目标具有结合特异性。相对于本发明,结合分子来源于抗体。用于制备结合分子的技术包括但不限于:具有不同特异性的两个免疫球蛋白重链-轻链对的重组共表达(参见Milstein及Cuello,Nature 305:537(1983))、WO93/08829及Traunecker等人,EMBO J.10:3655(1991)),及“杵-臼”工程改造(参见例如美国专利第5,731,168号)。本发明的结合分子亦可如下制备:用于制备抗体Fc-杂二聚分子的工程改造静电导向效应(WO 2009/089004A1);使两种或更多种抗体或片段交联(参见例如美国专利第4,676,980号及Brennan等人,Science,229:81(1985));使用亮氨酸拉链产生双特异性抗体(参见例如Kostelny等人,Immunol.,148(5):1547-1553(1992));使用用于制备双特异性抗体片段的“双抗体”技术(参见例如Hollinger等人,Proc.Natl.Acad.Sci.USA,90:6444-6448(1993));及使用单链Fv(sFv)二聚体(参见例如Gruber等人,J.Immunol.,152:5368(1994));及如例如Tutt等人,J.Immunol.147:60(1991)中所描述制备三特异性抗体。
在一个实施方案中,结合分子包含以下或由以下组成:至少一个与血管内皮生长因子(VEGF),优选为VEGF-A特异性结合的抗原结合位点;及至少一个与原肌球蛋白受体激酶B(TrkB)特异性结合的抗原结合位点。在一相关实施方案中,结合分子是双特异性的且是四价的。
在另一实施方案中,结合分子包含以下或由以下组成:至少一个与血管内皮生长因子(VEGF)特异性结合的抗原结合位点;及至少一个与原肌球蛋白受体激酶B(TrkB)特异性结合的抗原结合位点,其中该至少一个与VEGF特异性结合的抗原结合位点为免疫球蛋白(Ig)分子,优选地IgG分子。在一相关实施方案中,结合分子是双特异性的且是四价的。
在另一实施方案中,结合分子包含以下或由以下组成:至少一个与血管内皮生长因子(VEGF)特异性结合的抗原结合位点;及至少一个与原肌球蛋白受体激酶B(TrkB)特异性结合的抗原结合位点,其中该至少一个与TrkB特异性结合的抗原结合位点包含一个或多个scFv,优选地在N端至C端呈VL-VH定向。在一相关实施方案中,结合分子是双特异性的且是四价的。
在另一实施方案中,结合分子包含以下或由以下组成:至少一个与血管内皮生长因子(VEGF)特异性结合的抗原结合位点;及至少一个与原肌球蛋白受体激酶B(TrkB)特异性结合的抗原结合位点,其中该至少一个与VEGF特异性结合的抗原结合位点为免疫球蛋白(Ig)分子,优选地IgG分子,且其中该至少一个与TrkB特异性结合的抗原结合位点与Ig分子重链的C端融合。在一相关实施方案中,结合分子是双特异性的且是四价的。
在另一实施方案中,结合分子包含以下或由以下组成:至少一个与血管内皮生长因子(VEGF)特异性结合的抗原结合位点;及至少一个与原肌球蛋白受体激酶B(TrkB)特异性结合的抗原结合位点,其中该至少一个与VEGF特异性结合的抗原结合位点为免疫球蛋白(Ig)分子,优选地IgG分子,且其中该至少一个与TrkB特异性结合的抗原结合位点包含一个或多个scFv,优选地在N端至C端呈VL-VH定向。在一相关实施方案中,结合分子是双特异性的且是四价的。
在另一实施方案中,结合分子包含以下或由以下组成:至少一个与血管内皮生长因子(VEGF)特异性结合的抗原结合位点;及至少一个与原肌球蛋白受体激酶B(TrkB)特异性结合的抗原结合位点,其中该至少一个与VEGF特异性结合的抗原结合位点为免疫球蛋白(Ig)分子,优选地IgG分子,且其中该至少一个与TrkB特异性结合的抗原结合位点包含一个或多个scFv,优选地在N端至C端呈VL-VH定向,且与Ig分子重链的C端融合。在一相关实施方案中,结合分子是双特异性的且是四价的。
在一优选实施方案中,本发明的结合分子包含以下或由以下组成:(i)两条重链,其各自包含以下或由以下组成:对VEGF具有特异性的重链可变区、恒定IgG域及对TrkB具有特异性的scFv;及(ii)两条轻链,其各自包含以下或由以下组成:对VEGF具有特异性的轻链可变区。
另外,这些单链Fv片段可通过经由并入半胱氨酸残基将二硫键并入VH与VL域之间、VH域内或VL域内来进一步稳定。术语N端表示多肽链的第一个氨基酸,而术语C端表示多肽链的C端的最后一个氨基酸。因此,本发明的一个实施方案为其中一个或多个scFv包含额外半胱氨酸残基以形成二硫键。
在一个实施方案中,本发明提供一种结合分子,其为多特异性结合蛋白,其包含(i)具有两条重链及两条轻链的与VEGF特异性结合的Ig分子,及(ii)两个各自与TrkB特异性结合的scFv分子(scFv(s))。优选地,Ig分子的各重链具有一个与其C端融合的scFv,从而形成双特异性四价结合蛋白。
在一个实施方案中,本发明提供一种结合分子(本文中也称为多特异性结合蛋白或经修饰的Ig分子),其具有:
(i)两条重链,其自N端至C端各自包含:
-对VEGF具有特异性的重链可变域(例如鼠类、人源化或人类VH域)
-IgG(例如人类IgG1或IgG4)的恒定域
-肽接头(例如GS迷你接头)及
-对TrkB具有特异性的scFv(例如自N端至C端包含VH域(例如鼠类、人源化或人类VH域)、接头及VL域(例如鼠类、人源化或人类VL域)或反过来VL域、接头及VH域的scFv);及
(ii)两条轻链,其自N端至C端各自包含:
对VEGF具有特异性的轻链可变域(例如鼠类、人源化或人类VL域),
轻链恒定域(例如人类κ链)。
本发明提供一种结合分子,其具有至少一个与血管内皮生长因子(VEGF)特异性结合的抗原结合位点及至少一个与原肌球蛋白受体激酶B(TrkB)特异性结合的抗原结合位点。
制备与特异性目标抗原结合的结合位点的方法为本领域所熟知。技术人员可容易地使用这些方法来设计具有对于VEGF或TrkB目标抗原的必需特异性的抗原结合位点。
产生抗体及抗体片段的方法为本领域所熟知。举例而言,抗体可经由采用以下的若干方法中的任一者产生:诱导抗体分子的体内产生、筛选免疫球蛋白库(Orlandi等人,1989.Proc.Natl.Acad.Sci.U.S.A.86:3833-3837;Winter等人1991,Nature 349:293-299)或通过培养中的细胞株产生单克隆抗体分子。这些包括但不限于杂交瘤技术、人类B细胞杂交瘤技术及埃-巴二氏病毒(EBV)杂交瘤技术(Kohler等人1975.Nature 256:4950497;Kozbor等人1985.J.Immunol.Methods 81:31 -42;Cote等人1983.Proc.Natl.Acad.Sci.USA 80:2026-2030;Cole等人1984.Mol.Cell.Biol.62:109-120)。
使用本领域已知及本文所描述的方法,本领域技术人员将常规制备具有结合位点的抗体,该结合位点对于VEGF和/或TrkB目标抗原具有必需的特异性;以及本文所描述的结合分子。自此类抗体分离结合域为常规实践,且实际上关于可用于产生如本文所描述的抗体及结合分子方法的其他信息提供于随附实施例中。
本发明人构想的本发明的针对VEGF/TrkB的结合分子,如表1中所示;及制备一系列那些分子且论述于随附实施例中。
表1:
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
在另一实施方案中,本发明的结合分子或TrkB结合分子可基于下文公开的TrkB结合剂(其亦公开于WO2018/224630中)中的任一者。
表2:
/>
/>
/>
在一优选实施方案中,结合分子包含至少一个与血管内皮生长因子(VEGF)特异性结合的抗原结合位点及至少一个与原肌球蛋白受体激酶B(TrkB)特异性结合的抗原结合位点,其中与TrkB特异性结合的抗原结合位点包含:轻链CDR,其包含SEQ ID NO:201(CDR1)、SEQ ID NO:202(CDR2)及SEQ ID NO:203(CDR3)的氨基酸序列或由其组成;及重链CDR,其包含SEQ ID NO:204(CDR1)、SEQ ID NO:205(CDR2)及SEQ ID NO:206(CDR3)的氨基酸序列或由其组成;或重链CDR,其包含SEQ ID NO:207(CDR1)、SEQ ID NO:208(CDR2)及SEQ ID NO:209(CDR3)的氨基酸序列或由其组成;或重链CDR,其包含SEQ ID NO:210(CDR1)、SEQ IDNO:211(CDR2)及SEQ ID NO:212(CDR3)的氨基酸序列或由其组成;且其中与VEGF特异性结合的抗原结合位点包含:轻链CDR,其包含SEQ ID NO:145(CDR1)、SEQ ID NO:146(CDR2)及SEQ ID NO:147(CDR3)的氨基酸序列或由其组成;及重链CDR,其包含SEQ ID NO:148(CDR1)、SEQ ID NO:149(CDR2)及SEQ ID NO:150(CDR3)的氨基酸序列或由其组成;或重链CDR,其包含SEQ ID NO:151(CDR1)、SEQ ID NO:152(CDR2)及SEQ ID NO:153(CDR3)的氨基酸序列或由其组成;或重链CDR,其包含SEQ ID NO:154(CDR1)、SEQ ID NO:155(CDR2)及SEQID NO:156(CDR3)的氨基酸序列或由其组成。
在一另外优选实施方案中,结合分子包含至少一个与血管内皮生长因子(VEGF)特异性结合的抗原结合位点及至少一个与原肌球蛋白受体激酶B(TrkB)特异性结合的抗原结合位点,其中与TrkB特异性结合的抗原结合位点包含:轻链可变域,其包含与SEQ ID NO:213或215的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列或由其组成;及重链可变域,其包含与SEQ ID NO:214或216的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列或由其组成;且其中与VEGF特异性结合的抗原结合位点包含:轻链可变域,其包含与SEQ ID NO:189或193的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列或由其组成;及重链可变域,其包含与SEQ ID NO:190、191、192或194的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列或由其组成。
在一另外优选实施方案中,结合分子包含至少一个与血管内皮生长因子(VEGF)特异性结合的抗原结合位点及至少一个与原肌球蛋白受体激酶B(TrkB)特异性结合的抗原结合位点,其中与TrkB特异性结合的抗原结合位点包含:轻链可变域,其包含SEQ ID NO:213或215的氨基酸序列或由其组成;及重链可变域,其包含SEQ ID NO:214或216的氨基酸序列或由其组成;且其中与VEGF特异性结合的抗原结合位点包含:轻链可变域,其包含SEQ IDNO:189或193的氨基酸序列或由其组成;及重链可变域,其包含SEQ ID NO:190、191、192或194的氨基酸序列或由其组成。
在一另外优选实施方案中,结合分子包含至少一个与血管内皮生长因子(VEGF)特异性结合的抗原结合位点及至少一个与原肌球蛋白受体激酶B(TrkB)特异性结合的抗原结合位点,其中与TrkB特异性结合的抗原结合位点包含:轻链可变域,其包含SEQ ID NO:213的氨基酸序列或由其组成;及重链可变域,其包含SEQ ID NO:214的氨基酸序列或由其组成;且其中与VEGF特异性结合的抗原结合位点包含:轻链可变域,其包含SEQ ID NO:193的氨基酸序列或由其组成;及重链可变域,其包含SEQ ID NO:191的氨基酸序列或由其组成。
在一另外优选实施方案中,结合分子包含至少一个与血管内皮生长因子(VEGF)特异性结合的抗原结合位点及至少一个与原肌球蛋白受体激酶B(TrkB)特异性结合的抗原结合位点,其中与TrkB特异性结合的抗原结合位点包含:轻链可变域,其包含与SEQ ID NO:213或215的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列或由其组成;及重链可变域,其包含与SEQ ID NO:214或216的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列或由其组成,其中轻链可变域中的轻链CDR由SEQ IDNO:201(CDR1)、SEQ ID NO:202(CDR2)及SEQ ID NO:203(CDR3)的氨基酸序列组成,且重链可变域中的重链CDR由SEQ ID NO:204(CDR1)、SEQ ID NO:205(CDR2)及SEQ ID NO:206(CDR3)的氨基酸序列组成;或重链可变域中的重链CDR由SEQ ID NO:207(CDR1)、SEQ IDNO:208(CDR2)及SEQ ID NO:209(CDR3)的氨基酸序列组成;或重链可变域中的重链CDR由SEQ ID NO:210(CDR1)、SEQ ID NO:211(CDR2)及SEQ ID NO:212(CDR3)的氨基酸序列组成;且其中与VEGF特异性结合的抗原结合位点包含:轻链可变域,其包含与SEQ ID NO:189或193的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列或由其组成;及重链可变域,其包含与SEQ ID NO:190、191、192或194的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列或由其组成,其中轻链可变域中的轻链CDR由SEQID NO:145(CDR1)、SEQ ID NO:146(CDR2)及SEQ ID NO:147(CDR3)的氨基酸序列组成,且重链可变域中的重链CDR由SEQ ID NO:148(CDR1)、SEQ ID NO:149(CDR2)及SEQ ID NO:150(CDR3)的氨基酸序列组成;或重链可变域中的重链CDR由SEQ ID NO:151(CDR1)、SEQ IDNO:152(CDR2)及SEQ ID NO:153(CDR3)的氨基酸序列组成;或重链可变域中的重链CDR由SEQ ID NO:154(CDR1)、SEQ ID NO:155(CDR2)及SEQ ID NO:156(CDR3)的氨基酸序列组成。
在一另外优选实施方案中,结合分子包含至少一个与血管内皮生长因子(VEGF)特异性结合的抗原结合位点及至少一个与原肌球蛋白受体激酶B(TrkB)特异性结合的抗原结合位点,其中与TrkB特异性结合的抗原结合位点包含:轻链可变域,其包含SEQ ID NO:213的氨基酸序列或由其组成;及重链可变域,其包含SEQ ID NO:214的氨基酸序列或由其组成,其中轻链可变域中的轻链CDR由SEQ ID NO:201(CDR1)、SEQ ID NO:202(CDR2)及SEQ IDNO:203(CDR3)的氨基酸序列组成;且重链可变域中的重链CDR由SEQ ID NO:204(CDR1)、SEQID NO:205(CDR2)及SEQ ID NO:206(CDR3)的氨基酸序列组成;或重链可变域中的重链CDR由SEQ ID NO:207(CDR1)、SEQ ID NO:208(CDR2)及SEQ ID NO:209(CDR3)的氨基酸序列组成;或重链可变域中的重链CDR由SEQ ID NO:210(CDR1)、SEQ ID NO:211(CDR2)及SEQ IDNO:212(CDR3)的氨基酸序列组成;且其中与VEGF特异性结合的抗原结合位点包含:轻链可变域,其包含SEQ ID NO:193的氨基酸序列或由其组成;及重链可变域,其包含SEQ ID NO:191的氨基酸序列或由其组成,其中轻链可变域中的轻链CDR由SEQ ID NO:145(CDR1)、SEQID NO:146(CDR2)及SEQ ID NO:147(CDR3)的氨基酸序列组成;且重链可变域中的重链CDR由SEQ ID NO:148(CDR1)、SEQ ID NO:149(CDR2)及SEQ ID NO:150(CDR3)的氨基酸序列组成;或重链可变域中的重链CDR由SEQ ID NO:151(CDR1)、SEQ ID NO:152(CDR2)及SEQ IDNO:153(CDR3)的氨基酸序列组成;或重链可变域中的重链CDR由SEQ ID NO:154(CDR1)、SEQID NO:155(CDR2)及SEQ ID NO:156(CDR3)的氨基酸序列组成。
在一个实施方案中,结合分子包含至少一个与血管内皮生长因子(VEGF)特异性结合的抗原结合位点及至少一个与原肌球蛋白受体激酶B(TrkB)特异性结合的抗原结合位点,其中与TrkB特异性结合的抗原结合位点包含:轻链CDR,其包含SEQ ID NO:228(CDR1)、SEQ ID NO:229(CDR2)及SEQ ID NO:230(CDR3)的氨基酸序列或由其组成;及重链CDR,其包含SEQ ID NO:231(CDR1)、SEQ ID NO:232(CDR2)及SEQ ID NO:23(CDR3)的氨基酸序列或由其组成;或重链CDR,其包含SEQ ID NO:234(CDR1)、SEQ ID NO:235(CDR2)及SEQ ID NO:236(CDR3)的氨基酸序列或由其组成;或重链CDR,其包含SEQ ID NO:237(CDR1)、SEQ ID NO:238(CDR2)及SEQ ID NO:239(CDR3)的氨基酸序列或由其组成;且其中与VEGF特异性结合的抗原结合位点包含:轻链CDR,其包含SEQ ID NO:145(CDR1)、SEQ ID NO:146(CDR2)及SEQID NO:147(CDR3)的氨基酸序列或由其组成;及重链CDR,其包含SEQ ID NO:148(CDR1)、SEQID NO:149(CDR2)及SEQ ID NO:150(CDR3)的氨基酸序列或由其组成;或重链CDR,其包含SEQ ID NO:151(CDR1)、SEQ ID NO:152(CDR2)及SEQ ID NO:153(CDR3)的氨基酸序列或由其组成;或重链CDR,其包含SEQ ID NO:154(CDR1)、SEQ ID NO:155(CDR2)及SEQ ID NO:156(CDR3)的氨基酸序列或由其组成。
在另一实施方案中,结合分子包含至少一个与血管内皮生长因子(VEGF)特异性结合的抗原结合位点及至少一个与原肌球蛋白受体激酶B(TrkB)特异性结合的抗原结合位点,其中与TrkB特异性结合的抗原结合位点包含轻链可变域及重链可变域,其各自包含与SEQ ID NO:240及241、242及243、244及245、246及247、248及249、250及251、252及253、254及255或256及257的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列或由其组成;且其中与VEGF特异性结合的抗原结合位点包含:轻链可变域,其包含与SEQ IDNO:189或193的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列或由其组成;及重链可变域,其包含与SEQ ID NO:190、191、192或194的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列或由其组成。
在关于前述实施方案中任一者的另一个优选实施方案中,结合分子是双特异性的且是四价的。为避免疑问,通过本发明的结合分子与其各自的目标VEGF及TrkB的结合,本发明的结合分子分别充当VEGF拮抗剂或TrkB激动剂。
在关于前述实施方案中任一者的另一个优选实施方案中,与VEGF特异性结合的抗原结合位点为免疫球蛋白(Ig)分子,且至少一个与TrkB特异性结合的抗原结合位点包含一个或多个scFv。
在关于前述实施方案中任一者的另一个优选实施方案中,一个或多个scFv与Ig分子重链的C端融合。
在关于前述实施方案中任一者的另一个优选实施方案中,至少一个与VEGF特异性结合的抗原结合位点为免疫球蛋白(Ig)分子,更优选IgG,且至少一个与TrkB特异性结合的抗原结合位点包含一个或多个scFv,更优选两个scFv。
本文所描述的抗体分子或结合分子可与对抗体分子的特性具有所需影响的其他分子实体融合(呈融合蛋白)或者连接(通过共价或非共价键)。举例而言,可能需要改善本文所描述的抗体或结合分子的药物动力学特性,例如在诸如血液的体液中的稳定性,尤其在单链抗体或域抗体的情况下。关于此,特别是为了延长此类抗体分子的循环半衰期,已研发出大量技术,诸如聚乙二醇化(WO 98/25971;WO 98/48837;WO 2004081026),抗体分子与对如白蛋白的血清蛋白具有亲和力的另一抗体分子融合或共价连接(WO 2004041865;WO2004003019),或抗体分子表达为与如白蛋白或运铁蛋白的血清蛋白的全部或部分的融合蛋白(WO 01/79258)。
由于抗体的Fc区与多种Fc受体相互作用,此产生多种重要功能能力(其称为“效应功能”),所以在某些实施方案中,抗体为全长抗体或含有Fc区的一部分的抗体,后者只要抗体呈现与抗原的相关部分及Fc受体与补体两者特异性结合即可。恒定区的类型及长度的选择视效应功能(如补体结合或抗体依赖性细胞介导的细胞毒性)是否为所需特征以及视抗体蛋白的所需药理学特性而定。
在本发明的实施方案中,scFv部分的稳定性可通过并入紧密3维接近的两个半胱氨酸残基以在scFv内形成二硫键而增加。为了经由经工程改造的二硫键而实现稳定,这些位置处的残基优选经半胱氨酸残基取代。
如随附实施例中所显示,本发明人已显示,自N端至C端具有VL-VH定向的TrkBscFv可在本发明的结合分子中起作用以活化TrkB信号传递。虽然自N端至C端具有VH-VL定向的TrkB scFv亦可起作用,但在此定向中活性可能降低。因此,本发明的一个优选实施方案为其中自N端至C端的次序为VL-VH。
本发明的另一优选实施方案为,其中一个或多个与TrkB特异性结合的scFv通过肽接头,优选地长度为约4至20个氨基酸(例如6、9、10、12或15个中的任一者)的肽接头,与特异性结合VEGF的Ig分子(例如人类IgG1、IgG1(KO)、IgG1FcRnmut、IgG4Pro)融合。优选地,scFv与Ig分子重链的C端融合。优选地,Ig分子为IgG。
连接scFv分子与IgG分子重链的C端或连接scFv分子内的可变域的方法为本领域熟知。通常,使用甘氨酸及丝氨酸(称为GS迷你接头)氨基酸的小接头序列。接头中氨基酸的数目可在4(GGGS)(SEQ ID NO:227)、6(GGSGGS)(SEQ ID NO:217)、10(GGGGSGGGGS)(SEQ IDNO:218)、15(GGGGSGGGGSGGGGS)(SEQ ID NO:219)、20(GGGGSGGGGSGGGGSGGGGS)(SEQ IDNO:220)或更多变化。实际上,接头通常为通过将以下组合而形成:编码所关注IgG的核酸分子(在本发明的情况下,其将包括编码重链可变域(对于VEGF结合位点)及IgG类型的恒定域的核酸);与编码所需scFv的核酸(在本发明的情况下,其将包括编码重链及轻链的可变域的核酸,对于TrkB结合位点,其呈VL-VH或VH-VL定向),所述核酸由编码接头序列(例如具有5、10、15或20个氨基酸中的任一者的GS迷你接头,优选地SEQ ID NO:218的接头)的核酸分子隔开。接着如下文进一步解释,将此完整HC-scFv编码核酸分子置放于表达载体内且引入适当宿主细胞中,使得形成完整IgG重链-scFv单一多肽。
优选地,scFV分子与IgG分子重链的C端之间的GS迷你接头为10L1(SEQ ID NO:218)。
在本发明的一个实施方案中,通过本发明中的结合分子与补体产物C1q或Fcγ受体的结合为通过使用IgG4恒定区或在位置234及235处具有L至A定向诱变的IgG1恒定区来去除。
在本发明的一个实施方案中,本发明的结合分子可具有已经工程改造以避免可溶性Fcγ受体或补体C1q的不希望的交联的Fc区或其相关区段。在一个实施方案中,此类结合分子或抗体变体对Fcγ受体及补体C1q的亲和力比亲本抗体低得多。(在下文中,若不另外陈述,则在抗体分子上下文中或在IgG或Fc区上下文中,术语“亲本”分别是指未经工程改造的衍生突变(经工程改造)分子的抗体分子、Fc区或IgG。)。因此,本发明的一个实施方案为其中Ig分子包含对Fcγ受体或补体受体或两者的亲和力相较于野生型Fc区降低的Fc变体。此类Ig分子在本文中称为IgG1(KO)。
亦考虑包含Fc区或其相关区段的结合分子,该Fc区或其相关区段已经工程改造以通过优化其与新生Fc受体(FcRn)的相互作用,例如通过CH2域中位置H310A处的点突变或位置H435A处的点突变,而调节血清含量(半衰期)。此类Ig分子在本文中称为IgG1FcRnmut。
进一步考虑包含Ig分子的结合分子,该Ig分子包含去除重链与其他IgG4分子的交换的IgG4的铰链区变体。此类Ig分子在本文中称为IgG4Pro。
本发明的另一方面提供编码本发明的结合分子或本发明的抗体分子的经分离的核酸分子;或包含此类核酸分子的表达载体。
在一些实施方案中,本发明的结合分子或本发明的抗体分子包含抗体重链和/或轻链多肽。如技术人员可了解,可容易地制备编码重链多肽、轻链多肽或重链多肽及轻链多肽的核酸分子。
编码轻链及重链的核酸分子可通过聚合酶链反应(PCR)使用标准方法以化学及酶方式合成。首先,可利用本领域已知的方法(例如Gait,1984)合成合适寡核苷酸,其可用于产生合成基因。自寡核苷酸产生合成基因的方法为本领域已知(例如Stemmer等人,1995;Ye等人,1992;Hayden et Mandecki,1988;Frank等人,1987)。
本发明的核酸分子包括但不限于编码序列表中显示的多肽序列的DNA分子。此外,本发明还涉及核酸分子,所述核酸分子在高严格度结合及洗涤条件下,与编码序列表中显示的多肽序列的DNA分子杂交,如WO 2007/042309中所定义。优选的分子(自mRNA观点)为与本文所描述的DNA分子中的一个具有至少75%或80%(优选地至少85%,更优选地至少90%且最佳地至少95%)同源性或序列一致性的那些分子。借助于实施例,鉴于在真核细胞中表达抗体,序列表显示中的DNA序列已设计成匹配真核细胞中的密码子使用。若需要在大肠杆菌(E.coli)中表达抗体,则可改变这些序列以匹配大肠杆菌密码子使用。可以若干种不同方式构筑本发明的DNA分子的变体,如例如WO 2007/042309中所描述。
本发明的另一方面提供一种制备本文所描述的结合分子或抗体分子的方法,其包含:
(a)在允许该分子表达的条件下培养本发明的宿主细胞;及
(b)回收该分子;及任选
本发明的该方面的一个实施方案为其中该制备方法进一步包含步骤(c)进一步纯化和/或修饰和/或调配本发明的结合分子。
为了制备本发明的结合分子或抗体,将编码全长轻链和/或重链或其片段的DNA分子插入表达载体中,使得序列与转录及翻译控制序列可操作地连接。
为了制造本发明的结合分子或抗体,本领域技术人员可自本领域熟知的大量表达系统选择,例如由Kipriyanov及Le Gall,Curr Opin Drug Discov Devel.2004年3月;7(2):233-42综述的那些表达系统。
表达载体包括质体、反转录病毒、黏质体、EBV源性游离基因组及其类似物。选择表达载体及表达控制序列以与宿主细胞兼容。可将抗体轻链基因及抗体重链基因或本文所描述的结合分子的重链基因(例如包含C端与scFv序列连接的免疫球蛋白重链序列的基因)插入单独载体中。在某些实施方案中,将DNA序列、轻链及重链序列两者插入同一表达载体中。适宜载体为编码功能完整的人类CH或CL免疫球蛋白序列且具有经工程改造以使得可容易地插入及表达任何VH或VL序列的适当限制位点的载体,如上文所描述。对于抗体轻链,恒定链通常为κ或λ,对于抗体重链,其可为但不限于任何IgG同型(IgG1、IgG2、IgG3、IgG4)或其他免疫球蛋白,包括等位基因变体。
重组表达载体亦可编码有助于自宿主细胞分泌抗体链(例如本文所描述的结合分子或抗体的重链及轻链)的信号肽。可将编码抗体链的DNA克隆至载体中,使得信号肽框内连接于成熟抗体链DNA的氨基端。信号肽可为免疫球蛋白信号肽或来自非免疫球蛋白蛋白质的异源肽。替代地,编码抗体链(例如本文所描述的结合分子或抗体的重链及轻链)的DNA序列可能已经含有信号肽序列。
除编码抗体链(例如本文所描述的结合分子或抗体的重链及轻链)的DNA序列以外,重组表达载体携带调控序列,包括启动子、增强子、终止及聚腺苷酸化信号以及其他控制抗体链在宿主细胞中表达的表达控制组件。启动子序列的例子(针对在哺乳动物细胞中表达所例示)为来源于CMV(诸如CMV猿猴病毒40(SV40)(诸如SV40启动子/增强子))、腺病毒(例如腺病毒主要晚期启动子(AdMLP))、多瘤病毒的启动子和/或增强子,及强哺乳动物启动子,诸如天然免疫球蛋白及肌蛋白启动子。聚腺苷酸化信号的例子为BGH polyA、SV40晚期或早期polyA;替代地,可使用免疫球蛋白基因的3′UTR等。
重组表达载体亦可携带调控宿主细胞中载体复制的序列(例如复制起点)及可选标记基因。可根据本领域熟知的转染方法,包括脂质体介导的转染、聚阳离子介导的转染、原生质体融合、显微注射、磷酸钙沉淀、电穿孔或通过病毒载体转移,将编码本文所描述的结合分子或抗体的重链或其抗原结合部分和/或轻链或其抗原结合部分的核酸分子及包含这些DNA分子的载体引入宿主细胞,例如细菌细胞或高级真核细胞(例如哺乳动物细胞)中。
优选地,编码本文所描述的结合分子或抗体的重链及轻链的核酸分子存在于两个载体上,该两个载体共转染至宿主细胞,优选地哺乳动物细胞中。
因此,另一方面提供一种包含含有编码重链的核酸分子的表达载体的宿主细胞以及一种包含编码本文所描述的结合分子或抗体的轻链的核酸分子的表达载体。
可用作宿主进行表达的哺乳动物细胞株为本领域熟知且尤其包括中国仓鼠卵巢(CHO、CHO-DG44)细胞、NSO、SP2/0细胞、HeLa细胞、幼仓鼠肾(baby hamster kidney;BHK)细胞、猴肾细胞(COS)、人类癌瘤细胞(例如Hep G2)、A549细胞、3T3细胞或任何此类细胞株的衍生物/后代。可使用其他哺乳动物细胞,包括但不限于人类、小鼠、大鼠、猴及啮齿动物细胞株;或其他真核细胞,包括但不限于酵母、昆虫及植物细胞;或原核细胞,诸如细菌。本发明的结合分子通过将宿主细胞培养一段足以允许在宿主细胞中表达结合分子的时间来制备。
如本文所描述的结合分子及抗体分子优选地自培养基作为分泌多肽回收,或若例如在无分泌信号的情况下表达,则其可自宿主细胞溶解物回收。有必要以获得实质上均匀的如本文所描述的结合分子或抗体制剂的方式,使用重组蛋白及宿主细胞蛋白所使用的标准蛋白质纯化方法来纯化本文所描述的结合分子或抗体分子。借助于实施例,适用于获得本发明的结合分子及抗体的最佳技术纯化方法包括自培养基或溶解物移除细胞和/或颗粒细胞碎片作为第一步骤。接着例如通过在免疫亲和力或离子交换柱上分级分离、乙醇沉淀、反相HPLC、葡聚糖凝胶色谱、二氧化硅色谱或在阳离子交换树脂上自杂质可溶性蛋白质、多肽及核酸纯化出结合分子或抗体。作为用于获得如本文所描述的VEGF及TrkB单一结合分子的方法中的最终步骤,纯化的结合分子可经干燥,例如冻干,如下文关于治疗性应用所描述。
本发明的另一方面提供本发明的结合分子,其用于药物中。应理解,此药物中的用途及用于治疗如以下中所描述的疾病的用途亦包括根据本发明的TrkB结合分子、scFv及抗体。
本发明的结合分子经指示例如用于眼部或视网膜或神经退化性疾病的疗法/治疗中,优选地用于治疗神经/神经元眼部或视网膜疾病。在另一方面中,本发明涉及用于治疗和/或预防眼部或视网膜或神经退化性疾病的方法,该方法包含向人类(例如罹患wAMD或处于发展地图状萎缩风险下的个体)施用有效量的本发明的结合分子,从而改善眼部或视网膜或神经退化性疾病的一个或多个症状。
如本文所用,术语“治疗”及“疗法”及其类似术语意谓包括疾病或病症的治疗以及防治性,或遏制措施,从而产生任何临床上所需或有益的效果,包括但不限于缓解或减轻一个或多个症状、消退、减缓或停止疾病或病症的进展。因此,举例而言,术语治疗包括在疾病或病症的症状发作之前或之后施用结合分子,从而预防或移除疾病或病症的一个或多个征象。作为另一实施例,该术语包括在疾病的临床表达之后施用结合分子,以对抗疾病的症状。此外,在施用影响疾病或病症的临床参数,诸如组织损伤程度或癌转移的量或程度的情况下,无论治疗是否引起疾病得到改善,在发作之后及已发展临床症状之后施用结合分子包含如本文所使用的“治疗”或“疗法”。此外,只要相较于在不存在使用结合分子的情况下的症状相比,单独本发明的组合物或与另一治疗剂组合缓解或改善所治疗的病症的至少一个症状,则结果应视为对潜在病症的有效治疗,而与病症的所有症状是否得到缓解无关。
可向患有眼部或视网膜疾病或处于罹患眼部或视网膜疾病风险下的个体施用本发明的结合分子。本发明进一步提供一种结合分子的用途,其用于制造用于预防和/或治疗眼部或视网膜疾病的药物。如本文所用,术语“个体”意谓可向其施用结合分子的任何哺乳动物患者,包括例如人类及非人类哺乳动物,诸如灵长类动物、啮齿动物及狗。特定预期使用本文所描述的方法治疗的个体包括人类。结合分子可单独或与其他组合物组合施用。
在一个实施方案中,使用本发明的结合分子来治疗黄斑变性、老年性黄斑变性、糖尿病性视网膜病变、糖尿病性黄斑水肿、色素性视网膜炎、遗传性视网膜营养性萎缩、遗传性黄斑营养不良、近视变性、地图状萎缩、继发于老年性黄斑变性的地图状萎缩、视网膜动脉阻塞、眼内炎、葡萄膜炎、囊样黄斑水肿、继发于任何视网膜疾病的脉络膜新生血管性膜、视神经病、青光眼、视网膜脱落、毒性视网膜病、辐射性视网膜病、及创伤性视网膜病、前驱性及轻度至中度阿尔茨海默氏症,延迟患有阿尔茨海默氏病、亨廷顿氏症、帕金森氏症、严重抑郁症、精神分裂症、与精神分裂症相关的认知障碍的患者的疾病进展,预防患有减弱精神病综合征的个体的第一次精神病发作,预防患有精神分裂症、难治性抑郁、暴食、肥胖症或代谢综合征的患者复发。
在一优选实施方案中,本发明的结合分子在治疗wAMD中具有效用。更优选的,本发明的结合分子在治疗wAMD及治疗地图状萎缩中具有效用。在又另一优选实施方案中,本发明的结合分子在治疗继发于老年性黄斑变性的地图状萎缩中具有效用。在一另外优选实施方案中,本发明的结合分子在治疗地图状萎缩或治疗处于发展地图状萎缩风险下的患者中具有效用。在一另外优选实施方案中,本发明的结合分子在预防地图状萎缩中具有效用。在一最佳实施方案中,本发明的结合分子在治疗处于发展地图状萎缩风险下的患者的wAMD中具有效用。
在另一实施方案中,本发明的结合分子可适用于治疗听力损失,尤其顺铂诱发的听力损失以及噪音及年龄相关的听力损失。
本发明的结合分子通过任何合适的手段,包括玻璃体内、经口、非经肠、皮下、腹膜内、肺内及鼻内施用。非经肠输注包括肌肉内、静脉内、动脉内、腹膜内或皮下施用。另外,本发明的结合分子适合通过脉冲输注,尤其在降低剂量的情况下施用。在一个方面中,部分视施用的短期或长期性而定,可通过注射,最佳地静脉内或皮下注射给药。优选地,本发明的结合分子为经由玻璃体内注射至眼睛中给与。
在另一方面中,本发明的结合分子与适用于施用结合分子的装置,诸如注射器、注射笔或其他装置组合使用。在另一方面中,本发明的结合分子包含于分装部分的试剂盒(kit of parts)中,其例如亦包括具有使用结合分子的指示的药品说明书。
视涉及的特定疾病而定,可使用任何适合的体外分析、基于细胞的分析、体内分析和/或本身已知的动物模型或其任何组合测试本发明的结合分子及包含其的组合物的功效。适合的分析及动物模型对技术人员将为清楚的,且例如包括下文实施例中所用的分析及动物模型。
当然实际药学上有效量或治疗剂量将视而本领域技术人员已知的因素而定,诸如患者的年龄及体重、施用途径及疾病的严重程度。在任何情况下,本发明的结合分子将基于患者的独特病状以允许递送药学上有效量的剂量及方式施用。
本发明的结合分子可独自使用或与其他药理学上活性成分(诸如最佳技术或标准照护化合物)组合使用。
因此,本发明的另一方面提供一种药物组合物,其包含本发明的结合分子以及药学上可接受的载剂及任选一种或多种其他活性成分。
对于结合分子的玻璃体内注射而言,优选的是治疗之间之间隔一般较长。在一个实施方案中,每6周,优选每7周,亦优选每8周,更优选每9周,更优选每10周,更优选每11周及更优选每12周施用本发明的结合分子。在一另外优选实施方案中,每3个月一次施用TrkB抗体。视本发明的特异性结合分子及其特定药物动力学及其他特性而定,施用频率甚至可更长,诸如每13周、14周、15周、16周、17周、18周、19周或20周。
替代地,可应用其他给药方案,包括例如负载剂量,其中本发明的结合分子可每月一次注射持续3个负载剂量及接着每12周一次。同样,施用频率亦可在此类情况下延长,且甚至可更长,诸如每13周、14周、15周、16周、17周、18周、19周或20周。
大致2.5mg/眼的预测的人类估计剂量对应于50mg/mL调配物,其中50μL将注射至眼睛中。
为了用于疗法中,将本发明的结合分子调配成适合于便于向动物或人类施用的药物组合物。本文所描述的结合分子或抗体分子的典型调配物可通过将结合分子与生理学上可接受的载剂、赋形剂或稳定剂混合而制备,呈冻干或干燥调配物或水溶液或水性或非水性悬浮液形式。载剂、赋形剂、调节剂或稳定剂在所采用的剂量及浓度下无毒性。其包括缓冲剂系统,诸如磷酸盐、柠檬酸盐、乙酸盐及其他无机酸或有机酸及其盐;抗氧化剂,包括抗坏血酸及甲硫氨酸;防腐剂,诸如氯化十八烷基二甲基苯甲基铵;氯化六羟季铵、氯化苄烷铵、氯化苯索宁;苯酚、丁醇或苯甲醇;对羟苯甲酸烷酯,诸如对羟基苯甲酸甲酯或对羟基苯甲酸丙酯;儿茶酚;间苯二酚;环己醇;3-戊醇;及间甲酚;蛋白质,诸如血清白蛋白、明胶或免疫球蛋白;亲水性聚合物,诸如聚乙烯吡咯烷酮或聚乙二醇(PEG);氨基酸,诸如甘氨酸、谷氨酰胺、天冬酰胺、组氨酸、精氨酸或赖氨酸;单糖、双糖、寡糖或多糖及其他碳水化合物,包括葡萄糖、甘露糖、蔗糖、海藻糖、糊精或聚葡萄糖;螯合剂,诸如EDTA;糖醇,诸如甘露醇或山梨醇;成盐相对离子,诸如钠;金属络合物(例如Zn-蛋白质络合物);和/或离子或非离子表面活性剂,诸如TWEENTM(聚山梨醇酯)、PLURONICSTM或脂肪酸酯、脂肪酸醚或糖酯。有机溶剂亦可含于调配物中,诸如乙醇或异丙醇。赋形剂亦可具有修饰释放或修饰吸收的功能。
通常,水溶液或悬浮液将是优选的。一般而言,治疗蛋白,诸如本发明的结合分子的适合的调配物为缓冲蛋白质溶液,诸如包括适合浓度(诸如0.001至400mg/ml,优选地0.005至200mg/mL,更优选地0.01至200mg/mL,更优选地1.0-100mg/ml)的蛋白质的溶液。
然而,本领域技术人员将清楚,如上文所给出的成分及其量仅表示一种优选选择。其替代方案及变体对本领域技术人员将直接显而易知,或可易于自以上公开内容开始进行构想。
TrkB结合分子
基于出人意料的发现,本发明的结合分子中的TrkB结合位点(两个scFv)的设计明显支持TrkB结合及活化的最佳空间形成—其可与其他抗原结合位点(诸如VEGF结合位点)或VEGF诱导的聚类机制无关—本发明进一步为针对一种TrkB结合分子,其包含两个scFv或由其组成,其中各scFv与TrkB特异性结合且两者共同充当TrkB激动剂。
不希望受理论所束缚,本发明人相信,通过将两个scFv组合至TrkB结合分子中,达成其最佳空间形成,导致所观测到的完全TrkB促效活性。因此,在一个方面中,TrkB结合分子为完全TrkB激动剂,亦即TrkB结合分子在活化TrkB方面与天然配体BDNF一样有效。
应理解,TrkB结合分子中的两个scFv彼此连接以形成TrkB结合分子。Trkb结合分子中的两个scFv可彼此融合或彼此共价连接。替代地,两个scFv可经由肽接头,优选地例如长度为约4至20个氨基酸的肽接头且更优选地可挠性肽接头而连接。
TrkB结合分子中的各scFv可与TrkB蛋白内的相同或不同抗原决定基结合。优选地,两个scFv与相同TrkB抗原决定基结合。
TrkB结合分子中的scFv自N端至C端可包含VH域(例如鼠类、人源化或人类VH域)、接头及VL域(例如鼠类、人源化或人类VL域),或反过来VL域、接头及VH域)。优选地,TrkB结合分子中的scFv自N端至C端具有VL-VH定向。
另外,单链Fv片段可通过经由并入半胱氨酸残基将二硫键并入VH与VL域之间、VH域内或VL域内来进一步稳定。术语N端表示多肽链的第一个氨基酸,而术语C端表示多肽链的C端的最后一个氨基酸。因此,在一个实施方案中,一个或两个scFv包含额外半胱氨酸残基以形成二硫键。
在另一相关方面中,TrkB结合分子可进一步包含Ig分子。就此而言,Ig分子可为单克隆抗体;人类单克隆抗体;人源化单克隆抗体;嵌合抗体;抗体的片段,诸如Fv、Fab、Fab'或F(ab')2片段;单链抗体,诸如单链可变片段(scFv);小模块免疫药物(SMIP);域抗体;纳米抗体;或双抗体。
通过添加另一Ig分子,支持TrkB结合分子内的两个scFv的最佳空间形成以达成完全TrkB激动剂效果。认为此效果与Ig分子的特异性无关,因为该效果基于TrkB结合分子的空间形成而非Ig分子的特异性。因此,Ig分子可设计成与任何目标结合。由于相信所观测到的完全激动剂效果主要为基于TrkB结合分子内的scFv的空间形成,因此Ig分子亦可不特异性地与任何目标结合。
在一另外优选实施方案中,Ig分子包含Fc区或由其组成。优选地,在此实施方案中,各scFv与Fc区重链的C端融合。在关于此实施方案的另一实施方案中,各scFv通过肽接头,优选地长度为约4至20个氨基酸的肽接头与Fc区融合。
另外,此处,应理解TrkB结合分子中的两个scFv及Ig分子彼此连接以形成TrkB结合分子。scFv可与Ig分子融合或直接与Ig分子共价连接,或其可经由接头,优选地例如长度为约4至20个氨基酸的肽接头且更优选地可挠性肽接头而与Ig分子连接。
优选地,scFv与Ig分子重链的C端融合。优选地,Ig分子为IgG、F(ab)或F(ab')2。因此,在一优选实施方案中,TrkB结合分子包含以下或由以下组成:两个scFv及IgG、F(ab)或F(ab')2,其中各scFv与TrkB特异性结合。在一相关优选实施方案中,TrkB结合分子是双特异性的且是四价的且包含以下或由以下组成:两个scFv及IgG或F(ab')2,其中各scFv与TrkB特异性结合。在一优选实施方案中,Ig分子且更优选地IgG、F(ab)或F(ab')2与VEGF特异性结合。
连接scFv分子与Ig分子(例如IgG分子)重链的C端或连接scFv分子内的可变域的方法为本领域熟知。通常,使用甘氨酸及丝氨酸(称为GS迷你接头)氨基酸的小接头序列。接头中氨基酸的数目可在4(GGGS)(SEQ ID NO:227)、6(GGSGGS)(SEQ ID NO:217)、10(GGGGSGGGGS)(SEQ ID NO:218)、15(GGGGSGGGGSGGGGS)(SEQ ID NO:219)、20(GGGGSGGGGSGGGGSGGGGS)(SEQ ID NO:220)或更多变化。实际上,接头通常为通过将以下组合而形成:编码所关注Ig的核酸分子与编码所需scFv的核酸(在本发明的情况下,其将包括编码重链及轻链的可变域的核酸,对于TrkB结合位点,呈VL-VH或VH-VL定向),所述核酸分子由编码接头序列(例如具有5、10、15或20个氨基酸中的任一者的GS迷你接头,优选地SEQID NO:218的接头)的核酸分子隔开。接着如先前所解释,将此完整HC-scFv编码核酸分子置放于表达载体内且引入适当宿主细胞中,使得形成完整Ig重链-scFv单一多肽。
优选地,scFv分子与Ig分子重链的C端之间的GS迷你接头为10L1(SEQ ID NO:218)。
在一个方面中,与天然TrkB配体BDNF相比,TrkB结合分子更强效地诱导TrkB下游信号传递路径的活化。在另一方面中,TrkB结合分子经由TrkB介导的信号传递路径以与BDNF相当的模式调控基因表达。
在另一方面中,TrkB结合分子对TrkB磷酸化和/或活化具有特异性,且不会非特异性地磷酸化/活化TrkA或TrkC。
在一个实施方案中,TrkB结合分子包含以下或由以下组成:
(i)两条重链,其自N端至C端各自包含:
-(任选)重链可变域(例如鼠类、人源化或人类VH域)
-恒定域,优选地IgG(例如人类IgG1或IgG4)的恒定域
-(任选)肽接头(例如GS迷你接头)及
-对TrkB具有特异性的scFv(例如自N端至C端包含VH域(例如鼠类、人源化或人类VH域)、接头及VL域(例如鼠类、人源化或人类VL域)或反过来VL域、接头及VH域的scFv);及
(ii)两条轻链,其自N端至C端各自包含:
(任选)轻链可变域(例如鼠类、人源化或人类VL域),
轻链恒定域,优选地IgG的轻链恒定域(例如人类κ链)。
本发明现借助于以下非限制性实施例描述。
实施例
方法:
表达Trk受体的CHO细胞的培养
在补充有10%胎牛血清、格鲁塔玛(glutamax)、非必需氨基酸、20mM HEPES、5μg/mL杀稻瘟菌素及200μg/mL吉欧霉素(zeocin)的DMEM(Lonza,#BE12-604F)中,培养表达人类TrkB受体的CHO细胞(ThermoFisher Scientific,#K1491)及表达人类TrkA或TrkC受体的客制化CHO细胞。在具有5%胎牛血清、8mM谷氨酰胺、0.5mg/mL G418的Hams F12(Lonza#BE12-615F)及DMEM(Lonza#BE12-604F)的1:1混合物中,培养表达食蟹猕猴、兔或大鼠TrkB受体的客制化CHO细胞。在补充有10%胎牛血清、格鲁塔玛、10mM HEPES及0.8mg/mL G418的DMEM(Lonza#BE12-604F)中培养表达小鼠TrkB受体的客制化CHO细胞。
表达人类、食蟹猕猴、兔、大鼠或小鼠Trk受体的CHO细胞中的TrkA/B/C及ERK1/2磷酸化的分析
将五千个表达各自的Trk受体的CHO细胞接种于384孔透明组织培养盘(BDFalcon,#353963)的各空腔中,且在潮湿培育箱中在37℃及5% CO2下培育。在接种后二十四小时,细胞上清液用室温饥饿培养基(具有0.1% BSA(Sigma,#A-3059)但无其他补充剂的DMEM)置换。在15分钟之后,在室温添加饥饿培养基与增加浓度的人类BDNF(R&D#248-BD或Bachem#H-5594)、人类NGF(Biovision#4303R-20)、人类NT-3(Sigma#N1905)、促效抗体或同型对照,重复三次,持续45分钟,以刺激TrkB及ERK1/2磷酸化。单独饥饿培养基充当对照。
在一些实验中,在刺激细胞之前,将BDNF或促效抗体不与或与2、10、50或200ng/mL人类VEGF(R&D Systems#293-VE-050)一起预培育一小时。在这些实验中,与单独人类VEGF一起培育充当对照。
为了分析促效TrkB抗体是否极限BDNF诱导的TrkB的磷酸化和/或下游ERK1/2磷酸化,在具有或不具有0.3nM、1nM或3nM恒定浓度的BDNF的情况下,将表达人类TrkB受体的CHO细胞与增加浓度的抗体一起培育。
在刺激之后,移除细胞上清液,且在润湿冰上在溶解缓冲液(1x Triton溶解缓冲液(Cell Signaling Technology#9803-S),补充有完全迷你蛋白酶抑制剂片剂(Roche#04693124001)及磷酸酶抑制剂混合物2(Sigma#P5726)及3(Sigma#P0044),以及1mM PMSF(Sigma#93482))中溶解细胞20分钟。使用所得溶解物以根据制造商说明书,使用可商购分析(Perkin Elmer#ALSU-PTRKAB-A10K),对Y680/681处的TrkA磷酸化、Y706/707处的TrkB磷酸化或Y709/710处的TrkC磷酸化进行定量。根据制造商说明书,使用另一可商购分析(Perkin Elmer#TGRES10K或ALSU-PERK-A10K),类似地进行T202/Y204(ERK1)及T185/Y187(ERK2)处的ERK1/2磷酸化的定量。在Perking Elmer EnVision微量盘读取器上记录在570nm下受体珠粒的光发射,其反映磷酸化事件。准备数据以用GraphPad Prism(版本8)呈现,包括原始数据(平均值±SEM)及非线性回归(log(激动剂)相对于反应(三个参数))。
TkrB胞外域(TrkB-ECD)的功能特征
将稳定表达人类TrkB的CHO细胞与增加浓度的天然配体BDNF或10nM BDNF与增加浓度的TrkB-ECD(R&D Systems#1494-TB)一起培育。如上文所概述,通过测量Y706/707上的TrkB磷酸化评价TrkB活化。数据表示平均值+/-SEM。
TrkB受体内化分析
在刺激之前二十四小时,将25000个表达人类TrkB受体的CHO细胞接种于96孔黑色透明底组织培养盘(PerkinElmer,#6055300)的各空腔中,且在潮湿培育箱中在37℃及5%CO2下培育。CHO/hTrkB细胞的上清液用饥饿培养基(具有0.1% BSA(Sigma,#A-3059)及20mM Hepes(Lonza,#BE17-737F)的DMEM)置换,且在37℃培育细胞30分钟。接着,在饥饿培养基中,在37℃,用增加浓度的BDNF(R&D#248-BD或Bachem#H-5594)或单独促效TrkB抗体、或1nM BDNF与增加浓度的促效抗体的组合刺激细胞50分钟。将细胞在4%多聚甲醛中固定20分钟,洗涤,在含5%正常驴血清的PBS中阻断一小时,且在室温与1μg/mL山羊抗TrkB抗体(R&D Systems,#AF-397)一起培育隔夜,随后充分洗涤及在室温在2μg/mL AlexaFluor 647驴抗山羊抗体(ThermoFisher Scientific,#A21447)及1μg/mL Hoechst#H3570中培育2小时。在充分洗涤之后,在PBS/0.05% Tween-20中,细胞用2μg/mL HCS-Cellmask绿(ThermoFisher Scientific,#H32714)染色一小时。在配备有20x water物镜的PerkinElmer Opera Phenix高通量筛选系统上使细胞表面受体成像,且用PerkinElmerHarmony高通量成像及分析软件分析。数据呈现为热图,其中热图的深色及浅色场分别表示高于荧光临限值的高及低百分比的细胞;或呈现为表示表面TrkB染色强度高于临限值的细胞百分比的图。在后者情况下,准备数据以用GraphPad Prism(版本8)呈现,包括原始数据(平均值±SEM)及非线性回归(log(激动剂)相对于反应(三个参数))。
VEGF诱导的VEGF受体2磷酸化及下游信号传递的抑制
在明胶(Millipore#ES-006B)涂布的培养盘上在具有补充剂(Promocell#C-39210)及各10U/mL青霉素/链霉素的内皮细胞基础培养基(Promocell#C-22210)中培养人类视网膜微血管内皮细胞(HRMEC;Cell Systems#ACBRI181)。对于VEGF清除的分析而言,将12000个细胞接种于使用正常生长培养基的96孔透明组织培养盘的各空腔中,且在潮湿培育箱中在37℃及5% CO2下培育。二十四小时后,培养基用饥饿培养基(Promocell#C-22210,补充有0.1% BSA(Sigma,#A-3059)及10U/mL青霉素/链霉素)置换,且使细胞在潮湿培育箱中在37℃及5% CO2下饥饿20小时。在刺激VEGFR2信号传递之前,将50ng/mL人类VEGF(R&D Systems#293-VE-050)不与或与拮抗抗体或艾力雅一起在室温在饥饿培养基中预培育30-60分钟,且接着预温热至37℃持续15分钟。通过向细胞中添加预先形成的VEGF-抗体/艾力雅复合物或单独VEGF,在37℃保温板上进行细胞刺激5分钟。单独饥饿培养基充当对照。在室温在溶解缓冲液(Perkin Elmer#ALSU-PVGFR-A500)中溶解细胞10分钟,且接着在冰上培育额外10分钟。根据制造商说明书,使用可商购分析来定量以下:Y1175处的VEGFR2磷酸化(Perkin Elmer#ALSU-PVGFR-A500或#ALSU-PVGFR-A10K)、Y1214处的VEGFR2磷酸化(Perkin Elmer#ALSU-PVGFR-C500)、Y951处的VEGFR2磷酸化(Perkin Elmer#ALSU-PVGFR-B500)、T202/Y204处的(ERK1)及T185/Y187(ERK2)处的ERK1/2磷酸化(PerkinElmer#TGRES10K或ALSU-PERK-A10K)、Y419处的Src磷酸化(Perkin Elmer#ALSU-PSRC-A10K)、Thr180/Tyr182处的p38-MAPK磷酸化(Perkin Elmer#ALSU-PP38-B500)。在PerkingElmer EnVision微量盘读取器上在570nm下记录反映上文所提及的磷酸化事件的受体珠粒的光发射,且准备以用GraphPad Prism(版本8)呈现,包括原始数据(平均值±SEM)及非线性回归(log(激动剂)相对于反应(三个参数))。
为了研究TrkB结合对于通过双特异性且四价多普单抗进行的VEGF清除的影响,在不存在或存在TrkB-ECD下,在饥饿HRMEC中评价VEGF诱导的VEGFR2磷酸化的抑制。在刺激之前,将增加浓度的各自的多普单抗与100nM TrkB-ECD(R&D Systems#1494-TB)一起在饥饿培养基中在室温培育一小时,随后与50ng/mL人类VEGF一起另外培育小时。作为对照,将HRMEC与以下一起培育:(i)单独饥饿培养基,(ii)50ng/mL人类VEGF,(iii)50ng/mL人类VEGF与增加浓度的TrkB-ECD预先形成的复合物(在室温一小时),(iv)50ng/mL人类VEGF与增加浓度的各自的多普单抗预先形成的复合物(在室温一小时),及(v)增加浓度的单独TrkB-ECD。如上文所概述,通过测量Y1175处的VEGF受体2(VEGFR2)磷酸化评价VEGF-A清除。
VEGF诱导的HRMEC增殖的抑制
将三千个HRMEC接种于使用具有补充剂(Promocell#C-39210)及各10U/mL青霉素/链霉素的内皮细胞基础培养基(Promocell#C-22210)的透明平底96孔盘的各空腔中,且在潮湿培育箱中在37℃及5% CO2下培育。十六小时后,生长培养基经饥饿培养基(补充有2%胎牛血清的内皮细胞基础培养基(Promocell#C-22210))置换,且使细胞在潮湿培育箱中在37℃及5% CO2下饥饿八小时。在刺激之前,将人类VEGF(R&D Systems#293-VE-050)不与或与拮抗抗体或艾力雅一起在室温在饥饿培养基中预培育60分钟。通过向细胞中添加预先形成的VEGF-抗体/艾力雅复合物或单独VEGF进行细胞刺激。单独饥饿培养基充当对照(基础增殖)。通过总HRMEC核区域的自动化基于相差影像的定量(Essen Bioscience,IncuCyteS3)评价细胞增殖,该定量视为与HRMEC数目成比例。用10x物镜,每四个小时记录每孔四个影像,持续总共96小时时段。数据表示作为时间函数的相对细胞数目(时间点t处的细胞数目/t=0时的细胞数目);将在t=0时的细胞数目设定为一。对于一些实验而言,绘制针对各自的化合物浓度的十进制对数的各生长曲线与基础生长曲线(饥饿培养基中的增殖)之间的面积。准备数据以用GraphPad Prism(版本8)呈现,包括原始数据(平均值±SEM)及非线性回归(log(激动剂)相对于反应(三个参数))(若适用)。
VEGF诱导的HRMEC出芽的抑制
在基于HRMEC的球体分析中评价VEGF诱导的出芽的抑制。将HRMEC再悬浮于含有20%美多秀(Methocoel)的正常生长培养基(1.2%甲基纤维素及10%胎牛血清于内皮基础培养基中)中,且将含有500个HRMEC的25μl液滴涂覆在方形培养皿上。将培养盘颠倒以在悬挂液滴中培养细胞,此允许自发形成球体。在24小时之后,收集球体且包埋于48孔盘中的美多秀-胶原蛋白混合物(80%美多秀及20% FCS 1:1与3mg/mL大鼠尾胶原蛋白I(Corning#354236)混合于M199培养基中)中,且在潮湿培育箱中在37℃及5% CO2下培育30分钟,以进行胶原蛋白聚合。在刺激之前,将人类VEGF(R&D Systems#293-VE-050)不与或与拮抗抗体或艾力雅一起在室温在补充有2%胎牛血清的基础内皮生长培养基中预培育60分钟。通过向球体中添加预先形成的VEGF-抗体/艾力雅复合物或单独VEGF刺激出芽24小时。补充有2%胎牛血清而无VEGF的基础内皮生长培养基充当对照。在固定于4%多聚甲醛中之后,将细胞充分洗涤且在含有0.2% Triton X-100的PBS中用2μg/mL HCS-Cellmask绿(ThermoFisher Scientific,#H32714)染色隔夜。在ZEISS LSM 780共焦显微镜上分析球体。根据手动地且表述为积聚芽长度/球体(mm)或用Zeiss ZEN-成像软件半自动化地且表述为球体周界(像素)的Z-堆栈的最大投影影像来定量HRMEC的三维出芽。准备数据以用GraphPad Prism(版本8)呈现且表示平均值±SEM。
视网膜电描记术
通用程序
视网膜电描记术(ERG)为评价不同视网膜神经元的光诱导的电活动的非侵袭性电生理技术,且允许定量视网膜功能的不同方面,诸如弱光或色觉。使用Espion E3 ERG记录系统(Diagnosys LLC)将ERG测量为角膜与参考电极之间的电势变化。在ERG记录之前,使动物暗适应至少2h,且通过i.p.注射氯胺酮(Ketanest,大约100mg/kg)及赛拉嗪(xylazin)(Rompun,大约7mg/kg)来麻醉。将动物置放于加热台上以维持体温恒定于37℃。利用局部托品卡胺及10%苯肾上腺素使瞳孔扩大。在记录期间将一滴2%美多秀(Methocel)溶液(OmniVision)置放于角膜上以预防眼睛角膜干燥。用金环形电极,自两只眼睛同时执行记录。参考电极为用美多秀润湿且连接于动物颊部的无齿鳄鱼夹。对于电接地,将夹子连接于动物尾部。在1kHz下取样ERG信号且在0.15Hz低频及500Hz高频截止下进行记录。光刺激由通过一组发光二极管或氙气灯泡(对于闪光≥1cd·s/m2)递送的全场闪光(持续时间~4ms)组成。所有闪光通过Ganzfeld刺激器(ColorDome;Diagnosys)在黑暗中或在背景光上产生。
ERG方案
ERG反应首先自暗适应动物记录(以分离视杆驱动的反应),之后自适应红色背景光(50cd/m2,以分离UV视锥驱动的ERG反应)及最后适应绿-蓝色背景光(25.5cd/m2,以分离M视锥驱动的ERG反应)的动物记录。
在暗适应ERG的情况下,反应通过在1·10-5至100cd·s/m2范围内的一系列闪光诱发。对于亮度为1·10-5及3·10-5cd·s/m2的闪光,对20个试验的反应求平均。对于在1·10-4至0.05cd·s/m2之间的闪光,对10个试验的反应求平均;对于0.1cd·s/m2的闪光,对8个试验的反应求平均;且对于1cd·s/m2的闪光,对5个试验求平均。最后的10cd·s/m2闪光,我们记录3个试验的反应,且对于最终闪光100cd·s/m2,记录单一闪光。
单独闪光之间之间隔经选择以确保视网膜自各次闪光完全恢复(无闪光诱发的反应幅度减小或隐含时间缩短的指示)。基于这些标准,对于1·10-5及3·10-5cd·s/m2闪光,闪光间间隔为2秒,对于1·10-4至0.05cd·s/m2之间的闪光为5秒,对于0.1cd·s/m2的闪光为10秒,且对于1cd·s/m2的闪光为20s。在10cd·s/m2及100cd·s/m2的单一闪光之后,分别存在30s及120s的恢复时间。
对于UV视锥驱动及M视锥驱动的反应的记录而言,首先使动物光适应红色背景光2min,且之后适应绿色背景光。光反应为通过0.02、0.04、0.08、0.17、0.35、0.83、1.66、2.90及4.15μW/m2的UV闪光及分别通过0.1直至110cd·s/m2闪光的M视锥闪光诱发。对所有10个试验的反应求平均,其中闪光间间隔为3s。
动物及STZ治疗
雄性Brown Norway大鼠(BN大鼠)获自Charles River(德国)。通过i.p.注射STZ(65mg/kg体重)诱发高血糖症。在STZ施用后第7天,无反应或反应不良的动物不包括于研究中,亦即血糖浓度<20mM的动物。有规律地监测体重及血糖含量。在玻璃体内给药之前大约3周,施用STZ。
给药及玻璃体内注射
对于玻璃体内注射,大鼠用2.5%-3%异氟醚(Forene;Abbvie)麻醉。施用一滴4mg/ml盐酸奥布卡因(oxybuprocainhydrochlorid)(Novesine;Omnivision)以用于局部麻醉。经由34号(gauge)针(装配在10μl Hamilton玻璃注射器上)将5μL注射至恰好在各眼睛中的角膜缘后的玻璃体中。
数据分析
使用Espion E3 ERG记录系统(Diagnosys LLC)将ERG测量为角膜与参考电极之间的电势变化。
在用Matlab软件计算之前,证明不同组的各ERG闪光在计算来自各闪光的平均曲线之前为一致的。
为了测定ERG a/b波幅度,ERG数据使用MATLAB软件(版本R2014a;MathWorks)处理且分析。在我们的情况下,我们用单独的宏分类数据且为我们的Matlab例程准备档案。
自a波反应的底部至b波峰的峰值计算b波幅度。b波隐含时间测量为在闪光刺激之后达到b波峰值所需的时间。
通过使用最小平方拟合程序(GraphPad Prism,版本6.01及随后GraphPad Prism的更高版本)拟合作为刺激强度的函数的b波幅度。自基线(零基线)至负a波反应计算a波幅度。
通过单向ANOVA进行统计分析。
实施例1:
识别人类VEGF及人类TrkB的结合分子的总体设计
图1
本发明人已研发出结合VEGF及TrkB且分别充当VEGF拮抗剂及TrkB激动剂的结合分子。所用的分子设计具有对目标抗原具有特异性的IgG抗体(称为“主抗体”),以及与重链C端偶合的具有不同特异性的scFv。设计的示意图显示于图1中。优选地,结合分子是双特异性的且是四价的。
双特异性分子含有在scFv的可变重链(VH)与可变轻链(VL)域之间的可挠性肽序列,且scFv域经由其他系列接头与主IgG抗体连接。在一个构型中,scFv经定向以使得VL域形成scFv的“N端”末端,且因此与主抗体的重链的C端融合,而VH形成scFv的C端且实际上形成完整重链多肽。然而,可了解,此“N-VL-VH-C”结构可颠倒,亦即“N-VH-VL-C”。
为了测试此概念的可行性,制备基于图1中描绘的格式的多种不同双特异性分子,且自系列1开始至系列4历经若干个分子设计周期而经进一步优化。
以下实施例解释用于生成结合VEGF及TrkB的不同系列的双特异性分子以及这些分子的格式及生物活性的变体。
实施例2:
识别VEGF及TrkB的结合域的制备
图1
如可了解,为了制备与人类VEGF及TrkB结合的双特异性分子,需要获得与其单独目标抗原结合的可变域。
出于此目的,免疫球蛋白(Ig)VH及VL基因为获自不同VEGF及TrkB结合剂且经格式化为本发明的双特异性分子。总计三个不同VEGF结合域获自单独VEGF结合剂,称为B20、G6及兰尼单抗。为了与TrkB结合,结合域为获自单独TrkB结合剂,称为C2(WO2010086828)。
单独结合剂格式化为本发明的双特异性分子为通过本领域技术人员已知的常规方法进行。简言之,为了构筑编码scFv的基因区段,通过编码肽序列GGSEGKSSGSGSESKSTGGS(SEQ ID NO:221)的可挠性接头的基因区段,将编码可变域的VL及VH基因对接合。所得scFv编码基因区段转而框内克隆至编码人类IgG抗体的重链的基因的3'端。这些编码区段为通过重叠PCR方法合成且克隆至表达载体pTT5中。
接着,将编码Fab(2)部分的VL及VH基因对形式化为实施例1中概述的双特异性格式。将VH基因在编码人类Igγ的基因的5'端以框内融合物克隆至pTT5表达载体中。将编码scFv结合剂的基因框内克隆在相同Igγ编码区段的3'端处。类似地,将VL基因以与编码人类IgGκ轻链的基因框内融合物形式克隆至pTT5表达载体中。
在以上用于VH及VL基因的定向克隆的程序中使用HD克隆试剂盒(Clonetech,U.S.A.)。合成具有与线性化载体的末端互补的15bp延伸部分的用于VL/VH的PCR引物。使用制造商标准方案进行PCR且扩增子经纯化或用克隆增强子处理,接着克隆至适当载体中。接着根据制造商说明书(Clonetech,U.S.A.)将大肠杆菌转形。对DNA mini-prep定序。
各表达载体含有链编码基因(编码信号序列及重链或轻链的基因)的真核启动子组件、原核选择标记基因(诸如氨苄西林(ampicillin))的表达卡匣及复制起点。使这些DNA质体在抗氨苄西林性大肠杆菌菌落中繁殖且纯化。
将表达载体转染至CHO-E细胞中。在摇瓶中在140rpm搅动下在37℃及5%CO2下培养在无血清培养基中悬浮生长的经转染的CHO-E细胞且保持在指数生长的条件下。在转染当天,细胞经1mg轻链质体及0.5mg重链质体化学转染。接着,以1至2×106个细胞/毫升将其接种于1L的FreeStyleTMCHO表达培养基(LifeTechnologies,NY,US)中。接着在轨道振荡下将细胞培育10至12天,其中一次馈送150ml市售进料溶液以允许表达蛋白质。根据制造商说明书,使用/>仪(Pall ForteBio,CA,US)及protA生物传感器尖端测定细胞培养上清液中的结合分子效价。
通过蛋白A亲和色谱,使用MabSelectTMSuReTM(Cytiva),随后尺寸排阻色谱(Superdex 200,Cytiva)或阳离子交换色谱(POROSTM50HS,ThermoFisher)中的一个自培养上清液纯化重组结合分子,且储存于60mM NaOAc缓冲液、100mM NaCl(pH 5.0)中,通过质谱分析及分析型尺寸排阻色谱来评价样品的纯度及不均匀度。所有样品在功能测试之前确认单体含量≥90%且含有<10%杂质。
此导致经由如下表3中所示且在下文中也称为多普单抗(DMab)的不同系列1至系列4产生双特异性、四价结合分子(亦参见Vekataramani等人,Biochemical andBiophysical Research Communications,第504卷,第1期,2018年9月26日,第19-24页)。
表3:
/>
/>
/>
简言之,进行以下设计活动:
系列1
在系列1中,产生具有在双特异性结合分子中作为TrkB结合部分的抗原结合片段(Fab)的结合分子。将VEGF结合部分为scFv(2),且评估不同VEGF结合剂,例如B20、G6或兰尼单抗。此外,测试不同VL-VH或VH-VL定向,且在结合分子的设计中使用若干接头,诸如20L3、20L1、15L1、10L1、6GS。
系列2
在系列2中,产生具有在双特异性结合分子中作为VEGF结合部分的抗原结合片段(Fab)的结合分子,且再次评估不同VEGF结合剂。此时,将TrkB结合部分格式化为scFv(2),且测试不同VL-VH或VH-VL定向。
系列3
在系列3中,基于兰尼单抗,产生在双特异性结合分子中作为抗原结合片段(Fab)及VEGF结合部分的结合分子。将TrkB结合部分再次格式化为scFv(2),且为基于C2TrkB结合剂。测试VL-VH或VH-VL定向及不同接头的排列。
系列4
在最终系列4中,将不同突变引入兰尼单抗结合部分中,诸如VHE1Q、VHE6Q和/或VLD70G,且分析CC桥在TrkB结合scFv部分中的稳定效果。
这些设计活动的结果及其对于特性及生物活性的影响现在以下实施例中更详细地描述。
实施例3:
C2、BDNF以及四种第一系列的多普单抗TPP-11735、736、737及738进行的人类TrkB活化的比较
图2A至图2B
将稳定表达人类TrkB的CHO细胞与增加浓度的天然TrkB配体BDNF、C2抗体、IgG1同型对照或四种多普单抗TPP-11735、TPP-11736、TPP-11737、TPP-11738一起培育。通过测量(A)Y706/707上的TrkB磷酸化或(B)TrkB下游的分别T202/Y204(ERK1)及T185/Y187(ERK2)上的ERK1/2磷酸化评价TrkB活化。最低化合物浓度为仅溶剂。
结果:
通过DMab进行的TrkB活化几乎与亲本C2分子一致。此外,DMab显示与亲本C2分子相同的特性,且在约~40%-50%的BDNF(pTrkB)下充当部分TrkB激动剂,具有TrkB活化的功效。尽管DMab确实并入亲本C2抗体的整个(Fab)2部分而不改变序列或定向/布局,这是极令人鼓舞的结果,因为其显示,格式化为此特异性格式并不会不利地影响TrkB结合剂活化TrkB及TrkB下游信号传递的能力。如所预期,同型对照并不会活化TrkB。
实施例4:
通过C2、BDNF及第一系列的多普单抗TPP-11735/736进行的食蟹猕猴/兔/大鼠/小鼠TrkB活化的比较
图3A至图3D
将稳定表达(A)食蟹猕猴TrkB、(B)兔TrkB、(C)大鼠TrkB或(D)小鼠TrkB的CHO细胞与增加浓度的天然TrkB配体BDNF、C2抗体、或多普单抗TPP-11735或TPP-11736一起培育。通过测量Y706/707上的TrkB磷酸化评价TrkB活化。最低化合物浓度为仅溶剂。数据表示平均值+/-SEM。
结果:
同样,通过DMab进行的TrkB活化几乎与亲本C2分子一致,且活化与人类TrkB受体的活化相当。此外,在此分析中,DMab显示与亲本C2分子相同的特性,且在约~40%-50%的BDNF(pTrkB)下充当部分TrkB激动剂,具有TrkB活化的功效。
实施例5:
TPP-11735/736/737/738介导的TrkB活化的选择性
图4A至图4C
将稳定表达(A)人类TrkA、(B)人类TrkB或(C)人类TrkC的CHO细胞与增加浓度的C2抗体或四种多普单抗TPP-11735、TPP-11736、TPP-11737、TPP-11738一起培育。通过测量Y706/707上的受体磷酸化评价Trk受体的活化。与增加浓度的TrkA(NGF)、TrkB(BDNF)及TrkC(NT-3)的天然配体一起培育用作对照。最低化合物浓度为仅溶剂。数据表示平均值+/-SEM。
结果:
所测试多普单抗中无一者活化TrkA或TrkC。所有多普单抗对于TrkB极具特异性/选择性。
实施例6:
C2、TPP-11736和/或BDNF诱导的人类TrkB受体的内化的比较
图5A至图5B
(A)将稳定表达人类TrkB的CHO细胞与增加浓度的天然TrkB配体BDNF、或1nM BDNF与增加浓度的C2抗体或多普单抗TPP-11736一起培育。(B)通过在不渗透细胞的情况下对表面TrkB受体进行免疫荧光染色,随后共焦显微分析来评价TrkB内化。热图的深色及浅色场分别表示高于荧光临限值的高及低百分比的细胞。
结果:
BDNF诱导TrkB受体内化(泳道1+2;热图场自上而下变得更暗)。
抗体C2及TPP-11736降低BDNF诱导的TrkB受体的内化(泳道3-5及6-8;应注意热图场由下至上变得更暗)。
实施例7:
在存在或不存在人类VEGF下通过C2及TPP-11736(第一系列)进行的人类TrkB活化的比较
图6
在未预培育或与200ng/mL人类VEGF-A(hVEGF)一起预培育的情况下,将稳定表达人类TrkB的CHO细胞与增加浓度的C2工具抗体或多普单抗TPP-11736一起培育。通过测量TrkB下游的T202/Y204(ERK1)及T185/Y187(ERK2)上的ERK1/2磷酸化评价TrkB活化。在无抗体的情况下与增加浓度的人类VEGF-A一起培育充当对照。最低化合物浓度为仅溶剂。数据表示平均值。为了清晰起见,省略误差杆。
结果:
与单独人类VEGF一起培育并不会改变ERK1/2磷酸化。
此外,与人类VEGF一起预培育既不会实质上改变C2或TPP-11736的效能亦不会实质上改变其进行ERK1/2磷酸化的功效。
实施例8:
STZ诱导的糖尿病大鼠中的DMab 11736及C2的神经保护功效
图7
使用IVT注射促效TrkB工具抗体(C2)以及多普单抗TPP-11736,糖尿病诱导的视网膜神经退化大鼠模型中的TrkB活化的神经保护功能。动物用STZ处理以诱导高血糖症。通过在治疗前后进行视网膜电描记术(ERG)评价视网膜功能。糖尿病诱导导致在STZ治疗后3周内延迟隐含时间。在此时间点,对动物玻璃体内给药同型对照抗体(抗TNP)或C2(各19μg/5μl)、或等摩尔量的TPP-11736(25μg/5μl)。在治疗两周之后,重复ERG记录且分析。在即将玻璃体内施用抗体之前及其两周后的视杆驱动的B波隐含时间延迟显示于图7中;平均值+/-SEM;n.s.p>0.05,不显著;**p<0.01;***p<0.001;单向Anova与Tukey多比较测试。
结果:
在施用两周之后,相较于在抗TNP治疗之前的时间点,抗TNP抗体治疗并不会降低糖尿病诱导的视杆驱动的b波隐含时间(在t=2周时,15.4ms;相对于在t=0时,13.3ms;p>0.05,不显著)。
在施用两周之后,相较于在抗体治疗之前的时间点,TPP-11736及C2处理的动物显示糖尿病诱导的视杆驱动的b波隐含时间延迟显著降低(C2:在t=2周时,8.62ms;相对于在t=0时,14.4ms;***p<0.01;TPP-11736:在t=2周时,10.3ms;相对于在t=0时,16.1ms;**p<0.01)。
与TrkB活化的体外分析中的早先测量一致,C2及TPP-11736显示类似的体内神经保护功效。
实施例9:
通过艾力雅及第一系列的四种多普单抗TPP-11735、736、737及738进行的人类VEGF-A清除的比较--VEGF诱导的VEGFR2磷酸化的抑制
图8A至图8B
使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的指示结合分子或艾力雅一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。
通过测量Y1175上的VEGF受体2(VEGFR2)磷酸化评价VEGF-A清除。(A)多普单抗TPP-11735、TPP-736、TPP-737及TPP-738的比较。(B)TPP-11736及TPP-11738与艾力雅的比较。未刺激细胞(基础)及无抗体处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。
结果:
TPP-11737与TPP-11738:这些分子均具有G6抗VEGF分子作为scFv。737呈VH-VL定向连接,而738具有VL-VH定向。结果表明,基于G6抗VEGF抗体,VL-VH定向好很多地起作用。
TPP-11735与TPP-11736:这些分子均具有B20抗VEGF分子作为scFv。对于此分析中的B20 VEGF抗体,两个定向之间不存在许多效能差异。
TPP-11736与TPP-11738:这些分子具有B20(VL-VH)或G6(VL-VH)抗VEGF分子作为scFv。两种结合分子显示类似效能(IC50~4nM),但TPP-11736更有效。
相较于TPP-11736或TPP-11738(~4nM),艾力雅(IC50=0.7nM)强效许多。
实施例10:
通过艾力雅及第一系列的四种多普单抗TPP-11735、736、737及738进行的人类VEGF-A清除的比较--VEGF诱导的ERK1/2磷酸化的抑制
图9A至图9B
使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的指示抗体或艾力雅一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。
VEGF-A清除为通过测量T202/Y204(ERK1)及T185/Y187(ERK2)上的ERK1/2磷酸化评价的TrkB活化评价。(A)多普单抗TPP-11735、TPP-736、TPP-737及TPP-738的比较。(B)TPP-11736、TPP-738与艾力雅的比较。未刺激细胞(基础)及无抗体处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。
结果:
TPP-11737与TPP-11738:这些分子均具有G6抗VEGF分子作为scFv。737呈VH-VL定向连接,而738具有VL-VH定向。结果表明,基于G6抗VEGF抗体,VL-VH定向好很多地起作用。
TPP-11735与TPP-11736:这些分子均具有B20抗VEGF分子作为scFv。对于此分析中的B20 VEGF抗体,两个定向之间不存在许多效能差异。
TPP-11736与TPP-11738:这些分子具有B20(VL-VH)或G6(VL-VH)抗VEGF分子作为scFv。两种结合分子显示类似效能(IC50~4nM),但TPP-11736更有效。
相较于TPP-11736或TPP-11738(~10nM),艾力雅(IC50=2nM)强效许多。
实施例11:
通过艾力雅及第一系列的多普单抗TPP-11736进行的人类VEGF-A清除的比较--VEGF诱导的p38 MAPK磷酸化的抑制
图10
使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的TPP-11736或艾力雅一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。通过测量T180/Y182上的p38 MAPK磷酸化评价VEGF-A清除。未刺激细胞(基础)及无抗体处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。
结果:
艾力雅(IC50=~0.74nM)比TPP-11736(~7.4nM)更强效约10倍。
实施例12:
通过第一系列的四种多普单抗TPP-11735、736、737及738以及艾力雅进行的人类VEGF-A清除的比较--VEGF诱导的HRMEC增殖的抑制
图11A至图11E
使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的指示结合分子或艾力雅一起预培育或未预培育的情况下,与10ng/mL人类VEGF一起培育。分子浓度以mol/L为单位给出。通过自动化基于影像的HRMEC细胞数目定量(IncuCyte)评价VEGF-A清除。每四个小时记录影像,持续总共96小时的时段。显示相对细胞数目。将在t=0时的细胞数目设定为一。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。
结果:
TPP-11737与TPP-11738:这些分子均具有G6抗VEGF分子作为scFv。TPP-11737呈VH-VL定向连接,而TPP-11738具有VL-VH定向。显然,在G6的情况下,VL-VH定向好很多地起作用。TPP-11737几乎无效果。
TPP-11735(VH-VL)与TPP-11736(VL-VH):这些分子均具有B20抗VEGF分子作为scFv。同样,VL-VH定向表达得更好。
736与738:B20(VL-VH)与G6(VL-VH):在此分析中,TPP-11736(B20)明显更有效。
最后,艾力雅比TPP-11736更有效。
系列1:TPP-11735、TPP-11736、TPP-11737、TPP-11738的发现的概述
TrkB活化:
通过DMab进行的TrkB活化几乎与亲本C2分子一致。此并非出人意料的,因为C2TrkB结合剂的整个(Fab)2部分并入DMab中而不改变序列或定向/布局。此外,所有多普单抗(及C2)仅为部分TrkB激动剂。
VEGF清除:
明显地,对于G6及B20作为VEGF结合剂,VL-VH定向更优选地起作用,且B20(VL-VH)比G6(VL-VH)更有效。此外,两种多普单抗(B20及G6)体外均不如艾力雅。
基于这些初始发现,本发明人打算在以下实施例中产生及测试呈VL-VH定向的B20的不同接头,以改良多普单抗(TPP-16061至TPP-16064)的VEGF清除。
实施例13:
通过C2、BDNF及第一系列的四种多普单抗TPP-16061、16062、16063及16064进行的人类TrkB活化的比较;TrkB磷酸化
图12
将稳定表达人类TrkB的CHO细胞与增加浓度的天然TrkB配体BDNF、C2抗体、TPP-11736(B20,scFv,20L3,VL-VH)或以下具有不同接头的四种多普单抗一起培育:TPP-16061(B20,scFv,20L1,VL-VH)、TPP-16062(B20,scFv,15L1,VL-VH)、TPP-16063(B20,scFv,10L1,VL-VH)、TPP-16064(B20,scFv,6GS,VL-VH)。通过测量Y706/707上的TrkB磷酸化评价TrkB活化。最低化合物浓度为仅溶剂。数据表示平均值。为了清晰起见,省略误差杆。
结果:
通过DMab TPP-16061至16064进行的TrkB活化几乎与亲本C2分子及TPP-11736一致。TrkB活化似乎很大程度上与蛋白质的Fc与scFv(抗VEGF)部分之间的接头变体无关。尽管这是预期的—因为接头位于蛋白质的Fc与scFv(抗VEGF)部分之间的TrkB(Fab)2片段远程—但此仍为可在不影响结合分子的活性的情况下采用不同接头的良好确认。最后,所有显示的结合分子仅显示部分TrkB促效活性。
实施例14:
通过BDNF、TPP-11736及第一系列的两种多普单抗TPP-16061及16062进行的人类TrkB活化的比较;ERK1/2磷酸化
图13
将稳定表达人类TrkB的CHO细胞与增加浓度的天然TrkB配体BDNF、TPP-11736(B20,scFv,20L3,VL-VH)或具有不同接头的两种多普单抗TPP-16061(B20,scFv,20L1,VL-VH)及TPP-16062(B20,scFv,15L1,VL-VH)一起培育。通过测量T202/Y204(ERK1)及T185/Y187(ERK2)上的ERK1/2磷酸化评价TrkB活化。最低化合物浓度为仅溶剂。数据表示平均值+/-SEM。
结果:
通过DMab TPP-16061及16062进行的TrkB活化几乎与TPP-11736一致。本文中亦显示,TrkB活化很大程度上与接头变体无关,且所显示的结合分子仅显示部分TrkB促效活性。
实施例15:
通过第一系列的四种多普单抗TPP-16061、062、063及064与TPP-11736进行的人类VEGF-A清除的比较--(A)VEGF诱导的VEGFR2磷酸化的抑制,(B)ERK1/2磷酸化
图14A至图14B
使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的以下指示抗体一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育:TPP-11736(B20,scFv,20L3,VL-VH);或以下具有不同接头的四种多普单抗:TPP-16061(B20,scFv,20L1,VL-VH)、TPP-16062(B20,scFv,15L1,VL-VH)、TPP-16063(B20,scFv,10L1,VL-VH)、TPP-16064(B20,scFv,6GS,VL-VH)。通过分别测量(A)Y1175上的VEGF受体2(VEGFR2)磷酸化或(B)T202/Y204(ERK1)及T185/Y187(ERK2)上的ERK1/2磷酸化评价VEGF-A清除。未刺激细胞(基础)及无抗体处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。
结果:
接头的变化对于VEGF清除的效能或功效几乎无影响。这是略微出人意料的—鉴于接头位于VEGF结合位点附近—但进一步确认,可在不影响结合分子的活性的情况下采用不同接头。
实施例16:
通过第一系列的四种多普单抗TPP-16061、062、063及064进行的人类VEGF-A清除的比较--VEGF诱导的HRMEC增殖的抑制
图15
使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与0.5nM多普单抗或1nM艾力雅一起预培育或未预培育的情况下,与10ng/mL人类VEGF一起培育。通过自动化基于影像的HRMEC细胞数目定量(IncuCyte)评价VEGF-A清除。每四个小时记录影像,持续总共96小时的时段。显示相对细胞数目。将在t=0时的细胞数目设定为一。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。
结果:
类似于实施例15中显示的磷酸化分析,相较于亲本分子TPP-11736,接头变体并不会表达得更好(或更差)。艾力雅以1nM使用,因为推测艾力雅为单价分子,而多普单抗为二价。在这些条件下,艾力雅在VEGF诱导的HRMEC的增殖的抑制中表达得更好。
实施例17:
通过艾力雅、TPP-11736及第一系列的四种多普单抗TPP-16061、062、063及064进行的人类VEGF-A清除的比较--VEGF诱导的HRMEC出芽的抑制
图16
人类视网膜微血管内皮细胞(HRMEC)的球体包埋于胶原蛋白基质中。通过在与2.5nM的指示多普单抗或5nM艾力雅一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育24小时,来诱导内皮出芽24小时。内皮出芽通过共焦显微术评价且显示获自Z-堆栈的最大投影的球体周界。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。相对于50ng/mL hVEGF+2.5nM TPP-11736,n.s.p>0.05不显著。
结果:
类似于实施例15中显示的磷酸化分析,相较于亲本分子TPP-11736,接头变体并不会表达得更好(或更差)。艾力雅以1nM使用,因为推测艾力雅为单价分子,而多普单抗为二价。在这些条件下,艾力雅在VEGF诱导的HRMEC的增殖的抑制中表达得更好。
系列1:TPP-16061、TPP-16062、TPP-16063、TPP-16064的发现的概述
TrkB活化:相较于亲本分子TPP-11736,未观测到差异/改善。
VEGF清除:相较于亲本分子TPP-11736,无差异/改善。
基于这些发现,本发明人打算比较TPP-11736(B20作为scFv)与TPP-13788(B20IgG)的VEGF清除,以测试再格式化作为Fab的B20是否将改善VEGF清除。
实施例18:
通过TPP-11736及TPP-13788(B20 IgG)进行的人类VEGF-A清除的比较--VEGF诱导的VEGFR2、ERK1/2及p38 MAPK的磷酸化的抑制
图17A至图17C
使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在未预培育或与增加浓度的多普单抗TPP-11736(B20抗VEGF作为scFv)或TPP-13788(B20 IgG)一起预培育的情况下,与50ng/mL人类VEGF一起培育。通过测量(A)Y1175上的VEGF受体2(VEGFR2)磷酸化、(B)T202/Y204(ERK1)及T185/Y187(ERK2)上的ERK1/2磷酸化或(C)T180/Y182上的p38 MAPK磷酸化评价VEGF-A清除。无分子处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。下表4报导对应最佳拟合IC50值(非线性回归;log(激动剂)相对于反应(三个参数))。
表4:
TPP-11736 TPP-13788
IC50(VEGFR2磷酸化) 2.6nM 1.0nM
IC50(ERK1/2磷酸化) 9.1nM 3.0nM
IC50(p38MAPK磷酸化) 7.7nM 2.4nM
结果:
相对于TPP-11736,所测试的B20 IgG TPP-13788显示VEGF-A清除效能增加大致3倍
实施例19:
通过TPP-11736及TPP-13788(B20 IgG)进行的人类VEGF-A清除的比较--VEGF诱导的HRMEC出芽的抑制
图18
人类视网膜微血管内皮细胞(HRMEC)的球体包埋于胶原蛋白基质中。通过在未预培育或与2.5nM的多普单抗TPP-11736或2.5nM TPP-13788(B20 IgG)一起预培育的情况下,与50ng/mL人类VEGF一起培育,来诱导内皮出芽24小时。内皮出芽通过共焦显微术评价且显示获自Z-堆栈的最大投影的球体周界。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。相对于50ng/mL hVEGF+2.5nM TPP-11736,n.s.p>0.05不显著。
结果:
尽管在VEGFR2、ERK1/2及p38 MAPK磷酸化分析中VEGF清除改善,但TPP-13788(B20IgG)介导的VEGF诱导的出芽的抑制不比TPP-11736的抑制好。
实施例20:
通过BDNF、TPP-11736及第一系列的两种多普单抗TPP-14936及TPP-14937进行的人类TrkB活化的比较;TrkB及ERK1/2磷酸化
图19A至图19C
将稳定表达人类TrkB的CHO细胞与增加浓度的天然TrkB配体BDNF、TPP-11736(B20,scFv,20L3,VL-VH)或两种多普单抗TPP-13936(兰尼单抗,scFv,20L3,VH-VL)或TPP-14937(兰尼单抗,scFv,20L3,VL-VH)一起培育。通过测量(A)Y706/707上的TrkB磷酸化、(B及C)分别T202/Y204(ERK1)及T185/Y187(ERK2)上的ERK1/2磷酸化评价TrkB活化。最低化合物浓度为仅溶剂。数据表示平均值+/-SEM。
结果:
通过DMab TPP-14936及TPP-14937进行的TrkB活化几乎与TPP-11736一致。这是预期的,因为结合分子的TrkB结合组分始终为作为Fab片段的C2。
实施例21:
通过BDNF、TPP-11736及多普单抗TPP-14936进行的食蟹猕猴及大鼠TrkB活化的比较;TrkB磷酸化
图20A至图20B
将稳定表达(A)食蟹猕猴TrkB或(B)大鼠TrkB的CHO细胞与增加浓度的天然TrkB配体BDNF、TPP-11736(B20,scFv,20L3,VL-VH)或TPP-14936(兰尼单抗,scFv,20L3,VH-VL)一起培育。通过测量Y706/707上的TrkB磷酸化评价TrkB活化。最低化合物浓度为仅溶剂。数据表示平均值+/-SEM。
结果:
通过DMab TPP-14936进行的TrkB活化几乎与TPP-11736一致。同样,这是预期的,因为两种分子的TrkB结合组分在两种情况下均为作为Fab片段的C2。
实施例22:
通过TPP-11736、TPP-14936或TPP-14937进行的人类VEGF-A清除的比较--VEGF诱导的VEGFR2、ERK1/2及Src的磷酸化的抑制
图21A至图21C
使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的多普单抗TPP-11736(B20,scFv,20L3,VL-VH)、TPP-14936(兰尼单抗,scFv,20L3,VH-VL)或TPP-14937(兰尼单抗,scFv,20L3,VL-VH)一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。通过测量(A)Y1175上的VEGF受体2(VEGFR2)磷酸化、(B)T202/Y204及T185/Y187上的ERK1/2磷酸化或(C)Y419上的Src磷酸化评价VEGF-A清除。无抗体处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。下表5分别报导对应最佳拟合IC50值及绝对功效值(底部平线区)(非线性回归;log(激动剂)相对于反应(三个参数))。
表5:
结果:
TPP-11736与TPP-14936/TPP-14937之间的VEGF清除的效能(IC50)类似。
通过TPP-14936进行的VEGF清除的效能(IC50)比TPP-14937略微更优选→兰尼单抗scFv的VH-VL比VL-VH定向更优选。
通过TPP-14936及TPP-14937进行的VEGF清除比TPP-11736更有效(底部值较小)。
实施例23:
通过TPP-11736及多普单抗TPP-14936及TPP-14937进行的人类VEGF-A清除的比较--VEGF诱导的HRMEC出芽的抑制
图22
人类视网膜微血管内皮细胞(HRMEC)的球体包埋于胶原蛋白基质中。通过在与2.5nM的多普单抗TPP-11736(B20,scFv,20L3,VL-VH)、TPP-14936(兰尼单抗,scFv,20L3,VH-VL)或TPP-14937(兰尼单抗,scFv,20L3,VL-VH)一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育来诱导内皮出芽24小时。内皮出芽通过共焦显微术评价且显示获自Z-堆栈的最大投影的球体周界。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。n.s.p>0.05,不显著,****p<0.0001。
结果:
尽管通过TPP-14936及TPP-14937进行的VEGF清除在VEGFR2/ERK1_2/Src磷酸化分析中类似,但在VEGF诱导的出芽的抑制中存在显著差异。然而,TPP-11736与TPP-14937之间无显著差异,通过TPP-14936进行的VEGF诱导的HRMEC出芽的抑制比TPP-14937或TPP-11736更有效许多。
此出人意料的发现指示,抗VEGF scFv的VH-VL定向对于此分析中的效能至关重要:VH-VL比VL-VH好许多。有趣的是,在TPP-11735与736(B20)的情况下,VL-VH定向比VH-VL更优选,且在TPP-11737与738(G6)的情况下亦如此。
实施例24:
通过多普单抗TPP-11736、TPP-14936及TPP-14937、以及艾力雅进行的人类VEGF-A清除的比较--VEGF诱导的HRMEC增殖的抑制
图23A至图23D
使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的指示结合分子或艾力雅一起预培育或未预培育的情况下,与10ng/mL人类VEGF一起培育。结合分子/艾力雅浓度以mol/L为单位给出。通过自动化基于影像的HRMEC细胞数目定量(IncuCyte)评价VEGF-A清除。每四个小时记录影像,持续总共84小时的时段。显示相对细胞数目。将在t=0时的细胞数目设定为一。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。
结果:
相较于TPP-11736,TPP-14936及TPP-14937显示VEGF诱导的HRMEC增殖的抑制的效能及尤其功效更优选。TPP-14936比TPP-14937更强效。
极其出人意料地,TPP-14936及TPP-14937比艾力雅更有效。两种多普单抗均降低增殖,甚至低于基线。与艾力雅相比,其显示完全抑制VEGF诱导的增殖。然而,艾力雅仍比TPP-14936及14937更强效。
系列1:TPP-14936/14937的发现的概述
TrkB活化:相较于TPP-11736,未观测到差异/改善。因为两种结合分子均具有C2结合剂作为Fab片段,因此此在预期的中。
VEGF清除:
磷酸化分析:在TPP-11736与TPP-14936/TPP-14937之间,VEGF清除的效能(IC50)类似。通过TPP-14936及TPP-14937进行的VEGF清除比TPP-11736(底部值)更有效。
出芽分析:TPP-11736与TPP-14937之间无显著差异。TPP-14936对VEGF诱导的HRMEC出芽的抑制比TPP-14937或TPP-11736更有效许多。出乎意料地,抗VEGF兰尼单抗的VH-VL定向比VL-VH好许多。
增殖分析:相较于TPP-11736,TPP-14936及TPP-14937显示VEGF诱导的HRMEC增殖的抑制的效能及尤其功效更优选。TPP-14936比TPP-14937更强效,且TPP-14936及TPP-14937均比艾力雅更有效。
基于这些发现,本发明人打算更好地了解多普单抗的逆向布局,且尝试兰尼单抗/B20作为Fab以改善VEGF清除的效能(功效)及C2 TrkB结合剂作为scFv。现在以下实施例中产生且测试以下结合分子(系列2):TPP-14938(B20 Fab)、TPP-14939(B20 Fab)、TPP-14940(兰尼单抗Fab)、TPP-14941(兰尼单抗Fab)。
实施例25:
通过BDNF、TPP-11736及四种第二系列的多普单抗TPP-14938、TPP-14939、TPP-14940及TPP-14941进行的人类TrkB活化的比较;TrkB及ERK1/2磷酸化
图24A至图24B及图25
将稳定表达人类TrkB的CHO细胞与增加浓度的天然TrkB配体BDNF、TPP-11736(C2作为Fab)或四种第二系列的多普单抗TPP-14938(C2作为scFv,20L3,VH-VL)、TPP-14939(C2作为scFv,20L3,VL-VH)、TPP-14940(C2作为scFv,20L3,VH-VL)及TPP-14941(C2作为scFv,20L3,VL-VH)一起培育。通过(A)测量Y706/707上的TrkB磷酸化或通过(B)分别测量T202/Y204(ERK1)及T185/Y187(ERK2)上的ERK1/2磷酸化评价TrkB活化。最低化合物浓度为仅溶剂。数据表示平均值+/-SEM。
结果:
TPP-11736含有C2 CDR作为Fab。四种多普单抗TPP-14938、TPP-14939、TPP-14940及TPP-14941含有C2作为scFv。
与TPP-11736或初始C2抗体(两者均为部分TrkB受体激动剂)形成强烈对比,所有四种新多普单抗现在均显示完全TrkB受体激动剂活性。通过那些多普单抗进行的TrkB活化现与天然配体BDNF一样有效。此完全为出人意料的,因为初始C2抗体仅显示部分TrkB受体激动剂。不希望受理论所束缚,似乎VEGF诱导的与单一结合分子聚类以及结合分子的空间形成可为造成所观测到的TrkB活化的功效及效能增加的原因(亦参见图25)。
相较于TPP-14939及TPP-14941,利用多普单抗TPP-14938及TPP-14940进行的TrkB活化的效能亦略微更优选。因此C2 scFv的“VH-VL”定向显示更优选的TrkB活化效能。
实施例26:
通过BDNF、TPP-11736及四种第二系列的多普单抗TPP-14938、TPP-14939、TPP-14940及TPP-14941进行的食蟹猕猴/大鼠TrkB活化的比较;TrkB及ERK1/2磷酸化
图26A至图26B
将稳定表达(A)食蟹猕猴TrkB或(B)大鼠TrkB的CHO细胞与增加浓度的天然TrkB配体BDNF、TPP-11736(C2作为Fab)或两种第二系列的多普单抗TPP-14940(C2作为scFv,20L3,VH-VL)及TPP-14941(C2作为scFv,20L3,VL-VH)一起培育。通过测量Y706/707上的TrkB磷酸化评价TrkB活化。最低化合物浓度为仅溶剂。数据表示平均值+/-SEM。
结果:
实施例25利用人类TrkB的结果可在食蟹猕猴及大鼠模型中再现。同样在此处,与TPP-11736形成强烈对比,新多普单抗为完全TrkB受体激动剂。通过那些多普单抗进行的TrkB活化与天然配体BDNF一样有效。
同样,相较于TPP-14941,利用多普单抗TPP-14940的TrkB活化的效能略微更优选。因此C2 scFv的VH-VL定向显示更优选的TrkB活化效能。
实施例27:
在存在或不存在人类VEGF下,通过C2、TPP-14940及TPP-14941(第二系列)进行的人类TrkB活化(TrkB磷酸化)的比较--协同效应
图27A至图27C
在与200ng/mL人类VEGF-A(hVEGF)一起预培育或未预培育的情况下,将稳定表达人类TrkB的CHO细胞与增加浓度的多普单抗(A)TPP-14940、(B)TPP-14941或(C)C2一起培育。通过测量Y706/707上的TrkB磷酸化评价TrkB活化。最低化合物浓度为仅溶剂。数据表示平均值+/-SEM。
结果:
出人意料地,与人类VEGF一起预培育显著改善通过TPP-14941(C2作为scFv,20L3,VL-VH)进行的TrkB磷酸化(TrkB活化)的效能。
相较于TPP-14940,对于TPP-14941而言,VEGF对于TrkB磷酸化(TrkB活化)的效能的影响更大。因此,尽管两种分子对于TrkB磷酸化的效能均显示协同效应,但似乎多普单抗(scFv VL-VH与scFv VH-VL与Fab)的TrkB活化部分的定向/几何结构似乎对于协同效应具有影响,其中具有VL-VH定向的scFv为优选的。
VEGF预培育并不会影响通过C2(对照)进行的TrkB磷酸化(TrkB活化)的效能。
实施例28:
在存在或不存在人类VEGF下,通过C2、TPP-14940及TPP-14941(第二系列)进行的人类TrkB活化(ERK1/2磷酸化)的比较--协同效应
图28A至图28C
在与200ng/mL人类VEGF-A(hVEGF)一起预培育或未预培育的情况下,将稳定表达人类TrkB的CHO细胞与增加浓度的多普单抗(A)TPP-14940、(B)TPP-14941或(C)C2一起培育。通过测量TrkB下游的T202/Y204(ERK1)及T185/Y187(ERK2)上的ERK1/2磷酸化评价TrkB活化。最低化合物浓度为仅溶剂。数据表示平均值+/-SEM。
结果:
此处亦出人意料地,与人类VEGF一起预培育显著改善通过TPP-14941(C2作为scFv,20L3,VL-VH)进行的ERK1/2磷酸化(TrkB活化)的效能。
同样在此处,相较于TPP-14940,对于TPP-14941而言,VEGF对于ERK1/2磷酸化(TrkB活化)的效能的影响更大。同样,两种分子对于TrkB磷酸化的效能均显示协同效应,但似乎多普单抗(scFv VL-VH与scFv VH-VL与Fab)的TrkB活化部分的定向/几何结构似乎对于协同效应具有影响,其中具有VL-VH定向的scFv为优选的。
如先前所示,VEGF预培育亦确实不会影响通过TPP-11736(系列1,C2作为Fab)进行的ERK1/2磷酸化(TrkB活化)的效能。最后,VEGF预培育并不会影响通过C2(对照)进行的ERK1/2磷酸化(TrkB活化)的效能。
实施例29:
通过单独VEGF及与BDNF组合进行的人类TrkB活化(TrkB/ERK磷酸化)的比较--协同效应的对照实验
图29A至图29B
在具有或不具有200ng/mL固定浓度的hVEGF的情况下,将稳定表达人类TrkB的CHO细胞与增加浓度的单独人类VEGF-A(hVEGF)或增加浓度的BDNF一起培育。通过测量(A)Y706/707上的TrkB磷酸化或(B)TrkB下游的分别T202/Y204(ERK1)及T185/Y187(ERK2)上的ERK1/2磷酸化评价TrkB活化。最低化合物浓度为仅溶剂。数据表示平均值+/-SEM。
结果:
单独hVEGF并不会诱导TrkB或ERK1/2磷酸化。
BDNF剂量-反应曲线很大程度上与hVEGF无关。
实施例30:
在存在或不存在人类VEGF下,通过C2、TPP-14940及TPP-14941(第二系列)进行的食蟹猕猴TrkB活化(TrkB磷酸化)的比较--协同效应
图30A至图30C
在与200ng/mL人类VEGF-A(hVEGF)一起预培育或未预培育的情况下,将稳定表达食蟹猕猴TrkB的CHO细胞与增加浓度的多普单抗(A)TPP-14940、(B)TPP-14941或(C)C2一起培育。通过测量Y706/707上的TrkB磷酸化评价TrkB活化。最低化合物浓度为仅溶剂。数据表示平均值+/-SEM。
结果:
同样在此模型中,与人类VEGF一起预培育显著改善通过TPP-14941(C2作为scFv,20L3,VL-VH)进行的TrkB磷酸化(TrkB活化)的效能。VEGF对于通过TPP-14940(C2作为scFv,20L3,HL)进行的TrkB磷酸化(TrkB活化)的效能的影响较小。
实施例31:
在存在或不存在人类VEGF下,通过C2、TPP-14940及TPP-14941(第二系列)进行的食蟹猕猴TrkB活化(ERK1/2磷酸化)的比较--协同效应
图31A至图31C
在与200ng/mL人类VEGF-A(hVEGF)一起预培育或未预培育的情况下,将稳定表达食蟹猕猴TrkB的CHO细胞与增加浓度的多普单抗(A)TPP-14940、(B)TPP-14941或(C)C2一起培育。通过测量TrkB下游的T202/Y204(ERK1)及T185/Y187(ERK2)上的ERK1/2磷酸化评价TrkB活化。最低化合物浓度为仅溶剂。数据表示平均值+/-SEM。
结果:
同样在此模型中,与人类VEGF一起预培育显著改善通过TPP-14941(C2作为scFv,20L3,VL-VH)进行的ERK1/2磷酸化(TrkB活化)的效能。VEGF对于通过TPP-14940(C2作为scFv,20L3,HL)进行的ERK1/2磷酸化(TrkB活化)的效能的影响较小。
实施例32:
通过TPP-11736(B20作为scFv)、TPP-14938(B20作为Fab)或TPP-14939(B20作为Fab)进行的人类VEGF-A清除的比较--VEGF诱导的VEGFR2、ERK1/2及Src的磷酸化的抑制
图32A至图32C
使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的多普单抗TPP-11736(B20作为scFv)、TPP-14938(B20作为Fab)或TPP-14939(B20作为Fab)一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。通过测量(A)Y1175上的VEGF受体2(VEGFR2)磷酸化、(B)T202/Y204(ERK1)及T185/Y187(ERK2)上的ERK1/2磷酸化或(C)Y419上的Src磷酸化评价VEGF-A清除。无抗体处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。下表6分别报导对应最佳拟合IC50值及绝对功效值(底部平线区)(非线性回归;log(激动剂)相对于反应(三个参数))。
表6:
结果:
通过TPP-14938/39进行的VEGF清除的效能(IC50)比TPP-11736略微更好。
通过TPP-14938及TPP-14939进行的VEGF清除比TPP-11736更有效(底部值较小)。
总之B20 scFv与B20 Fab之间的差异相当小且充分对应于图17/18中显示的先前结果:TPP-11736与TPP-13788(B20 IgG)。总之B20明显相对优选地耐受自Fab重新格式化为scFv。
实施例33:
通过TPP-11736(B20 scFv)、TPP-14938(B20 Fab)或TPP-14939(B20 Fab)进行的人类VEGF-A清除的比较--VEGF诱导的HRMEC增殖的抑制
图33A至图33C
使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的指示结合分子一起预培育或未预培育的情况下,与10ng/mL人类VEGF一起培育。分子浓度以mol/L为单位给出。通过自动化基于影像的HRMEC细胞数目定量(IncuCyte)评价VEGF-A清除。每四个小时记录影像,持续总共84小时的时段。显示相对细胞数目。将在t=0时的细胞数目设定为一。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。
结果:
在增殖分析中,将B20 scFv(TPP-11736)重新格式化为B20 Fab(TPP-14938及TPP-14939)既不会改善VEGF-A清除的效能亦不会改善其功效。实际上,基于B20 Fab的抗体似乎略微比TPP-11736不太强效/有效。
实施例34:
通过TPP-14936(兰尼单抗,scFv,HL)或TPP-14937(兰尼单抗,scFv,LH)与TPP-14940及TPP-14941(兰尼单抗Fab)进行的人类VEGF-A清除的比较--VEGF诱导的VEGFR2、ERK1/2及Src的磷酸化的抑制
图34A至图34C
使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的多普单抗TPP-11736(B20作为scFv)、TPP-14936(兰尼单抗作为scFv,VH-VL)、TPP-14937(兰尼单抗作为scFv,VL-VH)、TPP-14940(兰尼单抗作为Fab)或TPP-14941(兰尼单抗作为Fab)一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。通过测量(A)Y1175上的VEGF受体2(VEGFR2)磷酸化、(B)T202/Y204(ERK1)及T185/Y187(ERK2)上的ERK1/2磷酸化或(C)Y419上的Src磷酸化评价VEGF-A清除。无抗体处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。下表7分别报导对应最佳拟合IC50值及绝对功效值(底部平线区)(非线性回归;log(激动剂)相对于反应(三个参数))。
表7.
结果:
在全部三个分析中,将兰尼单抗自scFv重新格式化为Fab显著改善VEGF清除的效能(IC50比兰尼单抗scFv或参考分子TPP-11736好10倍)。
通过基于兰尼单抗的分子进行的VEGF清除的功效比TPP-11736好许多(底部值)。
然而,兰尼单抗并不极好地耐受自Fab重新格式化为scFv(与B20相反,参见先前实施例)。
实施例35:
通过TPP-14936(兰尼单抗作为scFv,VH-VL)或TPP-14937(兰尼单抗作为scFv,VL-VH)与TPP-14940及TPP-14941(兰尼单抗Fab)进行的人类VEGF-A清除的比较--VEGF诱导的HRMEC增殖的抑制
图35A至图35D
使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的指示结合分子一起预培育或未预培育的情况下,与10ng/mL人类VEGF一起培育。分子浓度以mol/L为单位给出。通过自动化基于影像的HRMEC细胞数目定量(IncuCyte)评价VEGF-A清除。每四个小时记录影像,持续总共84小时的时段。显示相对细胞数目。将在t=0时的细胞数目设定为一。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。
结果:
在增殖分析中,将兰尼单抗作为scFv(TPP-11736/TPP-14937)重新格式化为兰尼单抗Fab(TPP-14940及TPP-14941)显著改善VEGF-A清除的效能。
在TPP-14940及TPP-14941的情况下,已在0.25nM的浓度下发现完全VEGF抑制,而完全抑制分别需要1nM TPP-14936及4nM TPP-14937。
在所有四种分子中,VEGF-A抑制的功效类似(全部为完全抑制剂)。
实施例36:
通过TPP-14938或TPP-14939(B20 Fab)与TPP-14940及TPP-14941(兰尼单抗Fab)进行的人类VEGF-A清除的比较--VEGF诱导的VEGFR2、ERK1/2及Src的磷酸化的抑制
图36A至图36C
使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的多普单抗TPP-11736(B20作为scFv)、TPP-13938(B20作为Fab)或TPP-13939(B20作为Fab)、TPP-14940(兰尼单抗作为Fab)或TPP-14941(兰尼单抗作为Fab)一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。通过测量(A)Y1175上的VEGF受体2(VEGFR2)磷酸化、(B)T202/Y204(ERK1)及T185/Y187(ERK2)上的ERK1/2磷酸化或(C)Y419上的Src磷酸化评价VEGF-A清除。无分子处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。下表8分别报导对应最佳拟合IC50值及绝对功效值(底部平线区)(非线性回归;log(激动剂)相对于反应(三个参数))。
表8:
/>
结果:
在所有三个分析中,具有兰尼单抗Fab的多普单抗显示VEGF清除的效能明显比基于B20 Fab的多普单抗更优选。
在所有三个分析中,具有兰尼单抗Fab的多普单抗显示VEGF清除的功效明显比基于B20 Fab的多普单抗更优选(底部值)。
实施例37:
通过TPP-14938或TPP-14939(B20作为Fab)与TPP-14940及TPP-14941(兰尼单抗作为Fab)进行的人类VEGF-A清除的比较--VEGF诱导的HRMEC增殖的抑制
图37A至图37D
使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的指示结合分子一起预培育或未预培育的情况下,与10ng/mL人类VEGF一起培育。分子浓度以mol/L为单位给出。通过自动化基于影像的HRMEC细胞数目定量(IncuCyte)评价VEGF-A清除。每四个小时记录影像,持续总共84小时的时段。显示相对细胞数目。将在t=0时的细胞数目设定为一。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。
结果:
相较于基于B20 Fab的分子TPP-14938及TPP-14939,通过基于兰尼单抗Fab的分子TPP-14940及TPP-14941抑制VEGF诱导的增殖的效能及功效明显更优。
即使在最高浓度(16nM)下,TPP-14938及TPP-14939未能充分抑制VEGF诱导的出芽。
相比之下,TPP-14940及TPP-14941已在低64倍的0.25nM浓度下充分抑制VEGF诱导的增殖。
实施例38:
通过多普单抗TPP-11736(B20作为scFv)、TPP-14936(兰尼单抗作为scFv,VH-VL)、TPP-14937(兰尼单抗作为scFv,VL-VH)、TPP-14938(B20作为Fab)或TPP-14939(B20 Fab)、TPP-14940(兰尼单抗作为Fab)、TPP-14941(兰尼单抗作为Fab)或艾力雅进行的人类VEGF-A清除的比较--VEGF诱导的HRMEC出芽的抑制
图38
人类视网膜微血管内皮细胞(HRMEC)的球体包埋于胶原蛋白基质中。通过在与2.5nM的多普单抗TPP-11736(B20 scFv)、TPP-14936(兰尼单抗scFv,VH-VL)、TPP-14937(兰尼单抗scFv,VL-VH)、TPP-14938(B20 Fab)、TPP-14939(B20 Fab)、TPP-14940(兰尼单抗Fab)、TPP-14941(兰尼单抗Fab)或5nM艾力雅一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育来诱导内皮出芽24小时。内皮出芽通过共焦显微术评价且显示获自Z-堆栈的最大投影的球体周界。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。n.s.p>0.05无显著差异;相较于50ng/mL hVEGF,§p<0.0001;相较于50ng/mL hVEGF,#p>0.05无显著差异。***p<0.001;单向Anova与Tukey多比较测试。
结果:
在此分析中,基于兰尼单抗Fab的多普单抗TPP-14940及TPP-14941明显为最佳VEGF清除剂。与艾力雅相比,TPP-14940及TPP-14941充分抑制VEGF诱导的出芽;在不存在VEGF(基础)下的内皮出芽与50ng/mL hVEGF(与2.5nM TPP-14940或TPP-14941一起预培育)的内皮出芽之间未发现统计学上显著差异。
通过TPP-14940及TPP-14941抑制VEGF诱导的EC出芽显著比通过任何其他多普单抗抑制更好。
通过TPP-14940及TPP-14941抑制VEGF诱导的EC出芽显著比通过艾力雅抑制更好。
此外,在用50ng/mL hVEGF与50ng/mL hVEGF(与艾力雅一起预培育)刺激的内皮出芽之间不存在统计学上显著差异。
实施例39:
通过多普单抗TPP-11940及艾力雅进行的人类VEGF-A清除的比较--在BrownNorway大鼠中,人类VEGF-A诱导的视网膜高渗透性的抑制
图39A至图39B
TPP-14940(但并非艾力雅)防止大鼠视网膜中的人类VEGF-A诱导的高渗透性。(A)显示实验程序的时间方案。在玻璃体内(ivt)施用抗VEGF化合物(每只眼睛13或26pmol的艾力雅或TPP-14940)或对照(26pmol TPP-11737)之后十五分钟,通过ivt注射每只眼睛施用13pmol人类VEGF-A。PBS注射充当对照。二十四小时后,在分离及固定眼睛之前通过静脉内(iv)注射施用1mL/kg伊凡氏蓝(Evans Blue;EB)溶液(45mg/mL于0.9%盐水中)30分钟。在相同时间点收集血浆样品以确认相等全身性EB暴露。(B)通过利用共焦显微术测量视网膜铺片中的EB外渗来定量Brown Norway大鼠的视网膜中的VEGF-A诱导的高渗透性。沿着锯齿缘切割眼睛,移除晶状体及玻璃体,且将眼杯固定在4℃下的多聚甲醛(4%)中1h且接着转移至在4℃的PBS隔夜。将视网膜与外部区段(巩膜及脉络膜)分开,且转移至载玻片并切割四次以达成平坦三叶草样结构。组织用封固剂(含有DNA染料DAPI的Vectashield H-1200)覆盖且将盖玻片置于顶部上以获得视网膜铺片。样品在639nm波长下激发,且用LSM 700共焦激光扫描显微镜(Carl Zeiss,Jena;放大率800,激光强度2%,60μm的5个堆栈)记录伊凡氏蓝在669nm下的发射,且获得具有最大强度投影的视网膜铺片的影像。在临限值为30的程序ImageJ中打开影像之后,进行荧光强度总和的分析。***p<0.001;*p<0.05;n.s.p>0.05;相对于TPP-11737+PBS,#p>0.05不显著。单向Anova与Tukey多比较测试,n=9-17。
结果:
在对照条件下,玻璃体内VEGF-A注射增加血管渗透性约60%。TPP-11737用作对照抗体,因为其该与TPP-14940相同的分子格式(多普单抗),但在先前体外分析中,该化合物并不清除VEGF。
在1:1及2:1分子比的结合分子与VEGF下,TPP-14940完全阻断血管高渗透性。然而,在急剧对比中,艾力雅在相同条件下且甚至在倍增浓度下未能显著降低血管渗漏。
系列2:TPP-14938、TPP-14939、TPP-14940、TPP-14941的发现的概述
TrkB活化:
与TPP-11736形成强烈对比,所有四种新多普单抗均为完全TrkB受体激动剂。通过那些多普单抗进行的TrkB活化与天然配体BDNF一样有效。
相对于TPP-14939及TPP-14941,具有“VH-VL”定向的多普单抗TPP-14938/40中的TrkB活化的效能略微更好。
出人意料地,与人类VEGF一起预培育显著改善通过TPP-14941[C2,scFv,20L3,VL-VH]进行的TrkB磷酸化(TrkB活化)的效能,从而指出协同效应。
与TPP-14941相比,VEGF对于通过TPP-14940[C2,scFv,20L3,VH-VL]进行的TrkB磷酸化(TrkB活化)的效能的影响相对较地更小。
VEGF清除:
在增殖分析中,将B20 scFv(TPP-11736)重新格式化为B20 Fab(TPP-14938及TPP-14939)既不会改善VEGF-A清除的效能亦不会改善其功效。
在增殖分析中,将兰尼单抗scFv(TPP-11736/TPP-14937)重新格式化为兰尼单抗Fab(TPP-14940及TPP-14941)显著改善VEGF-A清除的效能。
在TPP-14940及TPP-14941的情况下,已在低至0.25nM的浓度下发现完全VEGF抑制。
相较于基于B20 Fab的分子TPP-14938及TPP-14939,通过基于兰尼单抗Fab的分子TPP-14940及TPP-14941抑制VEGF诱导的增殖的效能及功效更优。
因为本发明人观测到结合分子中的接头截割(clipping)(数据未显示),所以在以下实施例中,基于以下衍生其他分子:TPP-14940:TPP-19986(VH-VL,10L1)、TPP-19987(VH-VL,20L1);及基于TPP-14941:TPP-19988(VL-VH,10L1)、TPP-19989(VL-VH,20L1),其全部均基于兰尼单抗作为Fab及C2作为scFv。
实施例40:
通过BDNF、TPP-14940[C2,scFv,20L3,VH-VL]或其接头变体TPP-19986[C2,scFv,10L1,VH-VL]或TPP-19987[C2,scFv,20L1,VH-VL]、或TPP-14941[C2,scFv,20L3,VL-VH]及其接头变体TPP-19988[C2,scFv,10L1,VL-VH]或TPP-19989[C2,scFv,20L1,VL-VH]进行的人类TrkB活化的比较;TrkB及ERK1/2磷酸化--系列3
图40A至图40D
将稳定表达人类TrkB的CHO细胞与增加浓度的天然TrkB配体BDNF、TPP-14940[C2,scFv,20L3,VH-VL]或其接头变体TPP-19986[C2,scFv,10L1,VH-VL]或TPP-19987[C2,scFv,20L1,VH-VL]、或TPP-14941[C2,scFv,20L3,V-VH]及其接头变体TPP-19988[C2,scFv,10L1,VL-VH]或TPP-19989[C2,scFv,20L1,VL-VH]一起培育。通过(A及B)测量Y706/707上的TrkB磷酸化或通过(C及D)分别测量T202/Y204(ERK1)及T185/Y187(ERK2)上的ERK1/2磷酸化评价TrkB活化。最低化合物浓度为仅溶剂。数据表示平均值+/-SEM。下表9及10分别报导TrkB及ERK1/2磷酸化的对应最佳拟合EC50值(非线性回归;log(激动剂)相对于反应(三个参数))。
表9:
BDNF TPP-14940 TPP-19986 TPP-19987
EC50(pTrkB) 1.22nM 3.21nM 2.00nM 2.16nM
EC50(pERK) 0.507nM 0.475nM 0.406nM 0.381nM
表10:
BDNF TPP-14941 TPP-19988 TPP-19989
EC50(pTrkB) 1.28nM 6.28nM 7.83nM 7.37nM
EC50(pERK) 0.282nM 1.29nM 2.05nM 1.77nM
结果:
亲本分子与各自的接头变体之间不存在显著差异。TrkB及ERK1/2磷酸化的效能及功效几乎一致。这是值得注意的,因为接头位于TrkB结合位点附近,但并不会影响结合分子的生物活性。
所有所测试分子均为完全TrkB激动剂。
同样,如先前所示,相较于TPP-14941分子及其接头变体(VL-VH定向),TPP-14940分子及其接头变体(VH-VL定向)的TrkB/ERK磷酸化的效能更好。
实施例41:
通过BDNF、TPP-14940[C2,scFv,20L3,VH-VL]或TPP-14941[C2,scFv,20L3,VL-VH]及接头变体TPP-19988[C2,scFv,10L1,VL-VH]或TPP-19989[C2,scFv,20L1,VL-VH]进行的人类TrkB内化的比较--系列3
图41A至图41B
将稳定表达食蟹猕猴TrkB的CHO细胞与增加浓度的天然TrkB配体BDNF、或1nMBDNF与增加浓度的第一系列的多普单抗TPP-14940[C2,scFv,20L3,VH-VL]或TPP-14941[C2,scFv,20L3,VL-VH]及接头变体TPP-19988[C2,scFv,10L1,VL-VH]或TPP-19989[C2,scFv,20L1,VL-VH]一起培育。通过在不渗透细胞的情况下对表面TrkB受体进行免疫荧光染色,随后共焦显微分析来评价TrkB内化。热图的深色及浅色场分别表示高于荧光临限值的高及低百分比的细胞。
结果:
BDNF诱导TrkB受体内化。尽管TPP-14940、TPP-14941、TPP-19988及TPP-19989为完全TrkB受体激动剂,但多普单抗中无一者增加BDNF诱导的受体内化而实际上降低BDNF诱导的TrkB受体的内化(注意:热图场由下至上变得更暗)。
实施例42:
通过TPP-14940及其接头变体TPP-19986、及TPP-14941及其接头变体TPP-19988进行的人类VEGF-A清除的比较--VEGF诱导的VEGFR2的磷酸化的抑制--系列3
图42
使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的多普单抗TPP-14940及其接头变体TPP-19986、及TPP-14941及其接头变体TPP-19988一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。通过测量Y1175上的VEGF受体2(VEGFR2)磷酸化评价VEGF-A清除。无分子处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。下表11报导VEGFR2磷酸化的抑制的对应最佳拟合IC50值(非线性回归;log(激动剂)相对于反应(三个参数))。
表11:
结果:
亲本分子TPP-14940/TPP-14941与各自的接头变体之间不存在显著差异。VEGF诱导的VEGFR2磷酸化的抑制的效能及功效几乎一致。
实施例43:
通过多普单抗TPP-14940[C2,scFv,20L3,VH-VL]或其接头变体TPP-19986[C2,scFv,10L1,VH-VL]或TPP-19987[C2,scFv,20L1,VH-VL]、或TPP-14941[C2,scFv,20L3,VL-VH]及其接头变体TPP-19988[C2,scFv,10L1,VL-VH]或TPP-19989[C2,scFv,20L1,VL-VH]进行的人类VEGF-A清除的比较--VEGF诱导的HRMEC出芽的抑制--系列3
图43
人类视网膜微血管内皮细胞(HRMEC)的球体包埋于胶原蛋白基质中。通过在与2.5nM的多普单抗TPP-11736(B20 scFv)、TPP-14940[C2,scFv,20L3,VH-VL]或其接头变体TPP-19986[C2,scFv,10L1,VH-VL]或TPP-19987[C2,scFv,20L1,VH-VL]、或TPP-14941[C2,scFv,20L3,VL-VH]及其接头变体TPP-19988[C2,scFv,10L1,VL-VH]或TPP-19989[C2,scFv,20L1,VL-VH]一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育来诱导内皮出芽24小时。内皮出芽通过共焦显微术评价且显示获自Z-堆栈的最大投影的球体周界。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。n.s.p>0.05无显著差异;相较于50ng/mLhVEGF,§p<0.0001;相较于50ng/mL hVEGF,#p>0.05无显著差异。***p<0.001;单向Anova与Tukey多比较测试。
结果:
亲本分子TPP-14940/TPP-14941与各自的接头变体之间未观测到显著差异。所有分子均充分抑制VEGF诱导的HRMEC出芽。
系列3:TPP-19986、19987、19988、19989的发现的概述
TrkB活化:
在亲本分子(TPP-14940/14941)与各自的接头变体之间未观测到显著差异。
所有所测试结合分子均为完全TrkB受体激动剂。VH-VL定向及其接头变体仍然更强效。
未观测到受体内化的变化。考虑到新多普单抗类似于BDNF为完全TrkB受体激动剂,这是极其出人意料。
VEGF清除:
在亲本分子(TPP-14940/14941)与各自的接头变体之间未观测到显著差异。
CMC特性:
在使用接头10L1及20L1接头的情况下,不再观测到接头截割(数据未显示)。
作为下一步骤,设计最后一个系列的结合分子(系列4),以改善结合分子的CMC以及生物物理学特性,但始终尝试保留本发明的结合分子的优良生物功能。
实施例44:
通过在TrkB scFv部分中不具有或具有二硫桥键(CC)的多普单抗进行的人类TrkB活化的比较;TrkB磷酸化--系列4
图44A至图44D
将稳定表达人类TrkB的CHO细胞与增加浓度的在抗TrkB scFv部分中具有/不具有CC桥键的指示多普单抗一起培育。(A)TPP-22180与TPP-22204;(B)TPP-22192与TPP-22216;(C)TPP-22190与TPP-22214;(D)TPP-22191与TPP-22215。通过测量Y706/707上的TrkB磷酸化评价TrkB活化。最低化合物浓度为仅溶剂。数据表示平均值+/-SEM。下表12分别报导TrkB活化的对应最佳拟合EC50值及绝对或相对功效值(顶部平线区)(非线性回归;log(激动剂)相对于反应(三个参数))。
表12:
/>
结果:
引入二硫桥键主要为了改善结合分子的CMC特性。出人意料地,通过在scFv抗TrkB部分中包括二硫桥键,进一步改善TrkB活化的效能及功效。在具有VL-VH定向的结合分子中观测到较大影响。
实施例45:
通过在TrkB scFv部分中具有或不具有二硫桥键(CC)的多普单抗进行的大鼠TrkB活化的比较;TrkB磷酸化--系列4
图45A至图45B
将稳定表达大鼠TrkB的CHO细胞与增加浓度的在抗TrkB scFv部分中具有/不具有CC桥键的指示多普单抗一起培育。(A)TPP-22180与TPP-22204;(B)TPP-22192与TPP-22216。通过测量Y706/707上的TrkB磷酸化评价TrkB活化。最低化合物浓度为仅溶剂。数据表示平均值+/-SEM。下表13分别报导TrkB活化的对应最佳拟合EC50值及绝对或相对功效值(顶部平线区)(非线性回归;log(激动剂)相对于反应(三个参数))。
表13:
/>
结果:
在scFv抗TrkB部分中包括二硫桥键改善TrkB活化的效能及功效。同样,对于VL-VH定向的结合分子的影响似乎较大。总体而言,数据与针对人类TrkB所获得的数据良好一致。
实施例46:
TPP-22204/22214介导的TrkB活化的选择性
图46
将稳定表达(A)人类TrkA、(B)人类TrkB或(C)人类TrkC的CHO细胞与增加浓度的C2抗体或多普单抗TPP-22204或TPP-22214一起培育。通过测量Y706/707上的受体磷酸化评价Trk受体的活化。与增加浓度的TrkA(NGF)、TrkB(BDNF)及TrkC(NT-3)的天然配体一起培育用作对照。最低化合物浓度为仅溶剂。数据表示平均值+/-SEM。
结果:
两种多普单抗对于TrkB均极具特异性/选择性--其中无一者活化TrkA或TrkC。
实施例47:
TPP-22214对于BDNF诱导的TrkB活化的影响
图47A至图47B
在具有或不具有0.3nM、1nM或3nM恒定浓度的BDNF的情况下,将稳定表达人类TrkB受体的CHO细胞与增加浓度的(A)C2抗体或(B)多普单抗TPP-22214一起培育。通过测量Y706/707上的受体磷酸化评价TrkB的活化。数据表示平均值+/-SEM。
结果:
与C2形成强烈对比,TPP-22214并不会限制BDNF诱导的TrkB活化。
实施例48:
在存在或不存在人类VEGF下,通过TPP-22214进行的人类TrkB活化(TrkB磷酸化)的比较
图48A至图48D
在与(A)200ng/mL人类VEGF-A(hVEGF)、(B)50ng/mL hVEGF、(C)10ng/mL hVEGF或(D)2ng/mL hVEGF一起预培育或未预培育的情况下,将稳定表达人类TrkB的CHO细胞与增加浓度的多普单抗TPP-22214一起培育。通过测量Y706/707上的TrkB磷酸化评价TrkB活化。最低化合物浓度为仅溶剂。数据表示平均值+/-SEM。
结果:
如之前所示,与200ng/mL人类VEGF一起预培育改善通过TPP-22214进行的TrkB磷酸化(TrkB活化)的效能。更重要的是,此协同效应在50、10及甚至2ng/mL hVEGF下很大程度上保留。在诸如食蟹猕猴的其他物种中亦获得类似效果(数据未显示)。
实施例49:
在存在或不存在人类VEGF下,通过TPP-22214进行的人类TrkB活化(ERK磷酸化)的比较
图49A至图49D
在与(A)200ng/mL人类VEGF-A(hVEGF)、(B)50ng/mL hVEGF、(C)10ng/mL hVEGF或(D)2ng/mL hVEGF一起预培育或未预培育的情况下,将稳定表达人类TrkB的CHO细胞与增加浓度的多普单抗TPP-22214一起培育。通过测量TrkB下游的T202/Y204(ERK1)及T185/Y187(ERK2)上的ERK1/2磷酸化评价TrkB活化。最低化合物浓度为仅溶剂。数据表示平均值+/-SEM。
结果:
同样,与200ng/mL人类VEGF一起预培育亦改善通过TPP-22214进行的TrkB活化下游的ERK磷酸化的效能。同样在此分析中,协同效应在低至2ng/mL hVEGF的浓度下很大程度上保留。在诸如食蟹猕猴的其他物种中亦获得类似效果(数据未显示)。
实施例50:
VEGF结合加强TrkB活化研究所提出的机制
图50
通过以所描述的摩尔比(1:1、4:1或20:1),将样品一起混合在1x杜氏PBS(Dulbecco's PBS)中来制备TPP-22214与hVEGF的复合物。在分析之前,在室温培育样品1小时。与迷你DAWN TREOS及Optilab REX串联使用Agilent 1200。使样品以0.6ml/min的流速在作为移动相的1x杜氏PBS中运行。将100μl复合物或单独TPP-22214注射至Superose6Increase柱(30cm×10mm)上,其中分子通过流体动力学体积进行分离。接着使用Astra6.1.1.17分析数据。
结果:
在VEGF-A存在下,TPP-22214形成复合物,其中最大复合物在1:1摩尔比下形成。这些复合物表明多普单抗及VEGF在超出1:1比率外复合。这些较大复合物可导致TrkB受体在细胞表面上聚类。实验数据支持所提出的机制。
实施例51:
通过增加浓度的BDNF或TPP-22214,及在1nM BDNF存在下增加浓度的TPP-22214进行的人类TrkB内化的比较
图51A至图51C
将稳定表达人类TrkB的CHO细胞与(A)增加浓度的天然TrkB配体BDNF、(B)增加浓度的TPP-22214或(C)1nM BDNF与增加浓度的TPP-22214一起培育。通过在不渗透细胞的情况下对表面TrkB受体进行免疫荧光染色,随后共焦显微分析来评价TrkB内化。数据表示表面TrkB染色强度高于临限值的细胞百分比;平均值+/-SEM。
结果:
(A)与BDNF一起培育诱导TrkB受体内化。
(B)TPP-22214并不会诱导TrkB受体内化。
(C)通过增加TPP-22214的浓度,BDNF诱导的受体内化降低/消除。
实施例52:
STZ诱导的糖尿病大鼠中的TPP-22214及C2的神经保护功效
图52
使用IVT注射促效TrkB抗体(C2)以及多普单抗TPP-22214,糖尿病诱导的视网膜神经退化大鼠模型中的TrkB活化的神经保护功能。动物用STZ处理以诱导高血糖症。通过在治疗前后进行视网膜电描记术(ERG)评价视网膜功能。糖尿病诱导导致在STZ治疗后3周内延迟隐含时间。在此时间点,对动物玻璃体内给药同型对照抗体(抗TNP)或C2(各19μg/5μl)、或等摩尔量的TPP-22214(25μg/5μl)。描绘在即将玻璃体内施用分子之前及其两周后的视杆驱动的B波隐含时间延迟;平均值+/-SEM;n.s.p>0.05;不显著(n.s.),****p<0.0001;单向Anova与Tukey多比较测试。
结果:
在施用之后两周,相较于在抗TNP治疗之前的时间点,抗TNP抗体治疗并不会降低糖尿病诱导的视杆驱动的b波隐含时间。实际上,相较于在抗TNP抗体施用之前的时间点,隐含时间延迟甚至显著增加(在t=2周时,17.1ms;相对于在t=0周时,11.2ms;****p<0.0001)。此指示,STZ诱导的视网膜损伤在t=0周时未完全确立,及抗TNP治疗不能阻止隐含时间延迟进一步增加。
在施用之后两周,C2抗体治疗阻断隐含时间延迟的进一步增加。然而,相较于在C2治疗之前的时间点,C2抗体治疗并不会显著降低糖尿病诱导的视杆驱动的b波隐含时间(在t=2周时,10.3ms;相对于在t=0周时,12.8ms,n.s .p>0.05;不显著)。
在施用之后两周,相较于在TPP-22214治疗之前的时间点,TPP-22214抗体治疗阻断隐含时间延迟的进一步增加,且甚至显著降低糖尿病诱导的视杆驱动的b波隐含时间超过40%(在t=2周时,8.3ms;相对于在t=0周时,14.2ms,****p<0.0001)。
实施例53:
通过不具有或具有二硫桥键(CC)的多普单抗以及亲本分子TPP-14940/TPP-14941进行的人类VEGF-A清除的比较--VEGF诱导的VEGFR2的磷酸化的抑制
图53A至图53B
通过测量Y1175上的VEGF受体2(VEGFR2)磷酸化评价VEGF-A清除。无分子处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。下表14报导对应最佳拟合IC50值(非线性回归;log(激动剂)相对于反应(三个参数))。
表14:
结果:
在亲本分子TPP-14940/TPP-14941与具有或不具有二硫桥键的各自的多普单抗变体之间不存在显著差异。VEGF诱导的VEGFR2磷酸化的抑制的效能及功效几乎一致。
实施例54:
通过TPP-22214或艾力雅进行的人类VEGF-A清除的比较--Y1175上及ERK1/2的VEGF诱导的VEGFR2磷酸化的抑制(两者均与EC增殖相关)
图54A至图54B
使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的TPP-22214或艾力雅一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。通过测量(A)Y1175上的VEGF受体2(VEGFR2)磷酸化或(B)T202/Y204(ERK1)及T185/Y187(ERK2)上的ERK1/2磷酸化评价VEGF-A清除。无分子处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。下表15报导形成非线性回归的对应最佳拟合值(log(激动剂)相对于反应(三个参数))。在艾力雅与TPP-22214之间显著不同(P<0.05)的最佳拟合值以粗体显示。P值亦在表15中报导。
表15:
结果:
相较于艾力雅,TPP-22214充分抑制VEGF诱导的Y1175上的VEGFR2的磷酸化及ERK1/2的磷酸化。亦可在底部平线区的值的高度显著差异上看见TPP-22214的VEGF清除的经改善功效(参见表15)。最后,TPP-22214在VEGF清除中比艾力雅显著更强效。
实施例55:
通过TPP-22204、TPP-22214或TPP-22216与艾力雅进行的人类VEGF-A清除的比较--VEGF诱导的HRMEC增殖的抑制
图55A至图55E
使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的指示结合分子:(A)TPPP-22204、(B)TPP-22214、(C)TPP-22216或(D)艾力雅一起预培育或未预培育的情况下,与10ng/mL人类VEGF一起培育。通过自动化基于影像的HRMEC细胞数目定量(IncuCyte)评价VEGF-A清除。每四个小时记录影像,持续总共84小时的时段。显示相对细胞数目。将在t=0时的细胞数目设定为一。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。(E)相对于艾力雅或TPP-22214的浓度的生长曲线及基础曲线下面积的差异的曲线。下表16报导形成非线性回归的对应最佳拟合值(log(激动剂)相对于反应(三个参数))。在艾力雅与TPP-22214之间显著不同(P<0.05)的最佳拟合值以粗体显示。P值亦在表16中报导。
表16:
结果:
通过多普单抗抑制VEGF诱导的增殖的效能及功效明显优于艾力雅(TPP-22214与艾力雅之间的LogIC50值及底部平线区值的高度显著差异)。
即使在最高浓度(16nM)下,艾力雅未能充分抑制VEGF诱导的出芽。相比之下,所有多普单抗已在降低64倍的浓度0.25nM下充分抑制VEGF诱导的增殖。
实施例56:
通过TPP-22214或艾力雅进行的人类VEGF-A清除的比较--Y1214上的VEGFR2及p38-MAPK的VEGF诱导的磷酸化的抑制
图56A至图56B
使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的TPP-22214或艾力雅一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。通过测量(A)Y1214上的VEGF受体2(VEGFR2)磷酸化或(B)T180/Y182上的p38-MAPK磷酸化评价VEGF-A清除。无分子处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。下表17报导形成非线性回归的对应最佳拟合值(log(激动剂)相对于反应(三个参数))。在艾力雅与TPP-22214之间显著不同(P<0.05)的最佳拟合值以粗体显示。P值亦在表17中报导。
表17:
/>
结果:
与艾力雅形成强烈对比,TPP-22214充分抑制Y1214上的VEGFR2及p38-MAPK的VEGF诱导的磷酸化。根据表17中底部平线区的值的高度显著差异可发现TPP-22214的更有效VEGF清除。此外,观测到通过TPP-22214进行的VEGF清除的效能比艾力雅更优选的趋势。
实施例57:
通过TPP-22204、TPP-22214、TPP-22215或TPP-22216与艾力雅进行的人类VEGF-A清除的比较--VEGF诱导的HRMEC出芽的抑制
图57A至图57B
人类视网膜微血管内皮细胞(HRMEC)的球体包埋于胶原蛋白基质中。通过在与2.5nM的TPP-22204、TPP-22214、TPP-22215或TPP-22216、或5nM艾力雅一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育来诱导内皮出芽24小时。(A)内皮出芽通过共焦显微术评价且显示获自Z-堆栈的最大投影的球体周界。未刺激细胞充当对照(基础)。数据表示平均值+/-SEM。n.s.p>0.05,不显著,****p<0.0001。(B)显示在基础条件下出芽24小时之后或在与2.5nM TPP-22214或5nM艾力雅一起预培育或未预培育的情况下用50ng/mL人类VEGF刺激之后,来自球体的代表性最大投影影像。条=100μm。
结果:
类似于Y1214 VEGFR2磷酸化分析,多普单抗在抑制VEGF诱导的HRMEC出芽中更有效许多。此外,多普单抗能够充分抑制VEGF诱导的内皮细胞出芽。值得注意的是,以相较于多普单抗两倍的分子浓度使用艾力雅,且仍不能够充分抑制细胞出芽。
实施例58:
通过TPP-22214或艾力雅进行的人类VEGF-A清除的比较--Y951上的VEGFR2及Src的VEGF诱导的磷酸化的抑制
图58A至图58B
使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的TPP-22214或艾力雅一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。通过测量(A)Y951上的VEGF受体2(VEGFR2)磷酸化或(B)Y419上的Src磷酸化评价VEGF-A清除。无抗体处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。下表18报导形成非线性回归的对应最佳拟合值(log(激动剂)相对于反应(三个参数))。在艾力雅与TPP-22214之间显著不同(P<0.05)的最佳拟合值以粗体显示。P值亦在表18中报导。
表18:
结果:
与艾力雅形成强烈对比,TPP-22214充分抑制Y951上的VEGFR2及Y419上的Src的VEGF诱导的磷酸化。根据底部平线区的值的高度显著差异可发现TPP-22214的更有效VEGF清除(表18)。
实施例59:
通过多普单抗TPP-22214及艾力雅进行的人类VEGF-A清除的比较--在BrownNorway大鼠中,人类VEGF-A诱导的视网膜高渗透性的抑制
图59A至图59B
TPP-22214防止大鼠视网膜中的人类VEGF-A诱导的高渗透性。(A)显示实验程序的时间方案。在玻璃体内(ivt)施用抗VEGF化合物(每只眼睛13或26pmol的艾力雅或TPP-14940)或对照(26pmol TPP-11737)之后十五分钟,通过ivt注射每只眼睛施用13pmol人类VEGF-A。PBS注射充当对照。二十四小时后,在分离及固定眼睛之前通过静脉内(iv)注射施用1mL/kg伊凡氏蓝(Evans Blue;EB)溶液(45mg/mL于0.9%盐水中)30分钟。在相同时间点收集血浆样品以确认相等全身性EB暴露。(B)通过利用共焦显微术测量视网膜铺片中的EB外渗来定量Brown Norway大鼠的视网膜中的VEGF-A诱导的高渗透性。沿着锯齿缘切割眼睛,移除晶状体及玻璃体,且将眼杯固定在4℃下的多聚甲醛(4%)中1h且接着转移至在4℃的PBS隔夜。将视网膜与外部区段(巩膜及脉络膜)分开,且转移至载玻片并切割四次以达成平坦三叶草样结构。组织用封固剂(含有DNA染料DAPI的Vectashield H-1200)覆盖且将盖玻片置于顶部上以获得视网膜铺片。样品在639nm波长下激发,且用LSM 700共焦激光扫描显微镜(Carl Zeiss,Jena;放大率800,激光强度2%,60μm的5个堆栈)记录伊凡氏蓝在669nm下的发射,且获得具有最大强度投影的视网膜铺片的影像。在临限值为30的程序ImageJ中打开影像之后,进行荧光强度总和的分析。***p<0.001;*p<0.05;n.s.p>0.05。单向Anova与Tukey多比较测试,n=9-17。显示与67:1摩尔比的艾力雅:VEGF一起的培育以用于比较。
结果:
在对照条件下,玻璃体内VEGF-A注射增加血管渗透性约60%。注意:TPP-11737用作对照分子,因为其具有与TPP-22214相同的分子格式(多普单抗),但在先前体外分析中,并不清除VEGF(参见上文)。
在1:1分子比的结合分子与VEGF下,TPP-22214完全阻断血管高渗透性。然而,在急剧对比中,艾力雅在相同条件下且甚至在倍增浓度下未能显著降低血管渗漏。仅在67:1的极高分子比率下,艾力雅能够抑制人类VEGF诱导的血管渗漏。
实施例60:
TrkB结合对于通过TPP-22214进行的VEGF清除的影响--在存在或不存在TrkB胞外域下通过TPP-22214进行的人类VEGF-A清除的比较
图60A至图60B
(A)TkrB胞外域(TrkB-ECD)的功能特征。将稳定表达人类TrkB的CHO细胞与增加浓度的天然配体BDNF或10nM BDNF与增加浓度的TrkB-ECD一起培育。通过测量Y706/707上的TrkB磷酸化评价TrkB活化。最低化合物浓度为仅溶剂。数据表示平均值+/-SEM。
(B)TPP-22214的TrkB-ECD结合对于抑制VEGF诱导的VEGFR2磷酸化的影响。使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着与50ng/mL人类VEGF、50ng/mL人类VEGF及增加浓度的TPP-22214、或50ng/mL人类VEGF及增加浓度的TPP-22214及100nm TrkB-ECD一起培育。在具有或不具有50ng/mL VEGF的情况下,HRMEC与增加浓度的TrkB-ECD一起培育以及未刺激的细胞(基础)充当对照。通过测量Y1175上的VEGF受体2(VEGFR2)磷酸化评价VEGF-A清除。数据表示平均值+/-SEM。
结果:
图(A):BDNF与增加浓度的TrkB-ECD一起预培育显著降低TrkB受体的活化。此显示,TrkB-ECD能够结合且清除BDNF,此可自功能性TrkB-ECD预期。
图(B):通过TPP-22214进行的VEGF清除与TrkB-ECD的存在与否无关。两个曲线几乎一致。此指示,TPP-22214的TrkB结合本身确实不限制多普单抗的VEGF清除,表明多普单抗可同时活化TrkB受体及清除VEGF。
实施例61:
为了改善系列3至系列4的CMC特性的工程改造工作
评价来自系列3及系列4的分子的生理特性。在分子制备期间,使用分析型尺寸排阻色谱测试通过单体百分比来测量的蛋白A后的品质。此外,在10mM组氨酸pH 6.0中评价各分子的热稳定性及聚集起始。使用热位移分析来测量热稳定性,该热位移分析使用Sypro橙染料测量蛋白质随温度的去折叠。各Tm计算为在整个温度中荧光信号的一阶导数的最大峰值。使用动态光散射来测量聚集起始,以测量作为温度的函数的流体力学半径。最后,通过测量在40℃或5℃2周后的聚集测试各种多普单抗的储存稳定性。使用分析型尺寸排阻色谱来测量聚集。
分子模型化用于鉴别可潜在地提高兰尼单抗的Fv部分的pI且因此潜在地提高其溶解性而不影响其构象稳定性的单点突变。此计算设计工作建议三个构架突变,即VH E1→Q、VH E6→Q及VL D70G,其中VH及VL分别是指兰尼单抗Fv中的重链及轻链的可变部分。重链中的突变VH E1→Q及VH E6→Q对应于这些位置处的人类生殖系残基。预期轻链中的突变VLD70→G将破坏兰尼单抗Fv的溶剂暴露的带负电小块。
工程改造工作已增加多普单抗的总体生理特性且转换成整个分子的改良的CMC特性。对于大部分所测试分子,发现在蛋白A后单体百分比增加。此改良分子的总体可制造性。Tm1及Tagg中所见的改良指示工程改造改良分子的构象及胶体稳定性。此进一步转换成在40℃及5℃下更优选的稳定性概况。
表19:
实施例62:
TPP-22214的玻璃体半衰期的测定
新西兰雌性白兔接受双侧玻璃体内施用TPP-22214或贝伐单抗(Bevacizumab)。在不同时间点收集玻璃体样品,且通过ELISA测定TPP-22214或贝伐单抗的浓度。在玻璃体内施用之前及之后以规律间隔,使动物进行眼部检查。
表20:
表20显示以实验方式测定的TPP-22214及贝伐单抗的玻璃体半衰期的结果,且比较贝伐单抗、兰尼单抗及阿柏西普的内部以实验方式测定的值与已知文献值。所报导的贝伐单抗半衰期与内部/以实验方式得到的值一致,确认所应用方法的准确度及数据集的可比较性。显示TPP-22214在兔中具有相较于例如贝伐单抗高大致50%的体内半衰期(6.7天相对于4.3天)。
表21:
表21报导湿性年龄相关的黄斑变性(wAMD)患者中的眼部VEGF浓度的文献值。
表22:
基于表21中显示的值,且仅通过使用贝伐单抗的人类玻璃体内半衰期(t1/2)(9.7天;Hutton-Smith,L.,Mol.Pharmaceutics,2016,13,2941-2950),计算TPP-22214的人类给药频率的保守估计(表21)。在2mg/眼的剂量下,4个月的给药间隔似乎合理。
实施例63:
通过BDNF、TPP-6830及两种多普单抗TPP-23457及TPP-23459进行的人类TrkB活化的比较
图61A至图61B
将稳定表达人类TrkB的CHO细胞与增加浓度的天然TrkB配体BDNF、TPP-6830(另一单克隆TrkB抗体)或两种多普单抗TPP-23457(TPP-6380作为scFv,10L1,VH-VL;兰尼单抗作为Fab)及TPP-23459(TPP6380作为scFv,10L1,VL-VH;兰尼单抗作为Fab)一起培育。
新的多普单抗分子现基于不同TrkB结合剂(TPP-6830),以评估在基于C2TrkB结合剂的多普单抗的情况下观测到的效果是否亦可在不同TrkB结合剂的情况下再现。
结果:
同样,与TPP-6830(初始TrkB抗体,为部分TrkB受体激动剂)形成强烈对比,两种新的多普单抗:TPP-23457及TPP-23459多普单抗现显示完全TrkB受体激动剂活性。通过那些多普单抗进行的TrkB活化至少与天然配体BDNF一样有效。
此进一步支持以下理论:结合分子的空间形成可为所观测到的功效增加与特定TrkB结合剂无关的原因。
实施例64:
在存在或不存在人类VEGF下,通过TPP-6830(TrkB单克隆抗体)及两种多普单抗TPP-23457及TPP-23459进行的人类TrkB活化(TrkB磷酸化)的比较
图62A至图62C
在与200ng/mL人类VEGF-A(hVEGF)一起预培育或未预培育的情况下,将稳定表达人类TrkB的CHO细胞与增加浓度的多普单抗(A)TPP-23457、(B)TPP-23459或(C)TPP-6830一起培育。通过测量Y706/707上的TrkB磷酸化评价TrkB活化。最低化合物浓度为仅溶剂。数据表示平均值+/-SEM。
结果:
同样,与人类VEGF一起预培育显著改善通过TPP-23457(TPP-6830作为scFv,10L1,VH-VL;兰尼单抗作为Fab)及TPP-23459(TPP-6380作为scFv,10L1,VL-VH;兰尼单抗作为Fab)进行的TrkB磷酸化(TrkB活化)的效能。
VEGF预培育并不会影响通过TPP-6830(对照)进行的TrkB磷酸化(TrkB活化)的效能。
此进一步支持以下理论:所观测到的效能增加与特定TrkB结合剂无关。
实施例65:
在存在或不存在人类VEGF下,通过TPP-6830(TrkB单克隆抗体)及两种多普单抗TPP-23457及TPP-23459进行的人类TrkB活化(ERK磷酸化)的比较
图63A至图63C
在与200ng/mL人类VEGF-A(hVEGF)一起预培育或未预培育的情况下,将稳定表达人类TrkB的CHO细胞与增加浓度的多普单抗(A)TPP-23457、(B)TPP-23459或(C)TPP-6830一起培育。通过测量TrkB下游的T202/Y204(ERK1)及T185/Y187(ERK2)上的ERK1/2磷酸化评价TrkB活化。最低化合物浓度为仅溶剂。数据表示平均值+/-SEM。
结果:
此处同样,与人类VEGF一起预培育显著改善通过TPP-23457(TPP-6830作为scFv,10L1,VH-VL;兰尼单抗作为Fab)及TPP-23459(TPP-6380作为scFv,10L1,VL-VH;兰尼单抗作为Fab)进行的ERK1/2磷酸化(TrkB活化)的效能。
如先前所示,VEGF预培育并不会影响通过TPP-6830(对照)进行的ERK1/2磷酸化(TrkB活化)的效能,从而进一步支持以下理论:所观测到的效能增加与特定TrkB结合剂无关。
实施例66:
TPP-23457对于BDNF诱导的TrkB活化(TrkB磷酸化)的影响
图64A至图64B
在具有或不具有0.3nM、1nM或3nM恒定浓度的BDNF的情况下,将稳定表达人类TrkB受体的CHO细胞与增加浓度的(A)C2抗体或(B)多普单抗TPP-23457一起培育。通过测量Y706/707上的受体磷酸化评价TrkB的活化。数据表示平均值+/-SEM。
结果:
与C2形成强烈对比,TPP-23457并不会限制BDNF诱导的TrkB活化。
实施例67:
TPP-23457对于BDNF诱导的TrkB活化(Erk磷酸化)的影响
图65A至图65B
在具有或不具有0.3nM、1nM或3nM恒定浓度的BDNF的情况下,将稳定表达人类TrkB受体的CHO细胞与增加浓度的(A)C2抗体或(B)多普单抗TPP-23457一起培育。通过测量TrkB下游的T202/Y204(ERK1)及T185/Y187(ERK2)上的ERK1/2磷酸化评价TrkB的活化。数据表示平均值+/-SEM。
结果:
与C2形成强烈对比,TPP-23457并不会限制TrkB下游BDNF诱导的Erk磷酸化。
实施例68:
通过TPP-22214、TPP-23457或TPP-23459进行的人类VEGF-A清除的比较--Y1175上及ERK1/2的VEGF诱导的VEGFR2磷酸化的抑制(两者均与EC增殖相关)
图66A至图66B
使人类视网膜微血管内皮细胞(HRMEC)饥饿,且接着在与增加浓度的TPP-22214、
TPP-23457或TPP23459一起预培育或未预培育的情况下,与50ng/mL人类VEGF一起培育。通过测量(A)Y1175上的VEGF受体2(VEGFR2)磷酸化或(B)T202/Y204(ERK1)及T185/Y187(ERK2)上的ERK1/2磷酸化评价VEGF-A清除。无分子处理的50ng/ml人类VEGF充当对照。数据表示平均值+/-SEM。
结果:
多普单抗TPP-23457及TPP-23459的VEGF清除几乎与TPP-22215一致。
如所预期,基于不同TrkB scFv结合剂的多普单抗(TPP-6830且非C2)亦不会对Fab的VEGF清除功能具有任何影响。
序列表
<110> 勃林格殷格翰国际有限公司
<120> 用于治疗眼部疾病的抗-VEGF及抗-TrkB双特异性结合分子
<130> 01-3412
<140> 202180070390.8
<141> 2021-10-20
<150> 20203030.0
<151> 2020-10-21
<160> 257
<170> BiSSAP 1.3.6
<210> 1
<211> 214
<212> PRT
<213> 人类
<400> 1
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 2
<211> 720
<212> PRT
<213> 人类
<400> 2
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Asp Ile Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe
50 55 60
Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser
450 455 460
Glu Ser Lys Ser Thr Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly
465 470 475 480
Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala
485 490 495
Ser Gly Phe Thr Ile Asn Ala Ser Trp Ile His Trp Val Arg Gln Ala
500 505 510
Pro Gly Lys Gly Leu Glu Trp Val Gly Ala Ile Tyr Pro Tyr Ser Gly
515 520 525
Tyr Thr Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ala
530 535 540
Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala
545 550 555 560
Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Trp Gly His Ser Thr Ser
565 570 575
Pro Trp Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
580 585 590
Ser Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys
595 600 605
Ser Thr Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu
610 615 620
Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln
625 630 635 640
Val Ile Arg Arg Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala
645 650 655
Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Ala Ser Gly Val Pro
660 665 670
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
675 680 685
Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser
690 695 700
Asn Thr Ser Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
705 710 715 720
<210> 3
<211> 214
<212> PRT
<213> 人类
<400> 3
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 4
<211> 720
<212> PRT
<213> 人类
<400> 4
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Asp Ile Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe
50 55 60
Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser
450 455 460
Glu Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
465 470 475 480
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
485 490 495
Ala Ser Gln Val Ile Arg Arg Ser Leu Ala Trp Tyr Gln Gln Lys Pro
500 505 510
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Ala Ser
515 520 525
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
530 535 540
Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
545 550 555 560
Gln Gln Ser Asn Thr Ser Pro Leu Thr Phe Gly Gln Gly Thr Lys Val
565 570 575
Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
580 585 590
Ser Lys Ser Thr Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly
595 600 605
Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser
610 615 620
Gly Phe Thr Ile Asn Ala Ser Trp Ile His Trp Val Arg Gln Ala Pro
625 630 635 640
Gly Lys Gly Leu Glu Trp Val Gly Ala Ile Tyr Pro Tyr Ser Gly Tyr
645 650 655
Thr Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ala Asp
660 665 670
Thr Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu
675 680 685
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Trp Gly His Ser Thr Ser Pro
690 695 700
Trp Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
705 710 715 720
<210> 5
<211> 214
<212> PRT
<213> 人类
<400> 5
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 6
<211> 719
<212> PRT
<213> 人类
<400> 6
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Asp Ile Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe
50 55 60
Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser
450 455 460
Glu Ser Lys Ser Thr Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly
465 470 475 480
Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala
485 490 495
Ser Gly Phe Thr Ile Ser Asp Tyr Trp Ile His Trp Val Arg Gln Ala
500 505 510
Pro Gly Lys Gly Leu Glu Trp Val Ala Gly Ile Thr Pro Ala Gly Gly
515 520 525
Tyr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ala
530 535 540
Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala
545 550 555 560
Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Phe Val Phe Phe Leu Pro
565 570 575
Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
580 585 590
Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser
595 600 605
Thr Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser
610 615 620
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp
625 630 635 640
Val Ser Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
645 650 655
Lys Leu Leu Ile Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser
660 665 670
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
675 680 685
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr
690 695 700
Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
705 710 715
<210> 7
<211> 214
<212> PRT
<213> 人类
<400> 7
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 8
<211> 719
<212> PRT
<213> 人类
<400> 8
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Asp Ile Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe
50 55 60
Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser
450 455 460
Glu Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
465 470 475 480
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
485 490 495
Ala Ser Gln Asp Val Ser Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro
500 505 510
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Phe Leu Tyr Ser
515 520 525
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
530 535 540
Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
545 550 555 560
Gln Gln Ser Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val
565 570 575
Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
580 585 590
Ser Lys Ser Thr Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly
595 600 605
Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser
610 615 620
Gly Phe Thr Ile Ser Asp Tyr Trp Ile His Trp Val Arg Gln Ala Pro
625 630 635 640
Gly Lys Gly Leu Glu Trp Val Ala Gly Ile Thr Pro Ala Gly Gly Tyr
645 650 655
Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ala Asp
660 665 670
Thr Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu
675 680 685
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Phe Val Phe Phe Leu Pro Tyr
690 695 700
Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
705 710 715
<210> 9
<211> 214
<212> PRT
<213> 人类
<400> 9
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 10
<211> 722
<212> PRT
<213> 人类
<400> 10
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Asp Ile Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe
50 55 60
Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser
450 455 460
Glu Ser Lys Ser Thr Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly
465 470 475 480
Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala
485 490 495
Ser Gly Tyr Asp Phe Thr His Tyr Gly Met Asn Trp Val Arg Gln Ala
500 505 510
Pro Gly Lys Gly Leu Glu Trp Val Gly Trp Ile Asn Thr Tyr Thr Gly
515 520 525
Glu Pro Thr Tyr Ala Ala Asp Phe Lys Arg Arg Phe Thr Phe Ser Leu
530 535 540
Asp Thr Ser Lys Ser Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala
545 550 555 560
Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Tyr Pro Tyr Tyr Tyr Gly
565 570 575
Thr Ser His Trp Tyr Phe Asp Val Trp Gly Gln Gly Thr Leu Val Thr
580 585 590
Val Ser Ser Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
595 600 605
Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser
610 615 620
Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Ser Ala
625 630 635 640
Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly
645 650 655
Lys Ala Pro Lys Val Leu Ile Tyr Phe Thr Ser Ser Leu His Ser Gly
660 665 670
Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
675 680 685
Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln
690 695 700
Gln Tyr Ser Thr Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu
705 710 715 720
Ile Lys
<210> 11
<211> 214
<212> PRT
<213> 人类
<400> 11
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 12
<211> 722
<212> PRT
<213> 人类
<400> 12
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Asp Ile Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe
50 55 60
Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser
450 455 460
Glu Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro
465 470 475 480
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Ser
485 490 495
Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro
500 505 510
Gly Lys Ala Pro Lys Val Leu Ile Tyr Phe Thr Ser Ser Leu His Ser
515 520 525
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
530 535 540
Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
545 550 555 560
Gln Gln Tyr Ser Thr Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val
565 570 575
Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
580 585 590
Ser Lys Ser Thr Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly
595 600 605
Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser
610 615 620
Gly Tyr Asp Phe Thr His Tyr Gly Met Asn Trp Val Arg Gln Ala Pro
625 630 635 640
Gly Lys Gly Leu Glu Trp Val Gly Trp Ile Asn Thr Tyr Thr Gly Glu
645 650 655
Pro Thr Tyr Ala Ala Asp Phe Lys Arg Arg Phe Thr Phe Ser Leu Asp
660 665 670
Thr Ser Lys Ser Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu
675 680 685
Asp Thr Ala Val Tyr Tyr Cys Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr
690 695 700
Ser His Trp Tyr Phe Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val
705 710 715 720
Ser Ser
<210> 13
<211> 214
<212> PRT
<213> 人类
<400> 13
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 14
<211> 720
<212> PRT
<213> 人类
<400> 14
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Asp Ile Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe
50 55 60
Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
465 470 475 480
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
485 490 495
Ala Ser Gln Val Ile Arg Arg Ser Leu Ala Trp Tyr Gln Gln Lys Pro
500 505 510
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Ala Ser
515 520 525
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
530 535 540
Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
545 550 555 560
Gln Gln Ser Asn Thr Ser Pro Leu Thr Phe Gly Gln Gly Thr Lys Val
565 570 575
Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
580 585 590
Ser Lys Ser Thr Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly
595 600 605
Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser
610 615 620
Gly Phe Thr Ile Asn Ala Ser Trp Ile His Trp Val Arg Gln Ala Pro
625 630 635 640
Gly Lys Gly Leu Glu Trp Val Gly Ala Ile Tyr Pro Tyr Ser Gly Tyr
645 650 655
Thr Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ala Asp
660 665 670
Thr Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu
675 680 685
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Trp Gly His Ser Thr Ser Pro
690 695 700
Trp Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
705 710 715 720
<210> 15
<211> 214
<212> PRT
<213> 人类
<400> 15
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 16
<211> 715
<212> PRT
<213> 人类
<400> 16
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Asp Ile Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe
50 55 60
Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala
465 470 475 480
Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Val Ile
485 490 495
Arg Arg Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
500 505 510
Leu Leu Ile Tyr Ala Ala Ser Asn Leu Ala Ser Gly Val Pro Ser Arg
515 520 525
Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser
530 535 540
Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Thr
545 550 555 560
Ser Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly
565 570 575
Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly
580 585 590
Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro
595 600 605
Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ile Asn
610 615 620
Ala Ser Trp Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
625 630 635 640
Trp Val Gly Ala Ile Tyr Pro Tyr Ser Gly Tyr Thr Asn Tyr Ala Asp
645 650 655
Ser Val Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr
660 665 670
Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
675 680 685
Tyr Cys Ala Arg Trp Gly His Ser Thr Ser Pro Trp Ala Met Asp Tyr
690 695 700
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
705 710 715
<210> 17
<211> 214
<212> PRT
<213> 人类
<400> 17
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 18
<211> 710
<212> PRT
<213> 人类
<400> 18
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Asp Ile Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe
50 55 60
Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
450 455 460
Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
465 470 475 480
Val Thr Ile Thr Cys Arg Ala Ser Gln Val Ile Arg Arg Ser Leu Ala
485 490 495
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala
500 505 510
Ala Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
515 520 525
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp
530 535 540
Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Thr Ser Pro Leu Thr Phe
545 550 555 560
Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser
565 570 575
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Glu Val Gln
580 585 590
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg
595 600 605
Leu Ser Cys Ala Ala Ser Gly Phe Thr Ile Asn Ala Ser Trp Ile His
610 615 620
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Ala Ile
625 630 635 640
Tyr Pro Tyr Ser Gly Tyr Thr Asn Tyr Ala Asp Ser Val Lys Gly Arg
645 650 655
Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gln Met
660 665 670
Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Trp
675 680 685
Gly His Ser Thr Ser Pro Trp Ala Met Asp Tyr Trp Gly Gln Gly Thr
690 695 700
Leu Val Thr Val Ser Ser
705 710
<210> 19
<211> 214
<212> PRT
<213> 人类
<400> 19
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 20
<211> 706
<212> PRT
<213> 人类
<400> 20
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Asp Ile Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe
50 55 60
Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Ser Gly Gly Ser Asp Ile Gln Met Thr Gln
450 455 460
Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr
465 470 475 480
Cys Arg Ala Ser Gln Val Ile Arg Arg Ser Leu Ala Trp Tyr Gln Gln
485 490 495
Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu
500 505 510
Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
515 520 525
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr
530 535 540
Tyr Cys Gln Gln Ser Asn Thr Ser Pro Leu Thr Phe Gly Gln Gly Thr
545 550 555 560
Lys Val Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly
565 570 575
Ser Glu Ser Lys Ser Thr Gly Gly Ser Glu Val Gln Leu Val Glu Ser
580 585 590
Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala
595 600 605
Ala Ser Gly Phe Thr Ile Asn Ala Ser Trp Ile His Trp Val Arg Gln
610 615 620
Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Ala Ile Tyr Pro Tyr Ser
625 630 635 640
Gly Tyr Thr Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser
645 650 655
Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg
660 665 670
Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Trp Gly His Ser Thr
675 680 685
Ser Pro Trp Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
690 695 700
Ser Ser
705
<210> 21
<211> 214
<212> PRT
<213> 人类
<400> 21
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 22
<211> 712
<212> PRT
<213> 人类
<400> 22
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Asp Ile Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe
50 55 60
Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val
450 455 460
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
465 470 475 480
Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr Gly Met
485 490 495
Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Trp
500 505 510
Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe Lys Arg
515 520 525
Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr Leu Gln
530 535 540
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys
545 550 555 560
Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val Trp Gly
565 570 575
Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Ser Glu Gly Lys Ser
580 585 590
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln
595 600 605
Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
610 615 620
Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp
625 630 635 640
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile Tyr Phe Thr
645 650 655
Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
660 665 670
Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe
675 680 685
Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp Thr Phe Gly
690 695 700
Gln Gly Thr Lys Val Glu Ile Lys
705 710
<210> 23
<211> 214
<212> PRT
<213> 人类
<400> 23
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 24
<211> 722
<212> PRT
<213> 人类
<400> 24
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Asp Ile Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe
50 55 60
Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly
465 470 475 480
Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala
485 490 495
Ser Gly Tyr Asp Phe Thr His Tyr Gly Met Asn Trp Val Arg Gln Ala
500 505 510
Pro Gly Lys Gly Leu Glu Trp Val Gly Trp Ile Asn Thr Tyr Thr Gly
515 520 525
Glu Pro Thr Tyr Ala Ala Asp Phe Lys Arg Arg Phe Thr Phe Ser Leu
530 535 540
Asp Thr Ser Lys Ser Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala
545 550 555 560
Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Tyr Pro Tyr Tyr Tyr Gly
565 570 575
Thr Ser His Trp Tyr Phe Asp Val Trp Gly Gln Gly Thr Leu Val Thr
580 585 590
Val Ser Ser Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
595 600 605
Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln Leu Thr Gln Ser Pro Ser
610 615 620
Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Ser Ala
625 630 635 640
Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly
645 650 655
Lys Ala Pro Lys Val Leu Ile Tyr Phe Thr Ser Ser Leu His Ser Gly
660 665 670
Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
675 680 685
Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln
690 695 700
Gln Tyr Ser Thr Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu
705 710 715 720
Ile Lys
<210> 25
<211> 214
<212> PRT
<213> 人类
<400> 25
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Val Ile Arg Arg Ser
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Thr Ser Pro Leu
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 26
<211> 720
<212> PRT
<213> 人类
<400> 26
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ile Asn Ala Ser
20 25 30
Trp Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Ala Ile Tyr Pro Tyr Ser Gly Tyr Thr Asn Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Trp Gly His Ser Thr Ser Pro Trp Ala Met Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser
450 455 460
Lys Ser Thr Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu
465 470 475 480
Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly
485 490 495
Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala Pro Gly
500 505 510
Gln Gly Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr
515 520 525
Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg Asp Thr
530 535 540
Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp
545 550 555 560
Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg Phe Arg
565 570 575
Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser
580 585 590
Ser Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys
595 600 605
Ser Thr Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu
610 615 620
Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu
625 630 635 640
Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala
645 650 655
Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro
660 665 670
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile
675 680 685
Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His Phe
690 695 700
Trp Gly Ser Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
705 710 715 720
<210> 27
<211> 214
<212> PRT
<213> 人类
<400> 27
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Val Ile Arg Arg Ser
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Thr Ser Pro Leu
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 28
<211> 720
<212> PRT
<213> 人类
<400> 28
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ile Asn Ala Ser
20 25 30
Trp Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Ala Ile Tyr Pro Tyr Ser Gly Tyr Thr Asn Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Trp Gly His Ser Thr Ser Pro Trp Ala Met Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser
450 455 460
Lys Ser Thr Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
465 470 475 480
Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr Ser
485 490 495
Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys
500 505 510
Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val
515 520 525
Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr
530 535 540
Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His
545 550 555 560
Phe Trp Gly Ser Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
565 570 575
Lys Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys
580 585 590
Ser Thr Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val
595 600 605
Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr
610 615 620
Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala Pro Gly Gln
625 630 635 640
Gly Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys
645 650 655
Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser
660 665 670
Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
675 680 685
Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg Phe Arg Tyr
690 695 700
Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
705 710 715 720
<210> 29
<211> 214
<212> PRT
<213> 人类
<400> 29
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 30
<211> 722
<212> PRT
<213> 人类
<400> 30
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser
450 455 460
Glu Ser Lys Ser Thr Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly
465 470 475 480
Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala
485 490 495
Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala
500 505 510
Pro Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp
515 520 525
Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg
530 535 540
Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser
545 550 555 560
Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg
565 570 575
Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr
580 585 590
Val Ser Ser Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
595 600 605
Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser
610 615 620
Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr
625 630 635 640
Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly
645 650 655
Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser Gly
660 665 670
Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe
675 680 685
Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln
690 695 700
His Phe Trp Gly Ser Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu
705 710 715 720
Ile Lys
<210> 31
<211> 214
<212> PRT
<213> 人类
<400> 31
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 32
<211> 722
<212> PRT
<213> 人类
<400> 32
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser
450 455 460
Glu Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
465 470 475 480
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
485 490 495
Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro
500 505 510
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser
515 520 525
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr
530 535 540
Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
545 550 555 560
Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu
565 570 575
Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
580 585 590
Ser Lys Ser Thr Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala
595 600 605
Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser
610 615 620
Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala Pro
625 630 635 640
Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp Gly
645 650 655
Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg Asp
660 665 670
Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu
675 680 685
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg Phe
690 695 700
Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val
705 710 715 720
Ser Ser
<210> 33
<211> 214
<212> PRT
<213> 人类
<400> 33
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 34
<211> 712
<212> PRT
<213> 人类
<400> 34
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
450 455 460
Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val
465 470 475 480
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile
485 490 495
Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Tyr
500 505 510
Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly
515 520 525
Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu
530 535 540
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
545 550 555 560
Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly
565 570 575
Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Ser Glu Gly Lys Ser
580 585 590
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln
595 600 605
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
610 615 620
Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp
625 630 635 640
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala
645 650 655
Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
660 665 670
Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile
675 680 685
Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly
690 695 700
Gln Gly Thr Lys Leu Glu Ile Lys
705 710
<210> 35
<211> 214
<212> PRT
<213> 人类
<400> 35
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 36
<211> 722
<212> PRT
<213> 人类
<400> 36
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly
465 470 475 480
Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala
485 490 495
Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala
500 505 510
Pro Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp
515 520 525
Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg
530 535 540
Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser
545 550 555 560
Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg
565 570 575
Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr
580 585 590
Val Ser Ser Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
595 600 605
Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser
610 615 620
Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr
625 630 635 640
Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly
645 650 655
Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser Gly
660 665 670
Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe
675 680 685
Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln
690 695 700
His Phe Trp Gly Ser Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu
705 710 715 720
Ile Lys
<210> 37
<211> 214
<212> PRT
<213> 人类
<400> 37
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 38
<211> 712
<212> PRT
<213> 人类
<400> 38
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
450 455 460
Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
465 470 475 480
Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala
485 490 495
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala
500 505 510
Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
515 520 525
Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp
530 535 540
Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe
545 550 555 560
Gly Gln Gly Thr Lys Leu Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser
565 570 575
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Gln Val Gln
580 585 590
Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys
595 600 605
Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile
610 615 620
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile
625 630 635 640
Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg
645 650 655
Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu
660 665 670
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu
675 680 685
Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln
690 695 700
Gly Thr Thr Val Thr Val Ser Ser
705 710
<210> 39
<211> 214
<212> PRT
<213> 人类
<400> 39
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 40
<211> 722
<212> PRT
<213> 人类
<400> 40
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
465 470 475 480
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
485 490 495
Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro
500 505 510
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser
515 520 525
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr
530 535 540
Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
545 550 555 560
Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu
565 570 575
Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
580 585 590
Ser Lys Ser Thr Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala
595 600 605
Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser
610 615 620
Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala Pro
625 630 635 640
Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp Gly
645 650 655
Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg Asp
660 665 670
Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu
675 680 685
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg Phe
690 695 700
Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val
705 710 715 720
Ser Ser
<210> 41
<211> 214
<212> PRT
<213> 人类
<400> 41
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 42
<211> 712
<212> PRT
<213> 人类
<400> 42
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
450 455 460
Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val
465 470 475 480
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile
485 490 495
Ile Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met Gly Tyr
500 505 510
Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly
515 520 525
Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu
530 535 540
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
545 550 555 560
Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly
565 570 575
Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Ser Glu Gly Lys Ser
580 585 590
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln
595 600 605
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
610 615 620
Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp
625 630 635 640
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala
645 650 655
Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
660 665 670
Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile
675 680 685
Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly
690 695 700
Cys Gly Thr Lys Leu Glu Ile Lys
705 710
<210> 43
<211> 214
<212> PRT
<213> 人类
<400> 43
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 44
<211> 722
<212> PRT
<213> 人类
<400> 44
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly
465 470 475 480
Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala
485 490 495
Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala
500 505 510
Pro Gly Gln Cys Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp
515 520 525
Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg
530 535 540
Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser
545 550 555 560
Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg
565 570 575
Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr
580 585 590
Val Ser Ser Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
595 600 605
Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser
610 615 620
Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr
625 630 635 640
Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly
645 650 655
Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser Gly
660 665 670
Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe
675 680 685
Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln
690 695 700
His Phe Trp Gly Ser Pro Phe Thr Phe Gly Cys Gly Thr Lys Leu Glu
705 710 715 720
Ile Lys
<210> 45
<211> 214
<212> PRT
<213> 人类
<400> 45
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 46
<211> 712
<212> PRT
<213> 人类
<400> 46
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
450 455 460
Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
465 470 475 480
Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala
485 490 495
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala
500 505 510
Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
515 520 525
Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp
530 535 540
Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe
545 550 555 560
Gly Cys Gly Thr Lys Leu Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser
565 570 575
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Gln Val Gln
580 585 590
Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys
595 600 605
Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile
610 615 620
Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met Gly Tyr Ile
625 630 635 640
Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg
645 650 655
Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu
660 665 670
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu
675 680 685
Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln
690 695 700
Gly Thr Thr Val Thr Val Ser Ser
705 710
<210> 47
<211> 214
<212> PRT
<213> 人类
<400> 47
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 48
<211> 722
<212> PRT
<213> 人类
<400> 48
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
465 470 475 480
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
485 490 495
Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro
500 505 510
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser
515 520 525
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr
530 535 540
Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
545 550 555 560
Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly Cys Gly Thr Lys Leu
565 570 575
Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
580 585 590
Ser Lys Ser Thr Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala
595 600 605
Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser
610 615 620
Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala Pro
625 630 635 640
Gly Gln Cys Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp Gly
645 650 655
Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg Asp
660 665 670
Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu
675 680 685
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg Phe
690 695 700
Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val
705 710 715 720
Ser Ser
<210> 49
<211> 214
<212> PRT
<213> 人类
<400> 49
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 50
<211> 712
<212> PRT
<213> 人类
<400> 50
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
450 455 460
Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val
465 470 475 480
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile
485 490 495
Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Tyr
500 505 510
Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly
515 520 525
Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu
530 535 540
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
545 550 555 560
Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly
565 570 575
Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Ser Glu Gly Lys Ser
580 585 590
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln
595 600 605
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
610 615 620
Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp
625 630 635 640
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala
645 650 655
Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
660 665 670
Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile
675 680 685
Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly
690 695 700
Gln Gly Thr Lys Leu Glu Ile Lys
705 710
<210> 51
<211> 214
<212> PRT
<213> 人类
<400> 51
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 52
<211> 712
<212> PRT
<213> 人类
<400> 52
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
450 455 460
Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val
465 470 475 480
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile
485 490 495
Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Tyr
500 505 510
Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly
515 520 525
Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu
530 535 540
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
545 550 555 560
Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly
565 570 575
Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Ser Glu Gly Lys Ser
580 585 590
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln
595 600 605
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
610 615 620
Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp
625 630 635 640
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala
645 650 655
Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
660 665 670
Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile
675 680 685
Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly
690 695 700
Gln Gly Thr Lys Leu Glu Ile Lys
705 710
<210> 53
<211> 214
<212> PRT
<213> 人类
<400> 53
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 54
<211> 712
<212> PRT
<213> 人类
<400> 54
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
450 455 460
Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val
465 470 475 480
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile
485 490 495
Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Tyr
500 505 510
Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly
515 520 525
Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu
530 535 540
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
545 550 555 560
Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly
565 570 575
Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Ser Glu Gly Lys Ser
580 585 590
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln
595 600 605
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
610 615 620
Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp
625 630 635 640
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala
645 650 655
Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
660 665 670
Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile
675 680 685
Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly
690 695 700
Gln Gly Thr Lys Leu Glu Ile Lys
705 710
<210> 55
<211> 214
<212> PRT
<213> 人类
<400> 55
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 56
<211> 712
<212> PRT
<213> 人类
<400> 56
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
450 455 460
Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val
465 470 475 480
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile
485 490 495
Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Tyr
500 505 510
Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly
515 520 525
Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu
530 535 540
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
545 550 555 560
Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly
565 570 575
Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Ser Glu Gly Lys Ser
580 585 590
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln
595 600 605
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
610 615 620
Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp
625 630 635 640
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala
645 650 655
Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
660 665 670
Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile
675 680 685
Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly
690 695 700
Gln Gly Thr Lys Leu Glu Ile Lys
705 710
<210> 57
<211> 214
<212> PRT
<213> 人类
<400> 57
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 58
<211> 712
<212> PRT
<213> 人类
<400> 58
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
450 455 460
Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val
465 470 475 480
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile
485 490 495
Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Tyr
500 505 510
Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly
515 520 525
Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu
530 535 540
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
545 550 555 560
Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly
565 570 575
Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Ser Glu Gly Lys Ser
580 585 590
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln
595 600 605
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
610 615 620
Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp
625 630 635 640
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala
645 650 655
Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
660 665 670
Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile
675 680 685
Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly
690 695 700
Gln Gly Thr Lys Leu Glu Ile Lys
705 710
<210> 59
<211> 214
<212> PRT
<213> 人类
<400> 59
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 60
<211> 712
<212> PRT
<213> 人类
<400> 60
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
450 455 460
Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val
465 470 475 480
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile
485 490 495
Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Tyr
500 505 510
Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly
515 520 525
Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu
530 535 540
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
545 550 555 560
Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly
565 570 575
Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Ser Glu Gly Lys Ser
580 585 590
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln
595 600 605
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
610 615 620
Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp
625 630 635 640
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala
645 650 655
Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
660 665 670
Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile
675 680 685
Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly
690 695 700
Gln Gly Thr Lys Leu Glu Ile Lys
705 710
<210> 61
<211> 214
<212> PRT
<213> 人类
<400> 61
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 62
<211> 722
<212> PRT
<213> 人类
<400> 62
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly
465 470 475 480
Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala
485 490 495
Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala
500 505 510
Pro Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp
515 520 525
Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg
530 535 540
Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser
545 550 555 560
Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg
565 570 575
Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr
580 585 590
Val Ser Ser Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
595 600 605
Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser
610 615 620
Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr
625 630 635 640
Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly
645 650 655
Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser Gly
660 665 670
Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe
675 680 685
Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln
690 695 700
His Phe Trp Gly Ser Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu
705 710 715 720
Ile Lys
<210> 63
<211> 214
<212> PRT
<213> 人类
<400> 63
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 64
<211> 722
<212> PRT
<213> 人类
<400> 64
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly
465 470 475 480
Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala
485 490 495
Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala
500 505 510
Pro Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp
515 520 525
Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg
530 535 540
Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser
545 550 555 560
Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg
565 570 575
Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr
580 585 590
Val Ser Ser Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
595 600 605
Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser
610 615 620
Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr
625 630 635 640
Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly
645 650 655
Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser Gly
660 665 670
Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe
675 680 685
Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln
690 695 700
His Phe Trp Gly Ser Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu
705 710 715 720
Ile Lys
<210> 65
<211> 214
<212> PRT
<213> 人类
<400> 65
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 66
<211> 722
<212> PRT
<213> 人类
<400> 66
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly
465 470 475 480
Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala
485 490 495
Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala
500 505 510
Pro Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp
515 520 525
Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg
530 535 540
Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser
545 550 555 560
Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg
565 570 575
Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr
580 585 590
Val Ser Ser Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
595 600 605
Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser
610 615 620
Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr
625 630 635 640
Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly
645 650 655
Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser Gly
660 665 670
Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe
675 680 685
Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln
690 695 700
His Phe Trp Gly Ser Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu
705 710 715 720
Ile Lys
<210> 67
<211> 214
<212> PRT
<213> 人类
<400> 67
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 68
<211> 722
<212> PRT
<213> 人类
<400> 68
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly
465 470 475 480
Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala
485 490 495
Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala
500 505 510
Pro Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp
515 520 525
Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg
530 535 540
Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser
545 550 555 560
Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg
565 570 575
Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr
580 585 590
Val Ser Ser Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
595 600 605
Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser
610 615 620
Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr
625 630 635 640
Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly
645 650 655
Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser Gly
660 665 670
Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe
675 680 685
Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln
690 695 700
His Phe Trp Gly Ser Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu
705 710 715 720
Ile Lys
<210> 69
<211> 214
<212> PRT
<213> 人类
<400> 69
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 70
<211> 722
<212> PRT
<213> 人类
<400> 70
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly
465 470 475 480
Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala
485 490 495
Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala
500 505 510
Pro Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp
515 520 525
Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg
530 535 540
Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser
545 550 555 560
Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg
565 570 575
Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr
580 585 590
Val Ser Ser Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
595 600 605
Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser
610 615 620
Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr
625 630 635 640
Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly
645 650 655
Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser Gly
660 665 670
Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe
675 680 685
Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln
690 695 700
His Phe Trp Gly Ser Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu
705 710 715 720
Ile Lys
<210> 71
<211> 214
<212> PRT
<213> 人类
<400> 71
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 72
<211> 722
<212> PRT
<213> 人类
<400> 72
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly
465 470 475 480
Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala
485 490 495
Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala
500 505 510
Pro Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp
515 520 525
Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg
530 535 540
Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser
545 550 555 560
Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg
565 570 575
Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr
580 585 590
Val Ser Ser Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
595 600 605
Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser
610 615 620
Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr
625 630 635 640
Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly
645 650 655
Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser Gly
660 665 670
Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe
675 680 685
Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln
690 695 700
His Phe Trp Gly Ser Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu
705 710 715 720
Ile Lys
<210> 73
<211> 214
<212> PRT
<213> 人类
<400> 73
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 74
<211> 712
<212> PRT
<213> 人类
<400> 74
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
450 455 460
Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
465 470 475 480
Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala
485 490 495
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala
500 505 510
Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
515 520 525
Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp
530 535 540
Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe
545 550 555 560
Gly Gln Gly Thr Lys Leu Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser
565 570 575
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Gln Val Gln
580 585 590
Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys
595 600 605
Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile
610 615 620
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile
625 630 635 640
Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg
645 650 655
Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu
660 665 670
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu
675 680 685
Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln
690 695 700
Gly Thr Thr Val Thr Val Ser Ser
705 710
<210> 75
<211> 214
<212> PRT
<213> 人类
<400> 75
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 76
<211> 712
<212> PRT
<213> 人类
<400> 76
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
450 455 460
Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
465 470 475 480
Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala
485 490 495
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala
500 505 510
Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
515 520 525
Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp
530 535 540
Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe
545 550 555 560
Gly Gln Gly Thr Lys Leu Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser
565 570 575
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Gln Val Gln
580 585 590
Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys
595 600 605
Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile
610 615 620
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile
625 630 635 640
Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg
645 650 655
Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu
660 665 670
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu
675 680 685
Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln
690 695 700
Gly Thr Thr Val Thr Val Ser Ser
705 710
<210> 77
<211> 214
<212> PRT
<213> 人类
<400> 77
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 78
<211> 712
<212> PRT
<213> 人类
<400> 78
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
450 455 460
Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
465 470 475 480
Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala
485 490 495
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala
500 505 510
Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
515 520 525
Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp
530 535 540
Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe
545 550 555 560
Gly Gln Gly Thr Lys Leu Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser
565 570 575
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Gln Val Gln
580 585 590
Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys
595 600 605
Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile
610 615 620
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile
625 630 635 640
Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg
645 650 655
Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu
660 665 670
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu
675 680 685
Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln
690 695 700
Gly Thr Thr Val Thr Val Ser Ser
705 710
<210> 79
<211> 214
<212> PRT
<213> 人类
<400> 79
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 80
<211> 712
<212> PRT
<213> 人类
<400> 80
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
450 455 460
Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
465 470 475 480
Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala
485 490 495
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala
500 505 510
Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
515 520 525
Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp
530 535 540
Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe
545 550 555 560
Gly Gln Gly Thr Lys Leu Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser
565 570 575
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Gln Val Gln
580 585 590
Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys
595 600 605
Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile
610 615 620
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile
625 630 635 640
Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg
645 650 655
Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu
660 665 670
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu
675 680 685
Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln
690 695 700
Gly Thr Thr Val Thr Val Ser Ser
705 710
<210> 81
<211> 214
<212> PRT
<213> 人类
<400> 81
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 82
<211> 712
<212> PRT
<213> 人类
<400> 82
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
450 455 460
Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
465 470 475 480
Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala
485 490 495
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala
500 505 510
Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
515 520 525
Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp
530 535 540
Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe
545 550 555 560
Gly Gln Gly Thr Lys Leu Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser
565 570 575
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Gln Val Gln
580 585 590
Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys
595 600 605
Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile
610 615 620
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile
625 630 635 640
Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg
645 650 655
Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu
660 665 670
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu
675 680 685
Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln
690 695 700
Gly Thr Thr Val Thr Val Ser Ser
705 710
<210> 83
<211> 214
<212> PRT
<213> 人类
<400> 83
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 84
<211> 712
<212> PRT
<213> 人类
<400> 84
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
450 455 460
Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
465 470 475 480
Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala
485 490 495
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala
500 505 510
Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
515 520 525
Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp
530 535 540
Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe
545 550 555 560
Gly Gln Gly Thr Lys Leu Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser
565 570 575
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Gln Val Gln
580 585 590
Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys
595 600 605
Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile
610 615 620
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile
625 630 635 640
Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg
645 650 655
Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu
660 665 670
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu
675 680 685
Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln
690 695 700
Gly Thr Thr Val Thr Val Ser Ser
705 710
<210> 85
<211> 214
<212> PRT
<213> 人类
<400> 85
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 86
<211> 722
<212> PRT
<213> 人类
<400> 86
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
465 470 475 480
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
485 490 495
Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro
500 505 510
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser
515 520 525
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr
530 535 540
Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
545 550 555 560
Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu
565 570 575
Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
580 585 590
Ser Lys Ser Thr Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala
595 600 605
Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser
610 615 620
Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala Pro
625 630 635 640
Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp Gly
645 650 655
Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg Asp
660 665 670
Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu
675 680 685
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg Phe
690 695 700
Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val
705 710 715 720
Ser Ser
<210> 87
<211> 214
<212> PRT
<213> 人类
<400> 87
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 88
<211> 722
<212> PRT
<213> 人类
<400> 88
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
465 470 475 480
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
485 490 495
Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro
500 505 510
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser
515 520 525
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr
530 535 540
Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
545 550 555 560
Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu
565 570 575
Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
580 585 590
Ser Lys Ser Thr Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala
595 600 605
Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser
610 615 620
Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala Pro
625 630 635 640
Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp Gly
645 650 655
Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg Asp
660 665 670
Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu
675 680 685
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg Phe
690 695 700
Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val
705 710 715 720
Ser Ser
<210> 89
<211> 214
<212> PRT
<213> 人类
<400> 89
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 90
<211> 722
<212> PRT
<213> 人类
<400> 90
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
465 470 475 480
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
485 490 495
Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro
500 505 510
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser
515 520 525
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr
530 535 540
Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
545 550 555 560
Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu
565 570 575
Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
580 585 590
Ser Lys Ser Thr Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala
595 600 605
Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser
610 615 620
Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala Pro
625 630 635 640
Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp Gly
645 650 655
Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg Asp
660 665 670
Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu
675 680 685
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg Phe
690 695 700
Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val
705 710 715 720
Ser Ser
<210> 91
<211> 214
<212> PRT
<213> 人类
<400> 91
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 92
<211> 722
<212> PRT
<213> 人类
<400> 92
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
465 470 475 480
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
485 490 495
Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro
500 505 510
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser
515 520 525
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr
530 535 540
Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
545 550 555 560
Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu
565 570 575
Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
580 585 590
Ser Lys Ser Thr Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala
595 600 605
Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser
610 615 620
Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala Pro
625 630 635 640
Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp Gly
645 650 655
Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg Asp
660 665 670
Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu
675 680 685
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg Phe
690 695 700
Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val
705 710 715 720
Ser Ser
<210> 93
<211> 214
<212> PRT
<213> 人类
<400> 93
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 94
<211> 722
<212> PRT
<213> 人类
<400> 94
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
465 470 475 480
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
485 490 495
Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro
500 505 510
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser
515 520 525
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr
530 535 540
Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
545 550 555 560
Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu
565 570 575
Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
580 585 590
Ser Lys Ser Thr Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala
595 600 605
Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser
610 615 620
Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala Pro
625 630 635 640
Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp Gly
645 650 655
Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg Asp
660 665 670
Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu
675 680 685
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg Phe
690 695 700
Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val
705 710 715 720
Ser Ser
<210> 95
<211> 214
<212> PRT
<213> 人类
<400> 95
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 96
<211> 722
<212> PRT
<213> 人类
<400> 96
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
465 470 475 480
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
485 490 495
Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro
500 505 510
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser
515 520 525
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr
530 535 540
Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
545 550 555 560
Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu
565 570 575
Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
580 585 590
Ser Lys Ser Thr Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala
595 600 605
Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser
610 615 620
Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala Pro
625 630 635 640
Gly Gln Gly Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp Gly
645 650 655
Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg Asp
660 665 670
Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu
675 680 685
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg Phe
690 695 700
Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val
705 710 715 720
Ser Ser
<210> 97
<211> 214
<212> PRT
<213> 人类
<400> 97
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 98
<211> 712
<212> PRT
<213> 人类
<400> 98
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
450 455 460
Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val
465 470 475 480
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile
485 490 495
Ile Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met Gly Tyr
500 505 510
Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly
515 520 525
Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu
530 535 540
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
545 550 555 560
Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly
565 570 575
Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Ser Glu Gly Lys Ser
580 585 590
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln
595 600 605
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
610 615 620
Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp
625 630 635 640
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala
645 650 655
Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
660 665 670
Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile
675 680 685
Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly
690 695 700
Cys Gly Thr Lys Leu Glu Ile Lys
705 710
<210> 99
<211> 214
<212> PRT
<213> 人类
<400> 99
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 100
<211> 712
<212> PRT
<213> 人类
<400> 100
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
450 455 460
Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val
465 470 475 480
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile
485 490 495
Ile Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met Gly Tyr
500 505 510
Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly
515 520 525
Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu
530 535 540
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
545 550 555 560
Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly
565 570 575
Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Ser Glu Gly Lys Ser
580 585 590
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln
595 600 605
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
610 615 620
Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp
625 630 635 640
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala
645 650 655
Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
660 665 670
Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile
675 680 685
Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly
690 695 700
Cys Gly Thr Lys Leu Glu Ile Lys
705 710
<210> 101
<211> 214
<212> PRT
<213> 人类
<400> 101
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 102
<211> 712
<212> PRT
<213> 人类
<400> 102
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
450 455 460
Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val
465 470 475 480
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile
485 490 495
Ile Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met Gly Tyr
500 505 510
Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly
515 520 525
Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu
530 535 540
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
545 550 555 560
Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly
565 570 575
Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Ser Glu Gly Lys Ser
580 585 590
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln
595 600 605
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
610 615 620
Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp
625 630 635 640
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala
645 650 655
Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
660 665 670
Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile
675 680 685
Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly
690 695 700
Cys Gly Thr Lys Leu Glu Ile Lys
705 710
<210> 103
<211> 214
<212> PRT
<213> 人类
<400> 103
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 104
<211> 712
<212> PRT
<213> 人类
<400> 104
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
450 455 460
Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val
465 470 475 480
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile
485 490 495
Ile Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met Gly Tyr
500 505 510
Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly
515 520 525
Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu
530 535 540
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
545 550 555 560
Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly
565 570 575
Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Ser Glu Gly Lys Ser
580 585 590
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln
595 600 605
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
610 615 620
Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp
625 630 635 640
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala
645 650 655
Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
660 665 670
Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile
675 680 685
Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly
690 695 700
Cys Gly Thr Lys Leu Glu Ile Lys
705 710
<210> 105
<211> 214
<212> PRT
<213> 人类
<400> 105
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 106
<211> 712
<212> PRT
<213> 人类
<400> 106
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
450 455 460
Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val
465 470 475 480
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile
485 490 495
Ile Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met Gly Tyr
500 505 510
Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly
515 520 525
Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu
530 535 540
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
545 550 555 560
Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly
565 570 575
Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Ser Glu Gly Lys Ser
580 585 590
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln
595 600 605
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
610 615 620
Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp
625 630 635 640
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala
645 650 655
Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
660 665 670
Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile
675 680 685
Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly
690 695 700
Cys Gly Thr Lys Leu Glu Ile Lys
705 710
<210> 107
<211> 214
<212> PRT
<213> 人类
<400> 107
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 108
<211> 712
<212> PRT
<213> 人类
<400> 108
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val
450 455 460
Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val
465 470 475 480
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile
485 490 495
Ile Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met Gly Tyr
500 505 510
Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly
515 520 525
Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu
530 535 540
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
545 550 555 560
Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly
565 570 575
Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Ser Glu Gly Lys Ser
580 585 590
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln
595 600 605
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
610 615 620
Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp
625 630 635 640
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala
645 650 655
Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
660 665 670
Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile
675 680 685
Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly
690 695 700
Cys Gly Thr Lys Leu Glu Ile Lys
705 710
<210> 109
<211> 214
<212> PRT
<213> 人类
<400> 109
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 110
<211> 722
<212> PRT
<213> 人类
<400> 110
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly
465 470 475 480
Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala
485 490 495
Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala
500 505 510
Pro Gly Gln Cys Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp
515 520 525
Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg
530 535 540
Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser
545 550 555 560
Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg
565 570 575
Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr
580 585 590
Val Ser Ser Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
595 600 605
Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser
610 615 620
Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr
625 630 635 640
Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly
645 650 655
Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser Gly
660 665 670
Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe
675 680 685
Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln
690 695 700
His Phe Trp Gly Ser Pro Phe Thr Phe Gly Cys Gly Thr Lys Leu Glu
705 710 715 720
Ile Lys
<210> 111
<211> 214
<212> PRT
<213> 人类
<400> 111
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 112
<211> 722
<212> PRT
<213> 人类
<400> 112
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly
465 470 475 480
Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala
485 490 495
Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala
500 505 510
Pro Gly Gln Cys Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp
515 520 525
Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg
530 535 540
Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser
545 550 555 560
Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg
565 570 575
Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr
580 585 590
Val Ser Ser Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
595 600 605
Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser
610 615 620
Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr
625 630 635 640
Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly
645 650 655
Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser Gly
660 665 670
Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe
675 680 685
Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln
690 695 700
His Phe Trp Gly Ser Pro Phe Thr Phe Gly Cys Gly Thr Lys Leu Glu
705 710 715 720
Ile Lys
<210> 113
<211> 214
<212> PRT
<213> 人类
<400> 113
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 114
<211> 722
<212> PRT
<213> 人类
<400> 114
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly
465 470 475 480
Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala
485 490 495
Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala
500 505 510
Pro Gly Gln Cys Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp
515 520 525
Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg
530 535 540
Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser
545 550 555 560
Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg
565 570 575
Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr
580 585 590
Val Ser Ser Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
595 600 605
Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser
610 615 620
Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr
625 630 635 640
Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly
645 650 655
Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser Gly
660 665 670
Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe
675 680 685
Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln
690 695 700
His Phe Trp Gly Ser Pro Phe Thr Phe Gly Cys Gly Thr Lys Leu Glu
705 710 715 720
Ile Lys
<210> 115
<211> 214
<212> PRT
<213> 人类
<400> 115
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 116
<211> 722
<212> PRT
<213> 人类
<400> 116
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly
465 470 475 480
Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala
485 490 495
Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala
500 505 510
Pro Gly Gln Cys Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp
515 520 525
Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg
530 535 540
Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser
545 550 555 560
Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg
565 570 575
Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr
580 585 590
Val Ser Ser Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
595 600 605
Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser
610 615 620
Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr
625 630 635 640
Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly
645 650 655
Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser Gly
660 665 670
Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe
675 680 685
Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln
690 695 700
His Phe Trp Gly Ser Pro Phe Thr Phe Gly Cys Gly Thr Lys Leu Glu
705 710 715 720
Ile Lys
<210> 117
<211> 214
<212> PRT
<213> 人类
<400> 117
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 118
<211> 722
<212> PRT
<213> 人类
<400> 118
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly
465 470 475 480
Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala
485 490 495
Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala
500 505 510
Pro Gly Gln Cys Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp
515 520 525
Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg
530 535 540
Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser
545 550 555 560
Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg
565 570 575
Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr
580 585 590
Val Ser Ser Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
595 600 605
Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser
610 615 620
Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr
625 630 635 640
Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly
645 650 655
Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser Gly
660 665 670
Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe
675 680 685
Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln
690 695 700
His Phe Trp Gly Ser Pro Phe Thr Phe Gly Cys Gly Thr Lys Leu Glu
705 710 715 720
Ile Lys
<210> 119
<211> 214
<212> PRT
<213> 人类
<400> 119
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 120
<211> 722
<212> PRT
<213> 人类
<400> 120
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly
465 470 475 480
Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala
485 490 495
Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala
500 505 510
Pro Gly Gln Cys Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp
515 520 525
Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg
530 535 540
Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser
545 550 555 560
Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg
565 570 575
Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr
580 585 590
Val Ser Ser Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
595 600 605
Ser Lys Ser Thr Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser
610 615 620
Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr
625 630 635 640
Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly
645 650 655
Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser Gly
660 665 670
Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe
675 680 685
Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln
690 695 700
His Phe Trp Gly Ser Pro Phe Thr Phe Gly Cys Gly Thr Lys Leu Glu
705 710 715 720
Ile Lys
<210> 121
<211> 214
<212> PRT
<213> 人类
<400> 121
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 122
<211> 712
<212> PRT
<213> 人类
<400> 122
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
450 455 460
Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
465 470 475 480
Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala
485 490 495
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala
500 505 510
Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
515 520 525
Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp
530 535 540
Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe
545 550 555 560
Gly Cys Gly Thr Lys Leu Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser
565 570 575
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Gln Val Gln
580 585 590
Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys
595 600 605
Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile
610 615 620
Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met Gly Tyr Ile
625 630 635 640
Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg
645 650 655
Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu
660 665 670
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu
675 680 685
Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln
690 695 700
Gly Thr Thr Val Thr Val Ser Ser
705 710
<210> 123
<211> 214
<212> PRT
<213> 人类
<400> 123
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 124
<211> 712
<212> PRT
<213> 人类
<400> 124
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
450 455 460
Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
465 470 475 480
Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala
485 490 495
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala
500 505 510
Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
515 520 525
Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp
530 535 540
Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe
545 550 555 560
Gly Cys Gly Thr Lys Leu Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser
565 570 575
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Gln Val Gln
580 585 590
Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys
595 600 605
Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile
610 615 620
Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met Gly Tyr Ile
625 630 635 640
Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg
645 650 655
Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu
660 665 670
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu
675 680 685
Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln
690 695 700
Gly Thr Thr Val Thr Val Ser Ser
705 710
<210> 125
<211> 214
<212> PRT
<213> 人类
<400> 125
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 126
<211> 712
<212> PRT
<213> 人类
<400> 126
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
450 455 460
Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
465 470 475 480
Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala
485 490 495
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala
500 505 510
Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
515 520 525
Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp
530 535 540
Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe
545 550 555 560
Gly Cys Gly Thr Lys Leu Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser
565 570 575
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Gln Val Gln
580 585 590
Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys
595 600 605
Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile
610 615 620
Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met Gly Tyr Ile
625 630 635 640
Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg
645 650 655
Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu
660 665 670
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu
675 680 685
Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln
690 695 700
Gly Thr Thr Val Thr Val Ser Ser
705 710
<210> 127
<211> 214
<212> PRT
<213> 人类
<400> 127
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 128
<211> 712
<212> PRT
<213> 人类
<400> 128
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
450 455 460
Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
465 470 475 480
Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala
485 490 495
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala
500 505 510
Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
515 520 525
Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp
530 535 540
Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe
545 550 555 560
Gly Cys Gly Thr Lys Leu Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser
565 570 575
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Gln Val Gln
580 585 590
Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys
595 600 605
Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile
610 615 620
Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met Gly Tyr Ile
625 630 635 640
Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg
645 650 655
Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu
660 665 670
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu
675 680 685
Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln
690 695 700
Gly Thr Thr Val Thr Val Ser Ser
705 710
<210> 129
<211> 214
<212> PRT
<213> 人类
<400> 129
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 130
<211> 712
<212> PRT
<213> 人类
<400> 130
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
450 455 460
Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
465 470 475 480
Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala
485 490 495
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala
500 505 510
Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
515 520 525
Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp
530 535 540
Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe
545 550 555 560
Gly Cys Gly Thr Lys Leu Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser
565 570 575
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Gln Val Gln
580 585 590
Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys
595 600 605
Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile
610 615 620
Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met Gly Tyr Ile
625 630 635 640
Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg
645 650 655
Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu
660 665 670
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu
675 680 685
Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln
690 695 700
Gly Thr Thr Val Thr Val Ser Ser
705 710
<210> 131
<211> 214
<212> PRT
<213> 人类
<400> 131
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 132
<211> 712
<212> PRT
<213> 人类
<400> 132
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile
450 455 460
Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
465 470 475 480
Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala
485 490 495
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala
500 505 510
Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
515 520 525
Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp
530 535 540
Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr Phe
545 550 555 560
Gly Cys Gly Thr Lys Leu Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser
565 570 575
Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Gln Val Gln
580 585 590
Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys
595 600 605
Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile
610 615 620
Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met Gly Tyr Ile
625 630 635 640
Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg
645 650 655
Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu
660 665 670
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu
675 680 685
Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln
690 695 700
Gly Thr Thr Val Thr Val Ser Ser
705 710
<210> 133
<211> 214
<212> PRT
<213> 人类
<400> 133
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 134
<211> 722
<212> PRT
<213> 人类
<400> 134
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
465 470 475 480
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
485 490 495
Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro
500 505 510
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser
515 520 525
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr
530 535 540
Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
545 550 555 560
Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly Cys Gly Thr Lys Leu
565 570 575
Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
580 585 590
Ser Lys Ser Thr Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala
595 600 605
Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser
610 615 620
Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala Pro
625 630 635 640
Gly Gln Cys Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp Gly
645 650 655
Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg Asp
660 665 670
Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu
675 680 685
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg Phe
690 695 700
Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val
705 710 715 720
Ser Ser
<210> 135
<211> 214
<212> PRT
<213> 人类
<400> 135
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 136
<211> 722
<212> PRT
<213> 人类
<400> 136
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
465 470 475 480
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
485 490 495
Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro
500 505 510
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser
515 520 525
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr
530 535 540
Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
545 550 555 560
Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly Cys Gly Thr Lys Leu
565 570 575
Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
580 585 590
Ser Lys Ser Thr Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala
595 600 605
Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser
610 615 620
Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala Pro
625 630 635 640
Gly Gln Cys Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp Gly
645 650 655
Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg Asp
660 665 670
Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu
675 680 685
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg Phe
690 695 700
Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val
705 710 715 720
Ser Ser
<210> 137
<211> 214
<212> PRT
<213> 人类
<400> 137
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 138
<211> 722
<212> PRT
<213> 人类
<400> 138
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
465 470 475 480
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
485 490 495
Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro
500 505 510
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser
515 520 525
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr
530 535 540
Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
545 550 555 560
Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly Cys Gly Thr Lys Leu
565 570 575
Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
580 585 590
Ser Lys Ser Thr Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala
595 600 605
Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser
610 615 620
Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala Pro
625 630 635 640
Gly Gln Cys Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp Gly
645 650 655
Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg Asp
660 665 670
Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu
675 680 685
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg Phe
690 695 700
Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val
705 710 715 720
Ser Ser
<210> 139
<211> 214
<212> PRT
<213> 人类
<400> 139
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 140
<211> 722
<212> PRT
<213> 人类
<400> 140
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
465 470 475 480
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
485 490 495
Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro
500 505 510
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser
515 520 525
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr
530 535 540
Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
545 550 555 560
Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly Cys Gly Thr Lys Leu
565 570 575
Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
580 585 590
Ser Lys Ser Thr Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala
595 600 605
Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser
610 615 620
Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala Pro
625 630 635 640
Gly Gln Cys Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp Gly
645 650 655
Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg Asp
660 665 670
Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu
675 680 685
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg Phe
690 695 700
Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val
705 710 715 720
Ser Ser
<210> 141
<211> 214
<212> PRT
<213> 人类
<400> 141
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 142
<211> 722
<212> PRT
<213> 人类
<400> 142
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
465 470 475 480
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
485 490 495
Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro
500 505 510
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser
515 520 525
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr
530 535 540
Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
545 550 555 560
Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly Cys Gly Thr Lys Leu
565 570 575
Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
580 585 590
Ser Lys Ser Thr Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala
595 600 605
Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser
610 615 620
Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala Pro
625 630 635 640
Gly Gln Cys Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp Gly
645 650 655
Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg Asp
660 665 670
Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu
675 680 685
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg Phe
690 695 700
Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val
705 710 715 720
Ser Ser
<210> 143
<211> 214
<212> PRT
<213> 人类
<400> 143
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 144
<211> 722
<212> PRT
<213> 人类
<400> 144
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro
465 470 475 480
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
485 490 495
Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro
500 505 510
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser
515 520 525
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr
530 535 540
Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
545 550 555 560
Gln His Phe Trp Gly Ser Pro Phe Thr Phe Gly Cys Gly Thr Lys Leu
565 570 575
Glu Ile Lys Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu
580 585 590
Ser Lys Ser Thr Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala
595 600 605
Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser
610 615 620
Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile Trp Val Arg Gln Ala Pro
625 630 635 640
Gly Gln Cys Leu Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp Gly
645 650 655
Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr Met Thr Arg Asp
660 665 670
Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu
675 680 685
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Lys Tyr Arg Arg Phe
690 695 700
Arg Tyr Tyr Ala Ile Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val
705 710 715 720
Ser Ser
<210> 145
<211> 11
<212> PRT
<213> 人类
<400> 145
Ser Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn
1 5 10
<210> 146
<211> 7
<212> PRT
<213> 人类
<400> 146
Phe Thr Ser Ser Leu His Ser
1 5
<210> 147
<211> 9
<212> PRT
<213> 人类
<400> 147
Gln Gln Tyr Ser Thr Val Pro Trp Thr
1 5
<210> 148
<211> 10
<212> PRT
<213> 人类
<400> 148
Gly Tyr Asp Phe Thr His Tyr Gly Met Asn
1 5 10
<210> 149
<211> 17
<212> PRT
<213> 人类
<400> 149
Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe Lys
1 5 10 15
Arg
<210> 150
<211> 14
<212> PRT
<213> 人类
<400> 150
Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
1 5 10
<210> 151
<211> 5
<212> PRT
<213> 人类
<400> 151
His Tyr Gly Met Asn
1 5
<210> 152
<211> 17
<212> PRT
<213> 人类
<400> 152
Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe Lys
1 5 10 15
Arg
<210> 153
<211> 14
<212> PRT
<213> 人类
<400> 153
Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
1 5 10
<210> 154
<211> 7
<212> PRT
<213> 人类
<400> 154
Gly Tyr Asp Phe Thr His Tyr
1 5
<210> 155
<211> 6
<212> PRT
<213> 人类
<400> 155
Asn Thr Tyr Thr Gly Glu
1 5
<210> 156
<211> 14
<212> PRT
<213> 人类
<400> 156
Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
1 5 10
<210> 157
<211> 11
<212> PRT
<213> 人类
<400> 157
Arg Ala Ser Gln Val Ile Arg Arg Ser Leu Ala
1 5 10
<210> 158
<211> 7
<212> PRT
<213> 人类
<400> 158
Ala Ala Ser Asn Leu Ala Ser
1 5
<210> 159
<211> 9
<212> PRT
<213> 人类
<400> 159
Gln Gln Ser Asn Thr Ser Pro Leu Thr
1 5
<210> 160
<211> 10
<212> PRT
<213> 人类
<400> 160
Gly Phe Thr Ile Asn Ala Ser Trp Ile His
1 5 10
<210> 161
<211> 17
<212> PRT
<213> 人类
<400> 161
Ala Ile Tyr Pro Tyr Ser Gly Tyr Thr Asn Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 162
<211> 12
<212> PRT
<213> 人类
<400> 162
Trp Gly His Ser Thr Ser Pro Trp Ala Met Asp Tyr
1 5 10
<210> 163
<211> 5
<212> PRT
<213> 人类
<400> 163
Ala Ser Trp Ile His
1 5
<210> 164
<211> 17
<212> PRT
<213> 人类
<400> 164
Ala Ile Tyr Pro Tyr Ser Gly Tyr Thr Asn Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 165
<211> 12
<212> PRT
<213> 人类
<400> 165
Trp Gly His Ser Thr Ser Pro Trp Ala Met Asp Tyr
1 5 10
<210> 166
<211> 7
<212> PRT
<213> 人类
<400> 166
Gly Phe Thr Ile Asn Ala Ser
1 5
<210> 167
<211> 6
<212> PRT
<213> 人类
<400> 167
Tyr Pro Tyr Ser Gly Tyr
1 5
<210> 168
<211> 12
<212> PRT
<213> 人类
<400> 168
Trp Gly His Ser Thr Ser Pro Trp Ala Met Asp Tyr
1 5 10
<210> 169
<211> 11
<212> PRT
<213> 人类
<400> 169
Arg Ala Ser Gln Asp Val Ser Thr Ala Val Ala
1 5 10
<210> 170
<211> 7
<212> PRT
<213> 人类
<400> 170
Ser Ala Ser Phe Leu Tyr Ser
1 5
<210> 171
<211> 9
<212> PRT
<213> 人类
<400> 171
Gln Gln Ser Tyr Thr Thr Pro Pro Thr
1 5
<210> 172
<211> 10
<212> PRT
<213> 人类
<400> 172
Gly Phe Thr Ile Ser Asp Tyr Trp Ile His
1 5 10
<210> 173
<211> 17
<212> PRT
<213> 人类
<400> 173
Gly Ile Thr Pro Ala Gly Gly Tyr Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 174
<211> 11
<212> PRT
<213> 人类
<400> 174
Phe Val Phe Phe Leu Pro Tyr Ala Met Asp Tyr
1 5 10
<210> 175
<211> 5
<212> PRT
<213> 人类
<400> 175
Asp Tyr Trp Ile His
1 5
<210> 176
<211> 17
<212> PRT
<213> 人类
<400> 176
Gly Ile Thr Pro Ala Gly Gly Tyr Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210> 177
<211> 11
<212> PRT
<213> 人类
<400> 177
Phe Val Phe Phe Leu Pro Tyr Ala Met Asp Tyr
1 5 10
<210> 178
<211> 7
<212> PRT
<213> 人类
<400> 178
Gly Phe Thr Ile Ser Asp Tyr
1 5
<210> 179
<211> 6
<212> PRT
<213> 人类
<400> 179
Thr Pro Ala Gly Gly Tyr
1 5
<210> 180
<211> 11
<212> PRT
<213> 人类
<400> 180
Phe Val Phe Phe Leu Pro Tyr Ala Met Asp Tyr
1 5 10
<210> 181
<211> 107
<212> PRT
<213> 人类
<400> 181
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Val Ile Arg Arg Ser
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Thr Ser Pro Leu
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
<210> 182
<211> 121
<212> PRT
<213> 人类
<400> 182
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ile Asn Ala Ser
20 25 30
Trp Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Ala Ile Tyr Pro Tyr Ser Gly Tyr Thr Asn Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Trp Gly His Ser Thr Ser Pro Trp Ala Met Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 183
<211> 107
<212> PRT
<213> 人类
<400> 183
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Thr Ala
20 25 30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Thr Thr Pro Pro
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
<210> 184
<211> 120
<212> PRT
<213> 人类
<400> 184
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ile Ser Asp Tyr
20 25 30
Trp Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Gly Ile Thr Pro Ala Gly Gly Tyr Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Phe Val Phe Phe Leu Pro Tyr Ala Met Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 185
<211> 214
<212> PRT
<213> 人类
<400> 185
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Val Ile Arg Arg Ser
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Thr Ser Pro Leu
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 186
<211> 450
<212> PRT
<213> 人类
<400> 186
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ile Asn Ala Ser
20 25 30
Trp Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Ala Ile Tyr Pro Tyr Ser Gly Tyr Thr Asn Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Trp Gly His Ser Thr Ser Pro Trp Ala Met Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205
Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys
210 215 220
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Pro Gly
450
<210> 187
<211> 214
<212> PRT
<213> 人类
<400> 187
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Thr Ala
20 25 30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Thr Thr Pro Pro
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 188
<211> 449
<212> PRT
<213> 人类
<400> 188
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ile Ser Asp Tyr
20 25 30
Trp Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Gly Ile Thr Pro Ala Gly Gly Tyr Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Phe Val Phe Phe Leu Pro Tyr Ala Met Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125
Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
130 135 140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190
Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
195 200 205
Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp
210 215 220
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
260 265 270
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
435 440 445
Gly
<210> 189
<211> 107
<212> PRT
<213> 人类
<400> 189
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
<210> 190
<211> 123
<212> PRT
<213> 人类
<400> 190
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 191
<211> 123
<212> PRT
<213> 人类
<400> 191
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 192
<211> 123
<212> PRT
<213> 人类
<400> 192
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 193
<211> 107
<212> PRT
<213> 人类
<400> 193
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
<210> 194
<211> 123
<212> PRT
<213> 人类
<400> 194
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 195
<211> 214
<212> PRT
<213> 人类
<400> 195
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 196
<211> 452
<212> PRT
<213> 人类
<400> 196
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
450
<210> 197
<211> 452
<212> PRT
<213> 人类
<400> 197
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
450
<210> 198
<211> 452
<212> PRT
<213> 人类
<400> 198
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
450
<210> 199
<211> 214
<212> PRT
<213> 人类
<400> 199
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 200
<211> 452
<212> PRT
<213> 人类
<400> 200
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
450
<210> 201
<211> 11
<212> PRT
<213> 人类
<400> 201
Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu Ala
1 5 10
<210> 202
<211> 7
<212> PRT
<213> 人类
<400> 202
Ala Ala Ser Asn Leu Gln Ser
1 5
<210> 203
<211> 9
<212> PRT
<213> 人类
<400> 203
Gln His Phe Trp Gly Ser Pro Phe Thr
1 5
<210> 204
<211> 10
<212> PRT
<213> 人类
<400> 204
Gly Tyr Thr Phe Thr Asn Tyr Asp Ile Ile
1 5 10
<210> 205
<211> 17
<212> PRT
<213> 人类
<400> 205
Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys
1 5 10 15
Gly
<210> 206
<211> 14
<212> PRT
<213> 人类
<400> 206
Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr
1 5 10
<210> 207
<211> 5
<212> PRT
<213> 人类
<400> 207
Asn Tyr Asp Ile Ile
1 5
<210> 208
<211> 17
<212> PRT
<213> 人类
<400> 208
Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys
1 5 10 15
Gly
<210> 209
<211> 14
<212> PRT
<213> 人类
<400> 209
Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr
1 5 10
<210> 210
<211> 7
<212> PRT
<213> 人类
<400> 210
Gly Tyr Thr Phe Thr Asn Tyr
1 5
<210> 211
<211> 6
<212> PRT
<213> 人类
<400> 211
Asn Pro Tyr Asn Asp Gly
1 5
<210> 212
<211> 14
<212> PRT
<213> 人类
<400> 212
Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr
1 5 10
<210> 213
<211> 107
<212> PRT
<213> 人类
<400> 213
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe
85 90 95
Thr Phe Gly Cys Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 214
<211> 123
<212> PRT
<213> 人类
<400> 214
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Asp Ile Ile Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met
35 40 45
Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe
50 55 60
Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 215
<211> 107
<212> PRT
<213> 人类
<400> 215
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 216
<211> 123
<212> PRT
<213> 人类
<400> 216
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Asp Ile Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe
50 55 60
Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 217
<211> 6
<212> PRT
<213> 人类
<400> 217
Gly Gly Ser Gly Gly Ser
1 5
<210> 218
<211> 10
<212> PRT
<213> 人类
<400> 218
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10
<210> 219
<211> 15
<212> PRT
<213> 人类
<400> 219
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10 15
<210> 220
<211> 20
<212> PRT
<213> 人类
<400> 220
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5 10 15
Gly Gly Gly Ser
20
<210> 221
<211> 20
<212> PRT
<213> 人类
<400> 221
Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser
1 5 10 15
Thr Gly Gly Ser
20
<210> 222
<211> 250
<212> PRT
<213> 人类
<400> 222
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe
85 90 95
Thr Phe Gly Cys Gly Thr Lys Leu Glu Ile Lys Gly Gly Ser Glu Gly
100 105 110
Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Gln
115 120 125
Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser
130 135 140
Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp
145 150 155 160
Ile Ile Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met Gly
165 170 175
Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys
180 185 190
Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met
195 200 205
Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala
210 215 220
Arg Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp
225 230 235 240
Gly Gln Gly Thr Thr Val Thr Val Ser Ser
245 250
<210> 223
<211> 250
<212> PRT
<213> 人类
<400> 223
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Asp Ile Ile Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met
35 40 45
Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe
50 55 60
Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Ser Glu Gly
115 120 125
Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Asp
130 135 140
Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp
145 150 155 160
Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu
165 170 175
Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
180 185 190
Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
195 200 205
Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu
210 215 220
Asp Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr
225 230 235 240
Phe Gly Cys Gly Thr Lys Leu Glu Ile Lys
245 250
<210> 224
<211> 250
<212> PRT
<213> 人类
<400> 224
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Gly Gly Ser Glu Gly
100 105 110
Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Gln
115 120 125
Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser
130 135 140
Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Asp
145 150 155 160
Ile Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly
165 170 175
Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys
180 185 190
Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met
195 200 205
Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala
210 215 220
Arg Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr Trp
225 230 235 240
Gly Gln Gly Thr Thr Val Thr Val Ser Ser
245 250
<210> 225
<211> 250
<212> PRT
<213> 人类
<400> 225
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Asp Ile Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe
50 55 60
Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Leu Leu Lys Tyr Arg Arg Phe Arg Tyr Tyr Ala Ile Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Ser Glu Gly
115 120 125
Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Ser Asp
130 135 140
Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp
145 150 155 160
Arg Val Thr Ile Thr Cys Arg Thr Ser Glu Asn Val Tyr Ser Asn Leu
165 170 175
Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
180 185 190
Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
195 200 205
Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu
210 215 220
Asp Ile Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Ser Pro Phe Thr
225 230 235 240
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
245 250
<210> 226
<211> 399
<212> PRT
<213> 人类
<400> 226
Cys Pro Thr Ser Cys Lys Cys Ser Ala Ser Arg Ile Trp Cys Ser Asp
1 5 10 15
Pro Ser Pro Gly Ile Val Ala Phe Pro Arg Leu Glu Pro Asn Ser Val
20 25 30
Asp Pro Glu Asn Ile Thr Glu Ile Phe Ile Ala Asn Gln Lys Arg Leu
35 40 45
Glu Ile Ile Asn Glu Asp Asp Val Glu Ala Tyr Val Gly Leu Arg Asn
50 55 60
Leu Thr Ile Val Asp Ser Gly Leu Lys Phe Val Ala His Lys Ala Phe
65 70 75 80
Leu Lys Asn Ser Asn Leu Gln His Ile Asn Phe Thr Arg Asn Lys Leu
85 90 95
Thr Ser Leu Ser Arg Lys His Phe Arg His Leu Asp Leu Ser Glu Leu
100 105 110
Ile Leu Val Gly Asn Pro Phe Thr Cys Ser Cys Asp Ile Met Trp Ile
115 120 125
Lys Thr Leu Gln Glu Ala Lys Ser Ser Pro Asp Thr Gln Asp Leu Tyr
130 135 140
Cys Leu Asn Glu Ser Ser Lys Asn Ile Pro Leu Ala Asn Leu Gln Ile
145 150 155 160
Pro Asn Cys Gly Leu Pro Ser Ala Asn Leu Ala Ala Pro Asn Leu Thr
165 170 175
Val Glu Glu Gly Lys Ser Ile Thr Leu Ser Cys Ser Val Ala Gly Asp
180 185 190
Pro Val Pro Asn Met Tyr Trp Asp Val Gly Asn Leu Val Ser Lys His
195 200 205
Met Asn Glu Thr Ser His Thr Gln Gly Ser Leu Arg Ile Thr Asn Ile
210 215 220
Ser Ser Asp Asp Ser Gly Lys Gln Ile Ser Cys Val Ala Glu Asn Leu
225 230 235 240
Val Gly Glu Asp Gln Asp Ser Val Asn Leu Thr Val His Phe Ala Pro
245 250 255
Thr Ile Thr Phe Leu Glu Ser Pro Thr Ser Asp His His Trp Cys Ile
260 265 270
Pro Phe Thr Val Lys Gly Asn Pro Lys Pro Ala Leu Gln Trp Phe Tyr
275 280 285
Asn Gly Ala Ile Leu Asn Glu Ser Lys Tyr Ile Cys Thr Lys Ile His
290 295 300
Val Thr Asn His Thr Glu Tyr His Gly Cys Leu Gln Leu Asp Asn Pro
305 310 315 320
Thr His Met Asn Asn Gly Asp Tyr Thr Leu Ile Ala Lys Asn Glu Tyr
325 330 335
Gly Lys Asp Glu Lys Gln Ile Ser Ala His Phe Met Gly Trp Pro Gly
340 345 350
Ile Asp Asp Gly Ala Asn Pro Asn Tyr Pro Asp Val Ile Tyr Glu Asp
355 360 365
Tyr Gly Thr Ala Ala Asn Asp Ile Gly Asp Thr Thr Asn Arg Ser Asn
370 375 380
Glu Ile Pro Ser Thr Asp Val Thr Asp Lys Thr Gly Arg Glu His
385 390 395
<210> 227
<211> 4
<212> PRT
<213> 人类
<400> 227
Gly Gly Gly Ser
1
<210> 228
<211> 17
<212> PRT
<213> 人类
<400> 228
Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu
1 5 10 15
Ala
<210> 229
<211> 7
<212> PRT
<213> 人类
<400> 229
Trp Ala Ser Thr Arg Glu Ser
1 5
<210> 230
<211> 9
<212> PRT
<213> 人类
<400> 230
Gln Gln Tyr Tyr Ser Tyr Pro Tyr Thr
1 5
<210> 231
<211> 10
<212> PRT
<213> 人类
<400> 231
Gly Tyr Thr Phe Thr Gly Tyr Trp Met His
1 5 10
<210> 232
<211> 17
<212> PRT
<213> 人类
<400> 232
Tyr Ile Asn Pro Ser Thr Asp Tyr Thr Glu Tyr Asn Gln Lys Phe Lys
1 5 10 15
Asp
<210> 233
<211> 6
<212> PRT
<213> 人类
<400> 233
Ser Arg Thr Gly Asn Tyr
1 5
<210> 234
<211> 5
<212> PRT
<213> 人类
<400> 234
Gly Tyr Trp Met His
1 5
<210> 235
<211> 17
<212> PRT
<213> 人类
<400> 235
Tyr Ile Asn Pro Ser Thr Asp Tyr Thr Glu Tyr Asn Gln Lys Phe Lys
1 5 10 15
Asp
<210> 236
<211> 6
<212> PRT
<213> 人类
<400> 236
Ser Arg Thr Gly Asn Tyr
1 5
<210> 237
<211> 7
<212> PRT
<213> 人类
<400> 237
Gly Tyr Thr Phe Thr Gly Tyr
1 5
<210> 238
<211> 6
<212> PRT
<213> 人类
<400> 238
Asn Pro Ser Thr Asp Tyr
1 5
<210> 239
<211> 6
<212> PRT
<213> 人类
<400> 239
Ser Arg Thr Gly Asn Tyr
1 5
<210> 240
<211> 113
<212> PRT
<213> 人类
<400> 240
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30
Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
100 105 110
Lys
<210> 241
<211> 115
<212> PRT
<213> 人类
<400> 241
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Tyr Ile Asn Pro Ser Thr Asp Tyr Thr Glu Tyr Asn Gln Lys Phe
50 55 60
Lys Asp Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Arg Thr Gly Asn Tyr Trp Gly Gln Gly Thr Leu Val Thr
100 105 110
Val Ser Ser
115
<210> 242
<211> 113
<212> PRT
<213> 人类
<400> 242
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30
Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
100 105 110
Lys
<210> 243
<211> 115
<212> PRT
<213> 人类
<400> 243
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr
20 25 30
Trp Met His Trp Val Arg Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Tyr Ile Asn Pro Ser Thr Asp Tyr Thr Glu Tyr Asn Gln Lys Phe
50 55 60
Lys Asp Arg Val Thr Leu Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Arg Thr Gly Asn Tyr Trp Gly Gln Gly Thr Thr Val Thr
100 105 110
Val Ser Ser
115
<210> 244
<211> 113
<212> PRT
<213> 人类
<400> 244
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30
Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
100 105 110
Lys
<210> 245
<211> 115
<212> PRT
<213> 人类
<400> 245
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr
20 25 30
Trp Met His Trp Val Arg Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Tyr Ile Asn Pro Ser Thr Asp Tyr Thr Glu Tyr Asn Gln Lys Phe
50 55 60
Lys Asp Arg Val Thr Leu Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Arg Thr Gly Asn Tyr Trp Gly Gln Gly Thr Thr Val Thr
100 105 110
Val Ser Ser
115
<210> 246
<211> 113
<212> PRT
<213> 人类
<400> 246
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30
Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
100 105 110
Lys
<210> 247
<211> 115
<212> PRT
<213> 人类
<400> 247
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr
20 25 30
Trp Met His Trp Val Arg Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Tyr Ile Asn Pro Ser Thr Asp Tyr Thr Glu Tyr Asn Gln Lys Phe
50 55 60
Lys Asp Arg Val Thr Leu Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Arg Thr Gly Asn Tyr Trp Gly Gln Gly Thr Thr Val Thr
100 105 110
Val Ser Ser
115
<210> 248
<211> 113
<212> PRT
<213> 人类
<400> 248
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30
Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
100 105 110
Lys
<210> 249
<211> 115
<212> PRT
<213> 人类
<400> 249
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Tyr Ile Asn Pro Ser Thr Asp Tyr Thr Glu Tyr Asn Gln Lys Phe
50 55 60
Lys Asp Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Arg Thr Gly Asn Tyr Trp Gly Gln Gly Thr Thr Val Thr
100 105 110
Val Ser Ser
115
<210> 250
<211> 113
<212> PRT
<213> 人类
<400> 250
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30
Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
100 105 110
Lys
<210> 251
<211> 115
<212> PRT
<213> 人类
<400> 251
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr
20 25 30
Trp Met His Trp Val Arg Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Tyr Ile Asn Pro Ser Thr Asp Tyr Thr Glu Tyr Asn Gln Lys Phe
50 55 60
Lys Asp Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Arg Thr Gly Asn Tyr Trp Gly Gln Gly Thr Thr Val Thr
100 105 110
Val Ser Ser
115
<210> 252
<211> 113
<212> PRT
<213> 人类
<400> 252
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30
Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
100 105 110
Lys
<210> 253
<211> 115
<212> PRT
<213> 人类
<400> 253
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr
20 25 30
Trp Met His Trp Val Arg Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Tyr Ile Asn Pro Ser Thr Asp Tyr Thr Glu Tyr Asn Gln Lys Phe
50 55 60
Lys Asp Arg Ala Thr Leu Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Arg Thr Gly Asn Tyr Trp Gly Gln Gly Thr Thr Val Thr
100 105 110
Val Ser Ser
115
<210> 254
<211> 113
<212> PRT
<213> 人类
<400> 254
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30
Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
100 105 110
Lys
<210> 255
<211> 115
<212> PRT
<213> 人类
<400> 255
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Tyr Ile Asn Pro Ser Thr Asp Tyr Thr Glu Tyr Asn Gln Lys Phe
50 55 60
Lys Asp Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Arg Thr Gly Asn Tyr Trp Gly Gln Gly Thr Thr Val Thr
100 105 110
Val Ser Ser
115
<210> 256
<211> 113
<212> PRT
<213> 人类
<400> 256
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30
Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
100 105 110
Lys
<210> 257
<211> 115
<212> PRT
<213> 人类
<400> 257
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Tyr Ile Asn Pro Ser Thr Asp Tyr Thr Glu Tyr Asn Gln Lys Phe
50 55 60
Lys Asp Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Arg Thr Gly Asn Tyr Trp Gly Gln Gly Thr Thr Val Thr
100 105 110
Val Ser Ser
115

Claims (50)

1.一种结合分子,其包含至少一个与血管内皮生长因子(Vascular EndothelialGrowth Factor;VEGF)特异性结合的抗原结合位点及至少一个与原肌球蛋白受体激酶B(Tropomyosin receptor kinase B;TrkB)特异性结合的抗原结合位点。
2.根据权利要求1的结合分子,其中该分子是双特异性的且是四价的。
3.根据权利要求1或2的结合分子,其中该至少一个与VEGF特异性结合的抗原结合位点为免疫球蛋白(Ig)分子。
4.根据权利要求3的结合分子,其中该至少一个与TrkB特异性结合的抗原结合位点与该Ig分子的重链的C端融合。
5.根据权利要求1至4中任一项的结合分子,其中该至少一个与TrkB特异性结合的抗原结合位点包含一个或多个scFv。
6.根据权利要求1至5中任一项的结合分子,其中该至少一个与VEGF特异性结合的抗原结合位点为免疫球蛋白(Ig)分子,且该至少一个与TrkB特异性结合的抗原结合位点包含一个或多个scFv。
7.根据权利要求5或6的结合分子,其中该一个或多个scFv自N端至C端具有VL-VH定向。
8.根据权利要求5至7中任一项的结合分子,其中该一个或多个scFv与该Ig分子的重链的C端融合。
9.根据权利要求3至8中任一项的结合分子,其中该Ig分子为单克隆抗体、人类单克隆抗体、人源化单克隆抗体、嵌合抗体、(scFv)2或抗体的片段,诸如F(ab')2片段。
10.根据权利要求3至9中任一项的结合分子,其中该Ig分子为IgG或F(ab')2。
11.根据权利要求5至10中任一项的结合分子,其中该一个或多个scFv通过肽接头,优选通过长度为约4至20个氨基酸的肽接头与该Ig分子融合。
12.根据权利要求1至11中任一项的结合分子,其中与TrkB特异性结合的该抗原结合位点选自:
a)包含轻链CDR的抗原结合位点,该轻链CDR包含SEQ ID NO:201(CDR1)、SEQ ID NO:202(CDR2)及SEQ ID NO:203(CDR3)的氨基酸序列,及
包含重链CDR的抗原结合位点,该重链CDR包含SEQ ID NO:204(CDR1)、SEQ ID NO:205(CDR2)及SEQ ID NO:206(CDR3)的氨基酸序列;或
包含重链CDR的抗原结合位点,该重链CDR包含SEQ ID NO:207(CDR1)、SEQ ID NO:208(CDR2)及SEQ ID NO:209(CDR3)的氨基酸序列;或
包含重链CDR的抗原结合位点,该重链CDR包含SEQ ID NO:210(CDR1)、SEQ ID NO:211(CDR2)及SEQ ID NO:212(CDR3)的氨基酸序列。
13.根据权利要求1至12中任一项的结合分子,其中与TrkB特异性结合的该抗原结合位点选自:
a)包含轻链可变域及重链可变域的抗原结合位点,该轻链可变域包含与SEQ ID NO:213或215的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列,该重链可变域包含与SEQ ID NO:214或216的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列。
14.根据权利要求1至13中任一项的结合分子,其包含SEQ ID NO:222的氨基酸序列、或SEQ ID NO:223的氨基酸序列、或SEQ ID NO:224的氨基酸序列或SEQ ID NO:225的氨基酸序列。
15.根据权利要求1至14中任一项的结合分子,其中与VEGF特异性结合的该抗原结合位点选自由抗原结合位点a)至c)组成的组:
a)包含轻链CDR的抗原结合位点,该轻链CDR包含SEQ ID NO:145(CDR1)、SEQ ID NO:146(CDR2)及SEQ ID NO:147(CDR3)的氨基酸序列,及
包含重链CDR的抗原结合位点,该重链CDR包含SEQ ID NO:148(CDR1)、SEQ ID NO:149(CDR2)及SEQ ID NO:150(CDR3)的氨基酸序列;或
包含重链CDR的抗原结合位点,该重链CDR包含SEQ ID NO:151(CDR1)、SEQ ID NO:152(CDR2)及SEQ ID NO:153(CDR3)的氨基酸序列;或
包含重链CDR的抗原结合位点,该重链CDR包含SEQ ID NO:154(CDR1)、SEQ ID NO:155(CDR2)及SEQ ID NO:156(CDR3)的氨基酸序列;
b)包含轻链CDR的抗原结合位点,该轻链CDR包含SEQ ID NO:157(CDR1)、SEQ ID NO:158(CDR2)及SEQ ID NO:159(CDR3)的氨基酸序列,及
包含重链CDR的抗原结合位点,该重链CDR包含SEQ ID NO:160(CDR1)、SEQ ID NO:161(CDR2)及SEQ ID NO:162(CDR3)的氨基酸序列;或
包含重链CDR的抗原结合位点,该重链CDR包含SEQ ID NO:163(CDR1)、SEQ ID NO:164(CDR2)及SEQ ID NO:165(CDR3)的氨基酸序列;或
包含重链CDR的抗原结合位点,该重链CDR包含SEQ ID NO:166(CDR1)、SEQ ID NO:167(CDR2)及SEQ ID NO:168(CDR3)的氨基酸序列;
c)包含轻链CDR的抗原结合位点,该轻链CDR包含SEQ ID NO:169(CDR1)、SEQ ID NO:170(CDR2)及SEQ ID NO:171(CDR3)的氨基酸序列,及
包含重链CDR的抗原结合位点,该重链CDR包含SEQ ID NO:172(CDR1)、SEQ ID NO:173(CDR2)及SEQ ID NO:174(CDR3)的氨基酸序列;或
包含重链CDR的抗原结合位点,该重链CDR包含SEQ ID NO:175(CDR1)、SEQ ID NO:176(CDR2)及SEQ ID NO:177(CDR3)的氨基酸序列;或
包含重链CDR的抗原结合位点,该重链CDR包含SEQ ID NO:178(CDR1)、SEQ ID NO:179(CDR2)及SEQ ID NO:180(CDR3)的氨基酸序列。
16.根据权利要求1至15中任一项的结合分子,其中与VEGF特异性结合的该抗原结合位点选自由抗原结合位点a)至d)组成的组:
a)包含轻链可变域及重链可变域的抗原结合位点,该轻链可变域包含与SEQ ID NO:181的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列,该重链可变域包含与SEQ ID NO:182的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列;
b)包含轻链可变域及重链可变域的抗原结合位点,该轻链可变域包含与SEQ ID NO:183的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列,该重链可变域包含与SEQ ID NO:184的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列;
c)包含轻链可变域及重链可变域的抗原结合位点,该轻链可变域包含与SEQ ID NO:189的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列,该重链可变域包含与SEQ ID NO:190、191、192或194的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列;
d)包含轻链可变域及重链可变域的抗原结合位点,该轻链可变域包含与SEQ ID
NO:193的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列,该重链可变域包含与SEQ ID NO:190、191、192或194的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列。
17.根据权利要求1至15中任一项的结合分子,其中与VEGF特异性结合的该抗原结合位点选自由抗原结合位点a)至d)组成的组:
a)包含轻链及重链的抗原结合位点,该轻链包含与SEQ ID NO:185的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列,该重链包含与SEQ ID NO:186的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列;
b)包含轻链及重链的抗原结合位点,该轻链包含与SEQ ID NO:187的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列,该重链包含与SEQ ID NO:188的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列;
c)包含轻链及重链的抗原结合位点,该轻链包含与SEQ ID NO:195的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列,该重链包含与SEQ ID NO:196、197、198或200的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列;
d)包含轻链及重链的抗原结合位点,该轻链包含与SEQ ID NO:199的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列,该重链包含与SEQ ID NO:196、197、198或200的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列。
18.一种结合分子,其包含轻链及重链,该轻链包含与SEQ ID NO:1、3、5、7、9、11、13、15、17、19、21、23、25、27、29、31、33、35、37、39、41、43、45、47、49、51、53、55、57、59、61、63、65、67、69、71、73、75、77、79、81、83、85、87、89、91、93、95、97、99、101、103、105、107、109、111、113、115、117、119、121、123、125、127、129、131、133、135、137、139、141或143的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列;该重链包含与SEQ IDNO:2、4、6、8、10、12、14、16、18、20、22、24、26、28、30、32、34、36、38、40、42、44、46、48、50、52、54、56、58、60、62、64、66、68、70、72、74、76、78、80、82、84、86、88、90、92、94、96、98、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、136、138、140、142或144的氨基酸序列至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或至少99%一致的氨基酸序列。
19.一种结合分子,其包含:(i)包含SEQ ID NO:41的氨基酸序列的轻链及包含SEQIDNO:42的氨基酸序列的重链;或(ii)包含SEQ ID NO:43的氨基酸序列的轻链及包含SEQIDNO:44的氨基酸序列的重链;或(iii)包含SEQ ID NO:45的氨基酸序列的轻链及包含SEQIDNO:46的氨基酸序列的重链;或(iv)包含SEQ ID NO:47的氨基酸序列的轻链及包含SEQIDNO:48的氨基酸序列的重链;或(v)包含SEQ ID NO:49的氨基酸序列的轻链及包含SEQ IDNO:50的氨基酸序列的重链;或(vi)包含SEQ ID NO:51的氨基酸序列的轻链及包含SEQ IDNO:52的氨基酸序列的重链;或(vii)包含SEQ ID NO:53的氨基酸序列的轻链及包含SEQ IDNO:54的氨基酸序列的重链;或(viii)包含SEQ ID NO:55的氨基酸序列的轻链及包含SEQID NO:56的氨基酸序列的重链;或(ix)包含SEQ ID NO:57的氨基酸序列的轻链及包含SEQID NO:58的氨基酸序列的重链;或(x)包含SEQ ID NO:59的氨基酸序列的轻链及包含SEQID NO:60的氨基酸序列的重链;或(xi)包含SEQ ID NO:61的氨基酸序列的轻链及包含SEQID NO:62的氨基酸序列的重链;或(xii)包含SEQ ID NO:63的氨基酸序列的轻链及包含SEQID NO:64的氨基酸序列的重链;或(xiii)包含SEQ ID NO:65的氨基酸序列的轻链及包含SEQ ID NO:66的氨基酸序列的重链;或(xiv)包含SEQ ID NO:67的氨基酸序列的轻链及包含SEQ ID NO:68的氨基酸序列的重链;或(xv)包含SEQ ID NO:69的氨基酸序列的轻链及包含SEQ ID NO:70的氨基酸序列的重链;或(xvi)包含SEQ ID NO:71的氨基酸序列的轻链及包含SEQ ID NO:72的氨基酸序列的重链;或(xvii)包含SEQ ID NO:73的氨基酸序列的轻链及包含SEQ ID NO:74的氨基酸序列的重链;或(xviii)包含SEQ ID NO:75的氨基酸序列的轻链及包含SEQ ID NO:76的氨基酸序列的重链;或(xix)包含SEQ ID NO:77的氨基酸序列的轻链及包含SEQ ID NO:78的氨基酸序列的重链;或(xx)包含SEQ ID NO:79的氨基酸序列的轻链及包含SEQ ID NO:80的氨基酸序列的重链;或(xxi)包含SEQ ID NO:81的氨基酸序列的轻链及包含SEQ ID NO:82的氨基酸序列的重链;或(xxii)包含SEQ ID NO:83的氨基酸序列的轻链及包含SEQ ID NO:84的氨基酸序列的重链;或(xxiii)包含SEQ ID NO:85的氨基酸序列的轻链及包含SEQ ID NO:86的氨基酸序列的重链;或(xxiv)包含SEQ ID NO:87的氨基酸序列的轻链及包含SEQ ID NO:88的氨基酸序列的重链;或(xxv)包含SEQ ID NO:89的氨基酸序列的轻链及包含SEQ ID NO:90的氨基酸序列的重链;或(xxvi)包含SEQ ID NO:91的氨基酸序列的轻链及包含SEQ ID NO:92的氨基酸序列的重链;或(xxvii)包含SEQ IDNO:93的氨基酸序列的轻链及包含SEQ ID NO:94的氨基酸序列的重链;或(xxviii)包含SEQID NO:95的氨基酸序列的轻链及包含SEQ ID NO:96的氨基酸序列的重链;或(xxix)包含SEQ ID NO:97的氨基酸序列的轻链及包含SEQ ID NO:98的氨基酸序列的重链;或(xxx)包含SEQ ID NO:99的氨基酸序列的轻链及包含SEQ ID NO:100的氨基酸序列的重链;或(xxxi)包含SEQ ID NO:101的氨基酸序列的轻链及包含SEQ ID NO:102的氨基酸序列的重链;或(xxxii)包含SEQ ID NO:103的氨基酸序列的轻链及包含SEQ ID NO:104的氨基酸序列的重链;或(xxxiii)包含SEQ ID NO:105的氨基酸序列的轻链及包含SEQ ID NO:106的氨基酸序列的重链;或(xxxiv)包含SEQ ID NO:107的氨基酸序列的轻链及包含SEQ ID NO:108的氨基酸序列的重链;或(xxxv)包含SEQ ID NO:109的氨基酸序列的轻链及包含SEQ IDNO:110的氨基酸序列的重链;或(xxxvi)包含SEQ ID NO:111的氨基酸序列的轻链及包含SEQ ID NO:112的氨基酸序列的重链;或(xxxvii)包含SEQ ID NO:113的氨基酸序列的轻链及包含SEQ ID NO:114的氨基酸序列的重链;或(xxxviii)包含SEQ ID NO:115的氨基酸序列的轻链及包含SEQ ID NO:116的氨基酸序列的重链;或(xxxix)包含SEQ ID NO:117的氨基酸序列的轻链及包含SEQ ID NO:118的氨基酸序列的重链;或(xl)包含SEQ ID NO:119的氨基酸序列的轻链及包含SEQ ID NO:120的氨基酸序列的重链;或(xli)包含SEQ ID NO:121的氨基酸序列的轻链及包含SEQ ID NO:122的氨基酸序列的重链;或(xlii)包含SEQ IDNO:123的氨基酸序列的轻链及包含SEQ ID NO:124的氨基酸序列的重链;或(xliii)包含SEQ ID NO:125的氨基酸序列的轻链及包含SEQ ID NO:126的氨基酸序列的重链;或(xliv)包含SEQ ID NO:127的氨基酸序列的轻链及包含SEQ ID NO:128的氨基酸序列的重链;或(xlv)包含SEQ ID NO:129的氨基酸序列的轻链及包含SEQ ID NO:130的氨基酸序列的重链;或(xlvi)包含SEQ ID NO:131的氨基酸序列的轻链及包含SEQ ID NO:132的氨基酸序列的重链;或(xlvii)包含SEQ ID NO:133的氨基酸序列的轻链及包含SEQ ID NO:134的氨基酸序列的重链;或(xlviii)包含SEQ ID NO:135的氨基酸序列的轻链及包含SEQ IDNO:136的氨基酸序列的重链;或(xlix)包含SEQ ID NO:137的氨基酸序列的轻链及包含SEQ IDNO:138的氨基酸序列的重链;或(l)包含SEQ ID NO:139的氨基酸序列的轻链及包含SEQ IDNO:140的氨基酸序列的重链;或(li)包含SEQ ID NO:141的氨基酸序列的轻链及包含SEQID NO:142的氨基酸序列的重链;或(lii)包含SEQ ID NO:143的氨基酸序列的轻链及包含SEQ ID NO:144的重链。
20.一种TrkB结合分子,其包含两个scFv或由其组成,其中各scFv与TrkB特异性结合。
21.根据权利要求20的TrkB结合分子,其进一步包含Ig分子。
22.根据权利要求21的TrkB结合分子,其中该Ig分子为单克隆抗体;人类单克隆抗体;人源化单克隆抗体;嵌合抗体;抗体的片段,诸如Fv、Fab、Fab'或F(ab')2片段;单链抗体,诸如单链可变片段(single chain variable fragment;scFv);小模块免疫药物(SmallModular Immunopharmaceutical;SMIP);域抗体;纳米抗体;或双抗体。
23.根据权利要求22的TrkB结合分子,其中各scFv与该Ig分子的重链的C端融合。
24.根据权利要求21至23中任一项的TrkB结合分子,其中该Ig分子为IgG、F(ab)或F(ab')2。
25.根据权利要求21或23的TrkB结合分子,其中该Ig分子包含Fc区或由其组成。
26.根据权利要求21至23中任一项的TrkB结合分子,其中该TrkB结合分子是双特异性的且是四价的。
27.根据权利要求21至26中任一项的TrkB结合分子,其中各scFv通过肽接头,优选地长度为约4至20个氨基酸的肽接头与该Ig分子融合。
28.一种与TrkB特异性结合的scFv,其包含(i)包含SEQ ID NO:213的氨基酸序列的轻链可变域及包含SEQ ID NO:214的氨基酸序列的重链可变域;或(ii)包含SEQ ID NO:215的氨基酸序列的轻链可变域及包含SEQ ID NO:216的氨基酸序列的重链可变域。
29.根据权利要求28的scFv,其包含SEQ ID NO:222的氨基酸序列、或SEQ ID NO:223的氨基酸序列、或SEQ ID NO:224的氨基酸序列或SEQ ID NO:225的氨基酸序列。
30.一种与VEGF特异性结合的抗体分子,其包含:
(i)轻链可变域,其包含SEQ ID NO:189的氨基酸序列,及
重链可变域,其包含SEQ ID NO:191的氨基酸序列;或
重链可变域,其包含SEQ ID NO:192的氨基酸序列;或
重链可变域,其包含SEQ ID NO:194的氨基酸序列;
(ii)重链可变域,其包含SEQ ID NO:190的氨基酸序列,及
轻链可变域,其包含SEQ ID NO:192的氨基酸序列;或
轻链可变域,其包含SEQ ID NO:193的氨基酸序列。
31.根据权利要求30的抗体分子,其包含:
轻链,其包含SEQ ID NO:195或199的氨基酸序列,及
重链,其包含SEQ ID NO:196、197、198或200的氨基酸序列。
32.一种经分离的核酸分子,其编码根据权利要求1至19中任一项的结合分子的(i)重链或重链可变域和/或(ii)轻链或轻链可变域。
33.一种经分离的核酸分子,其编码根据权利要求20至27中任一项的TrkB结合分子的(i)重链或重链可变域和/或(ii)轻链或轻链可变域。
34.一种经分离的核酸分子,其编码根据权利要求28至29中任一项的scFv的(i)重链可变域和/或(ii)轻链可变域。
35.一种经分离的核酸分子,其编码根据权利要求30至31中任一项的抗体分子的(i)重链或重链可变域和/或(ii)轻链或轻链可变域。
36.一种病毒载体,其包含根据权利要求32至35中任一项的经分离的核酸分子。
37.一种表达载体,其包含根据权利要求32至35中任一项的经分离的核酸分子。
38.一种宿主细胞,其用根据权利要求37的表达载体转染。
39.一种制造根据权利要求1至19中任一项的结合分子、根据权利要求20至27中任一项的TrkB结合分子、根据权利要求28至29中任一项的scFv或根据权利要求30至31中任一项的抗体分子的方法,其包含
(a)在允许该分子表达的条件下培养根据权利要求38的宿主细胞;及
(b)回收该分子;及任选
(c)进一步纯化和/或修饰和/或调配该分子。
40.根据权利要求1至19中任一项的结合分子、根据权利要求20至27中任一项的TrkB结合分子、根据权利要求28至29中任一项的scFv或根据权利要求30至31中任一项的抗体分子,其用作药物。
41.根据权利要求40所用的结合分子、TrkB结合分子、scFv、或抗体分子,其中所述用途为用于治疗或预防眼部疾病或视网膜疾病或神经退化性疾病。
42.根据权利要求41所用的结合分子、TrkB结合分子、scFv、或抗体分子,其中所述用途为用于治疗神经/神经元眼部或视网膜疾病。
43.根据权利要求41所用的结合分子、TrkB结合分子、scFv、或抗体分子,其中所述用途为用于治疗黄斑变性、老年性黄斑变性、糖尿病性视网膜病变、糖尿病性黄斑水肿、色素性视网膜炎、遗传性视网膜营养性萎缩、遗传性黄斑营养不良、近视变性、地图状萎缩、视网膜动脉阻塞、眼内炎、葡萄膜炎、囊样黄斑水肿、继发于任何视网膜疾病的脉络膜新生血管性膜、视神经病、青光眼、视网膜脱落、毒性视网膜病、辐射性视网膜病、及创伤性视网膜病、前驱性及轻度至中度阿尔茨海默氏症(Alzheimer′s disease),延迟患有阿尔茨海默氏病、亨廷顿氏症(Huntington′s disease)、帕金森氏症(Parkinson′s disease)、严重抑郁症、精神分裂症、与精神分裂症相关的认知障碍的患者的疾病进展,预防患有减弱精神病综合征的个体的第一次精神病发作,预防患有精神分裂症、难治性抑郁、暴食、肥胖症或代谢综合征的患者复发。
44.根据权利要求40所用的结合分子、TrkB结合分子、scFv、或抗体分子,其中所述用途为用于治疗湿性年龄相关的黄斑变性(wet age-related macular degeneration;wAMD)。
45.根据权利要求40所用的结合分子、TrkB结合分子、scFv、或抗体分子,其中所述用途为用于治疗视网膜静脉阻塞(retinal vein occlusion;RVO)。
46.根据权利要求40所用的结合分子、TrkB结合分子、scFv、或抗体分子,其中该所述用途为用于治疗和/或预防地图状萎缩。
47.一种药物组合物,其包含药学上可接受的载剂及根据权利要求1至19中任一项的结合分子、根据权利要求20至27中任一项的TrkB结合分子、根据权利要求28至29中任一项的scFv或根据权利要求30至31中任一项的抗体分子。
48.一种用于治疗或预防眼部或视网膜或神经退化性疾病的方法,该方法包括向有需要的患者施用治疗有效量的根据权利要求1至19中任一项的结合分子、根据权利要求20至27中任一项的TrkB结合分子、根据权利要求28至29中任一项的scFv或根据权利要求30至31中任一项的抗体分子。
49.根据权利要求1至19中任一项的结合分子、根据权利要求20至27中任一项的TrkB结合分子、根据权利要求28至29中任一项的scFv或根据权利要求30至31中任一项的抗体分子在制备用于治疗或预防眼部或视网膜或神经退化性疾病的药物中的用途。
50.根据权利要求1至19中任一项的结合分子、根据权利要求20至27中任一项的TrkB结合分子、根据权利要求28至29中任一项的scFv或根据权利要求30至31中任一项的抗体分子,其用于治疗或预防眼部或视网膜或神经退化性疾病的药物的方法中。
CN202180070390.8A 2020-10-21 2021-10-20 用于治疗眼部疾病的抗-VEGF及抗-TrkB双特异性结合分子 Pending CN116829586A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20203030 2020-10-21
EP20203030.0 2020-10-21
PCT/EP2021/079010 WO2022084354A1 (en) 2020-10-21 2021-10-20 Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseases

Publications (1)

Publication Number Publication Date
CN116829586A true CN116829586A (zh) 2023-09-29

Family

ID=73005392

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180070390.8A Pending CN116829586A (zh) 2020-10-21 2021-10-20 用于治疗眼部疾病的抗-VEGF及抗-TrkB双特异性结合分子
CN202180078806.0A Pending CN117043186A (zh) 2020-10-21 2021-10-20 用于治疗眼部疾病的激动性TrkB结合分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180078806.0A Pending CN117043186A (zh) 2020-10-21 2021-10-20 用于治疗眼部疾病的激动性TrkB结合分子

Country Status (7)

Country Link
US (2) US20220119535A1 (zh)
EP (2) EP4232476A2 (zh)
JP (2) JP2023546229A (zh)
CN (2) CN116829586A (zh)
AR (1) AR123862A1 (zh)
TW (1) TW202233668A (zh)
WO (2) WO2022084355A2 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220119535A1 (en) * 2020-10-21 2022-04-21 Boehringer Ingelheim International Gmbh Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731A (en) 1848-08-22 Elisha k
US168A (en) 1837-04-17 Improvement in fire-arms
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
PT1498427E (pt) 1992-08-21 2010-03-22 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
DE69405102T2 (de) 1993-06-03 1998-01-15 Therapeutic Antibodies Inc Antikoerperfragmente in therapie
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
WO1998049198A1 (en) 1997-04-30 1998-11-05 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
CA2405912A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
RU2420537C2 (ru) 2001-01-17 2011-06-10 Трабьон Фармасьютикалз Инк. Слитые белки связывающий домен-иммуноглобулин
AU2002351896A1 (en) 2001-12-11 2003-06-23 Ablynx N.V. Method for displaying loops from immunoglobulin domains in different contexts
JP2006512895A (ja) 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
EP1900753B1 (en) 2002-11-08 2017-08-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
PL1639011T3 (pl) 2003-06-30 2009-05-29 Domantis Ltd Pegilowane przeciwciała jednodomenowe (dAb)
JP5362359B2 (ja) 2005-10-12 2013-12-11 モルフォシス アーゲー ヒトCD38に特異的な完全ヒトHuCALGOLD由来の治療抗体の生成とプロファイリング
CA2646508A1 (en) * 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
EA200970469A1 (ru) 2006-11-09 2010-04-30 АйАрЭм ЭлЭлСи Антитела-агонисты рецептора trkb и их применение
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
UY33707A (es) * 2010-11-04 2012-05-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2017192538A1 (en) * 2016-05-03 2017-11-09 The Scripps Research Institute Trkb agonist antibodies for treating neurodegenerative disorders
EP3596126A4 (en) * 2017-03-15 2021-03-03 Tsinghua University NEW ANTI-TRKB ANTIBODIES
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
US20220119535A1 (en) * 2020-10-21 2022-04-21 Boehringer Ingelheim International Gmbh Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseases

Also Published As

Publication number Publication date
EP4232474A1 (en) 2023-08-30
AR123862A1 (es) 2023-01-18
US20220119536A1 (en) 2022-04-21
WO2022084355A2 (en) 2022-04-28
JP2023546228A (ja) 2023-11-01
EP4232476A2 (en) 2023-08-30
WO2022084355A3 (en) 2022-06-02
WO2022084354A1 (en) 2022-04-28
US20220119535A1 (en) 2022-04-21
TW202233668A (zh) 2022-09-01
CN117043186A (zh) 2023-11-10
JP2023546229A (ja) 2023-11-01

Similar Documents

Publication Publication Date Title
JP6975508B2 (ja) 目的に合わせた親和性を有する抗トランスフェリンレセプター抗体
JP6993228B2 (ja) 抗トランスフェリン受容体/抗bace1多重特異性抗体および使用方法
KR102524165B1 (ko) 다중특이적 항체
JP2022062120A (ja) ヒトFcRn結合改変抗体及び使用方法
EP3495387B1 (en) Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
RU2604189C2 (ru) Биспецифические четырехвалентные антигенсвязывающие белки
KR101431318B1 (ko) 전장 항체 및 단일쇄 fab 단편을 포함하는 다중특이성 항체
RU2570633C2 (ru) Три- или тетраспецифические антитела
RU2573914C2 (ru) Биспецифические антигенсвязывающие белки
US11873334B2 (en) Method of treating ocular conditions by administering an antibody that activates Tie2 and binds VEGF
KR102455680B1 (ko) 신규 항인간 Tie2 항체
JP6983824B2 (ja) 新規抗体フォーマット
JP2023052217A (ja) a-syn/IGF1Rに対する二重特異抗体およびその用途
JP2022553830A (ja) N末端scFv多重特異性結合分子
US20230357412A1 (en) Bispecific antibody against alpha-syn/igf1r and use thereof
CN116829586A (zh) 用于治疗眼部疾病的抗-VEGF及抗-TrkB双特异性结合分子
WO2022127066A9 (zh) 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途
JP2023534214A (ja) 抗ベータセルリン抗体、その断片、及び多重特異性結合分子
CN117597365A (zh) 多特异性fgf21受体激动剂及其应用
KR20240004694A (ko) 항체

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination